var title_f29_16_29952="Probability resolution reflux";
var content_f29_16_29952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Percent chance of reflux persistence for one to five years following presentation as a function of grade of reflux, laterality, and age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 598px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Grades I, II and IV reflux. B) grade III reflux by patient age at presentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Elder JS, Peters CA, Arant BS Jr, et al. Pediatric Vesicoureteral Reflux Guidelines Panel summary report on the management of primary vesicoureteral reflux in children. J Urol 1997; 157:1846. Copyright &copy; 1997 American Urological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29952=[""].join("\n");
var outline_f29_16_29952=null;
var title_f29_16_29953="Piracetam: International drug information";
var content_f29_16_29953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Piracetam: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1980054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acetar (PT);",
"     </li>",
"     <li>",
"      Avigilen (DE);",
"     </li>",
"     <li>",
"      Axonyl (FR);",
"     </li>",
"     <li>",
"      Braintop (BE, LU);",
"     </li>",
"     <li>",
"      Cerebroforte (DE);",
"     </li>",
"     <li>",
"      Cerebropan (IT);",
"     </li>",
"     <li>",
"      Cerebrosteril (DE);",
"     </li>",
"     <li>",
"      Cerebryl (AT, HU);",
"     </li>",
"     <li>",
"      Cerepar N (DE);",
"     </li>",
"     <li>",
"      Cetam (IT);",
"     </li>",
"     <li>",
"      Ciclofalina (ES);",
"     </li>",
"     <li>",
"      Cintilan (BR);",
"     </li>",
"     <li>",
"      Cleveral (IT);",
"     </li>",
"     <li>",
"      Cuxabrain (DE);",
"     </li>",
"     <li>",
"      Dinagen (MX);",
"     </li>",
"     <li>",
"      Docpirace (BE);",
"     </li>",
"     <li>",
"      Encefalux (ES);",
"     </li>",
"     <li>",
"      Encetrop (CH, DE);",
"     </li>",
"     <li>",
"      Flavis (IT);",
"     </li>",
"     <li>",
"      Gabacet (FR);",
"     </li>",
"     <li>",
"      Genogris (ES);",
"     </li>",
"     <li>",
"      Geram (FR);",
"     </li>",
"     <li>",
"      Geratam (BE, LU);",
"     </li>",
"     <li>",
"      Huberdasen (ES);",
"     </li>",
"     <li>",
"      Kalicor (CZ);",
"     </li>",
"     <li>",
"      Lucetam (HU);",
"     </li>",
"     <li>",
"      Lytenur (DE);",
"     </li>",
"     <li>",
"      Merapiran (AR);",
"     </li>",
"     <li>",
"      Neuronova (ES);",
"     </li>",
"     <li>",
"      Noodis (BE, HU, LU);",
"     </li>",
"     <li>",
"      Noostan (AR, BE, PT);",
"     </li>",
"     <li>",
"      Nootron (BR);",
"     </li>",
"     <li>",
"      Nootrop (BE, DE);",
"     </li>",
"     <li>",
"      Nootropicon (AR);",
"     </li>",
"     <li>",
"      Nootropil (AT, BE, BR, CH, ES, GB, HU, IT, LU, MX, NL, PT, SE);",
"     </li>",
"     <li>",
"      Nootropyl (FR);",
"     </li>",
"     <li>",
"      Normabrain (DE, IN);",
"     </li>",
"     <li>",
"      Norzetam (IT);",
"     </li>",
"     <li>",
"      Novocephal (AT);",
"     </li>",
"     <li>",
"      Oikamid (CZ, HR);",
"     </li>",
"     <li>",
"      Pirabene (AT, DE, HU);",
"     </li>",
"     <li>",
"      Piracebral (DE, LU);",
"     </li>",
"     <li>",
"      Piracemed (BE);",
"     </li>",
"     <li>",
"      Piracetam AbZ (DE);",
"     </li>",
"     <li>",
"      Piracetam AL (DE);",
"     </li>",
"     <li>",
"      Piracetam EG (BE);",
"     </li>",
"     <li>",
"      Piracetam Faro (AT);",
"     </li>",
"     <li>",
"      Piracetam Heumann (DE);",
"     </li>",
"     <li>",
"      Piracetam Interpharm (AT);",
"     </li>",
"     <li>",
"      Piracetam Prodes (ES);",
"     </li>",
"     <li>",
"      Piracetam Stada (DE);",
"     </li>",
"     <li>",
"      Piracetam Verla (DE);",
"     </li>",
"     <li>",
"      piracetam von ct (DE);",
"     </li>",
"     <li>",
"      Piracetam-Elbe-Med (DE);",
"     </li>",
"     <li>",
"      Piracetam-Farmatrading (PT);",
"     </li>",
"     <li>",
"      Piracetam-neuraxpharm (DE);",
"     </li>",
"     <li>",
"      Piracetam-ratiopharm (DE, LU, PT);",
"     </li>",
"     <li>",
"      Piracetam-RPh (DE);",
"     </li>",
"     <li>",
"      Piracetop (BE);",
"     </li>",
"     <li>",
"      Piracetrop (DE);",
"     </li>",
"     <li>",
"      Pirax (CH);",
"     </li>",
"     <li>",
"      Pirazetam-Eurogenerics (LU);",
"     </li>",
"     <li>",
"      Psycoton (IT);",
"     </li>",
"     <li>",
"      Pyramen (HU);",
"     </li>",
"     <li>",
"      Sinapsan (DE);",
"     </li>",
"     <li>",
"      Stimubral (PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1980049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Nootropic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1980052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enhance cognition in the elderly; cortical myoclonus; sickle cell anemia",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1980048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 800 mg 3 times/day; doses up to 24 g/day reported",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1980051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Capsule: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Granules: 1200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Injection: 200 mg/mL (5 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Solution, oral: 200 mg/mL (120 mL); 330 mg/mL (300 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 800 mg, 1200 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10429 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29953=[""].join("\n");
var outline_f29_16_29953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980054\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980049\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980052\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980048\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821195\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980051\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10429\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10429|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_16_29954="Algorithm poor weight vomiting";
var content_f29_16_29954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    Algorithm for evaluating an infant with frequent regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 786px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; BUN: blood urea nitrogen; IgA: immunoglobulin A; tTG: tissue transglutaminase; GERD: gastroesophageal reflux disease; PPI: proton pump inhibitor.",
"     <br>",
"      * Warning signals include bilious vomiting, consistently forceful vomiting, abdominal tenderness or distension, fever or other systemic signs (see text).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29954=[""].join("\n");
var outline_f29_16_29954=null;
var title_f29_16_29955="Ocular cicatricial pemphigoid stage 1";
var content_f29_16_29955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Stage 1 ocular cicatricial pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the conjuncitivits. Subepithelial fibrosis, with a white \"feltwork\" of new collagen deposited under the conjunctival epithelium also is evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29955=[""].join("\n");
var outline_f29_16_29955=null;
var title_f29_16_29956="Nail changes in psoriatic juvenile idiopathic arthritis";
var content_f29_16_29956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Nail changes in psoriatic juvenile idiopathic arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 349px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFdAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDrIbVbdFkkJ+fOVbtUX26OK4KFdirgHaPvZ/rVmxWFz5dw8pVV6EdKna3jERRGRs/NuY/pWj8zlS00K8iNcfM7tFGPuKe9OuIp0jVBMFC8ncM5qOzMuxkmKls8bugFV57tWkMLzRyDIVgOw9qPJD82W4bYmFg00AY9SB1/Cq0FspkMzfu5Adqt1qKQQRXiGXMceP3YPr61POSzFGmG5/uAjANFluF2S3gdbHy96KB958YJptqYZLYQEkZOWA5IqNg07R21xs2p1GcFqcsPkxzKQtvzhSx60dAtrdjL60M8K+S4dImGNowT9aP3onRZnLseCiHgCrNnYAWuJ5JHkY7gEOBircVtHbrKwxsPc8HP1qbdy030K8oaJkMsKhI+Yxjp9aWS8+0nkhZR0RRnFRWrmeaYTk+XjjJ4NWtiW+1oVAJ4Cr1ansTvqildhI3QMF4HIPc0rzbgsiIXkAx8nQU++ieVMiIAcZVjjHuakEZaFYlcCMjonf8AGncXLvcoxXkSvsWNnfHVRkZqzbzXEkpAj2xoMMX5xVq12WcYEVvtCnk9arGaWeOUocLK38XHFD8gS6sZqFhHc+W9xJ8uckE4FFjB9nDgcx5+TaaJorq/xC8kcNsDgsTyRUljDHp935cbefxwXOcClZ2Kur3sOvljtIIkydy5LFeTis60kjG97fekJJLuelad2jFVOAqse3Uj0qKQyRpHCkAWNOT8vH400Q1roUUtZ7nfNE+1GPGOTWglnbxRAO7LtHzZPWllmSVcRXCIMYPHC1UlijjfIuGZcYY+pobuNJRGWVtDNdyug8uJSDk9Sa1J/s6n5UZmI4x/FVW0NpFdSRl22lQetSw3MS3LMoyo6F+1D3Bbaitb3QTbBEqqeu4/dqOa1tEMAYFiPmZj0zTr64mkbaMhmP5ihDKqBJdrOx4TrgUloU9XaxLKxLpHasjMx59hUk7yMDAPlA/vetVnimt7nzBGNnX5eSaSS7nunK+UNy/dC9vrRYV0txssuZUhUguOfl9akt4w0rvLjf8AxEnnHtTsXQtiGiHmkdQckVVtYWlkeN0cED5pAe9Mlbi3d5FFMgiUhEPzE96ZcyRTCOczuBnKxKepq8bCKaFUuyqDsB1aoQltYzZkVmZuE44Wlcpxe7JHt5BAC2ST0XPSo7dmlRxECNucluAan+1STbhF+8I6k9B+NRRSxojtLvcsceWKW+5d0thmnxedHLIQEK/wdc1IsUQkVZiBO/IbHAFRSXbLj7EEKnlgDytP0+5S9l81lJWPILU7dSOa+hOBHY3IQTMxfksR0p8sELOzMS64z6ZquzvLPgLmEcsWxk+gqSTzpVOFZG6IPWga00G2rrDaNJHGAwbO1h2qO5v0dk3R4mPfHSrEEX2eE+bl5jyU7Co7px9j2mMGZuuO1NNEtNIkiuI4LfGFLN1Pc0y9kjkRI84UdS1RJGinaQoXH3u9KyqwWFV2gdSB2pDtfRjT9mEbnPlkdTnk0FUeAeVHtXGT7mpmtrLYXJ3t6ntVWC4tld1WRnYjAx/DT3E9NCpbRiORQ8rIGY/IK0TJBCoUlnVvc0oijC7SBJMw6/3age2m8l0XAQHAJ6tTbuxJOKGRWAdmk2kMzZQ4xU0FlIbkglQD3PWrNpGUdd8w6YCelVr1n80hZSZf9njFTuyr8q1JbqWK03eaxO3gAelQ745FWSNQsfXkdaY07fZAwXzHB5JHNNiuElU4GdoywI4p2aE3FosyRLdbGWIiMHH1p/lbX4UlV7ntUdo8t2rlNqDovoKnW1kIx9pyvcDvQwWupVa6aYPEgXryRVe5guJ9jCPYi9WPXFXYbcxk5UZPAA5pLu9ki2qyfu1HTFNeQmrq7K72wa03cmXtz1qC0tD5m6beFA+5nOTU5vQ7q7jaOgUj+lTG48uNpGjy56AikG5Hy7MxgCqnrRDIZN0hQbAOAOSTU0bvMwMqhUPr3qWTT22H59iE5CrRcaT3RXtLXfM0jBVY9B1pJrcxviNlA6nAqGNbiOd1Ry3b6D1qe3tp97bpQzN3PUU72JST0Dc8ewLsb0pstvNM21XVievHSq9xbywXJ2yARnv3qe3M6oU3qoOee4o13HpsRQ27R70LnjqQelT2ohijd2LE9uc07yo4o/lcsScs3rSRRQAGVj83Zc0n3GlZ2AXCiWMKM7j0NS3cpA2j7x4wO1QzRRkZVSrn+L0ojSK3G7zST1JPNFgv0I45mhGSvAqKW+ZmyHVc9itTSuJWGw5DdsdKikhjRiqAOPUVWhFn0GwXMl6odNyMBgllwGpbS3muladHSKKLKkE5zUtyzWyqXmErkgBQKkLgwBPIYRqMse2fpU6dClfqNuYpZwkTKEtx/HuwT9BS2tnGi74oY28s8erD1qA754zLMHKE/IE44qd49iKUDmUjmMelGw3q72GXOq2i3gJh3yAY3svC086okl2GuIx5Y4i2rnmq9xKscahEG1z8ykdPWqRvES/YxDzUI+6gzgU7Jk8zRpSXCLIXeB5ZWwd/ZadNLaXhSMTkspyR702CZY4GNsrszHP3eKS1vkS5AmjQSAcqF6H60vQf+ImuJysbYDKi8ZI+97CoppJ7gQssTxxKMhGU/MaVtSuLlW2RFmycKBwpHvTIrzU5YlljQALwWfp+FKxXMrkUzM8scd5+5QnO3FXIbxUGETdMOEY8cUjStHCXuJUZ3xgoM1baS3lVWmTcyDrjGKbEr3M9Zbx2fznXDHAUNyPrUyWzPtO4eZj+HoopPs9qMuEmy/OQciltolhFxDuKKTksW5A9KPQe2jIpZbkhU3ItuTkux5b8KdHJu8uNZVkkPAAHSlvEtpxHFbTeZ0JQjqKiaJkYtZxIqj7x9fYUWQrslurCSKWJVUO4yzBjxmq0kZgUSuxB38lTk/Sp5pL3b5cW1pJeDk8rRHZLDbRtKGeRDkx44z60Jg49USuZJoI5mL+UT8qqOSR61Zh3zoVlmEcPXaR8xpum7Yo3Mr/Mfuo3aqV68CKsQmInkOenAGaWmxSbtdjrqYIdqxx7OgA7/WnWbRtgSQxeaCTz6VVltnuJ41hTbEv+sf1+lSWloRI8iHco4y4xx7UaWFZ81yxJPazSiUxhIoeTgYyame5hliNxHbh8DgKKrxWsizAFN8JGfm4P5Ukk09nOEFu2xuirzQGyuJbuVjkmuCyTOeFHJA7VbuI9kKZ4L/xgciqlkyrdyS3SspzwhGau3Ey7TGytvcfIAOBQwS0K0GoWpc26iTe4wHbvQgm84/Z4wyqeXzjNPtI0tpM3CI8x6e1OuLjdIfs+M44VeAKOugLa8hH+1QuizAqJM5Yc1WjzHJKQ5dP4V5G73qSaWYxAMSXUfM7dBUKXLSb7kMqiNcBcdaaQm/Mtwnd+8dwG6bf7tKY1hBDkO7A5JOcUl1arKqzMWAOCB0zSeavlOBDiQfnikVdJjpXicGIK4wOoHX61FNvVDJbr5jquGp1pMkMzMMvuHJJ6Gklut0iJuGM5wg/nRsF76jLaSRIREYwrP97Awfzp969rbKmTzxlVPWo0lCtNI7OVJxkA8VWtY0lneSdSsS/d3L96miZdkjUwsr748LCV/HNRW18YoHlkO5kOFB/nSEWsaneGxjgk8D6UXEVuYVB3nvk9KVx2aIbu5uJLfzYTkufmJ6ge1QWkEm+SabzNoOACTgDvTyXaZBbxO54O4cACrc0wA2OWAxubjqfSjRdA1erY4mOMRsoVwTn6Un9oqEbdtG7hRnJogtFkjbDhAf4T2FIbaytbdlfExz3o0G7k8Zhlt9r7dxOSAetVYYLVZyBtVuvBoe1UlJIUKxDgqODTbk2+FUwEDPzY600Jl7AErNGFOBxk1RnnMriIrtAOc+tFy0UiJuHkoo+XB5NMh3LcCQ7WGBjjgUkEn0JY1l+d5Q24DC454plstwoO6HJf7uetSXN/KHCopckcFBTraWY7mdhG3909RTDS9kVnS68l8RgDdzzzSPtFuvmKVPTC9DVi5eZtiqxZerdqJYt9uDkmRjgAc07kOI+0Y3G5VkKqvYVUmBjvWCOyoBkc5zV6ytSi7SjIP43NOmS1SMtb7ZJAfWlfUrl0uZdpczyFiAeT1birk5YRqhJdjyWpnmSeWWKqCvJGOKbcXjeUrP8AKpPbvT6kpq1iGV443J5aQfxN2+lTRSm5tm2EHJyarB4TL5hO5P7pHWpY7kRybUiJB52haYlvZktlBlzIWconQUJdlJn3PweApPSpxeIsflumHP8ACvaoFtbPDMfvk5JPWp9S7W+EhE7mQtCmU9MdafPO8H3UzIey+lXvOgSJVTAH6mqqujyO0AAdc8k9aNwtbqSQAzKkl0uxV5UEdaS4AuQPLAX6cGoUM1xOd42oOBirHzQMWkG5uwUdaAVmV50IVVjb5x1BolQoFZMFiO9WZtjKPNQpjk1SkjMjblLIn58UxNWGnzdzAOjH1PrUUVpNJJh5Aqnr71Csvk3BCsT7YrShkTG6UkCjbYVubVkjeXbwbMDe3GaWKMJGF4496dNtkgLjBz0qFLqGBBH1I61Ny0lfUaziKASIwGOjY6VCuo4haZJwVfg5Ayx9qfbi1ieRJ48Io+VS2QfwoZlVUl+zxOwyVI6BfpTtdheyGWt2J5PNiUvtGWJ4A9hV9pL25Ui3ARsZD8dKa1/blUCxgORkRr61FHdCa7ElwXiMfAiDdfqKVrjT5SwlnEkJe4czS5/hGKRVjs4WliiQSMDyFGD9amluIUjMhcpvOFKjNVZYJ9paZV+z/wB7PNCBrsPt5p54Q9ysSxD7gUYJNRN5olPniJLY856En3qO7u0RU8kn92Mr3Cimx4vFWXDyKTkZPU+v0pi3LkEciRuZJIkiI+TYOoqjdxzGKNvnSJffging3UUpgt1WeTGRzwn1okimkKC5kRN5wwBOPwpXa2Gop7ilraeMyWtruePqyt3pEKRwFpwryP8AMqbsihopISRHLF5R4CxnFLeQyuqhwjJt42Dmi3mCfkT22oPcKyeWkcSjDKvJpPKXyQ8vmuhPygHGf8azrXT1tdjXc0kKt8xUDPI9TVie9jlnAIcgf6sDgD8KHpsEddyZPKtCHjiQyuehOQBUpkcyBpQqoB92PnHuay0t4y7iUzs/Uc5C1csZpFhk8shlZsEt0WjS1wV72JYJ3uLz7THatII1wAflz7imT3V3NJItrasj9CSeB680SPPEF+Yuh6CPpRJdsw+zRpsVOWZePzo0YarQtDTIpPKa6l8yUDLBWxTWt7eBJZNsas3CjqTWXmRQXkmWONjnJPJxQZUkjYpvV8YUnnI9RQgb6Gl/aHkRqZFVWPAVapiSW7mZNvlNjJLHoKrxSyzyA5IWIdcZPHartqj3AkBRlLc+a/BNPYnWWjJI53RGjCsXAx5mecVDFqm+SMBzsX16k/WmXvmwwKZZNoBwGwKs6XPE58mNEGBkuw5zR5h5XJNRu5GtmZoTuIPzegpkNzFLbMkMcm8jHmN0qxcSf6Upm5t07jvUbxNdxtJEyLETgZ4NLoV1KbbTEkEB3y5+ZwOn41LpNlOYnkuH2KD8qqc5FV4MLcyJIQqAZBz1qaKZkRmBY7eFAPWn0JVr3JruwzECkjiLOXVjy1TGCER7bh1SGMDAA61VjW5mQtcSKmTwBzVmOGOOMmWZ3AwNrdKT0LTv0FW0iDCUSySjHyox4A+lJcqRCDE0aM5xg8kUOjSnbaM0aNyT0B+lU5IbeHyy88xYH5lz1oQS02J7RRbzFZ2DJ3Cj+dXFWAv50Z/dngDHFVJVHWIM1uwxwvNDtKIwXZVj6eWOppN9gStoyWd1MTpbnB64NNgmTyA0wBCckDvVSR41/wBRKf3hxtA6CknaOEqgc+Wo+ZVH9aepN1ctTX5kRMQKzE/KMfdFET/aGBZzEF5ZfU+lIhjRftMMRdm+UJ6e9MuZXAQReWX6sOu00ehXS7FlaaGYy8/NwuB0FE1xlliK5wNzS5pqywoolnk8wqMyE849sVYtWiuIMwrsjPUt1IosK91YoxsBOHSXeWOMHrVsxsZVUxnK8+xovJI43V7VAAg+Z8VWa6muIjLEzMQRwRTtcTajoWJo5mdnkk8kD+EGoppo1gdsbmPG4+vtUs821URwS74zTJJ4QAkmNx4yvagG7la3tZriNBKpUfeG7rViKCRosNtkjTg7auyyMke7cvl4xnuBVZpIIYm8uTZE4xkcnNK9xqKRXhjeKTznkyB92NRVoM1y4dbdlkHPJrPSYhHELnOPlJ9PWrFpdSmPhG29fMPeqaIi7iS5iuQb0MytyNp4AqaW4ZAr2wyo6IMVDOWk3PljGoztx3pwSF41aPO4fwdOaAXZBLfSpbFZSfNk6hecCpLCB1YssmCwwOKbIUhUq4O48lh/DVK1unHmlQcEYVmNTbsUnrqbH2V4xtZ/MJ5JziormO2EYBJ8wcKTyBWMrX8o2iUbRznPWnRNdybg8Z2A9OpIoS1HKVlsXGt7eBVkJVnU5JHrS2sjyhpju8v1AqSGKGO33yR/NjIU1XTUEjjKRrtUnhaZOxZygGI4ny/G4jJP1p6WyuWDnYB1Y0+3u40jzOQmOFUjk1HcyKYstkqf0oC2lyEWkMW6dHaVBwB6Cqdq0TzEqrK2fujqauRTlotsYxHnGemakijitSxznuD3zTuK2zQ4tHG2G9Og7U1ZdyqB1bueeKrwL5rO8rBYyeB3NWxFhlZc5PP0o0Q1djrl1EOxyGY+tSxQqbXBOSw/KqMkbPNgEM/YHpiiBLhpCoY4xhj2FKwX12Iv7PEe9oiWfsW5xUQiM0hL/wAPX0qyysgKrINnbB601bRo3ULIDnk1V7EtXHRwyMM9cngdhTJNkblXgUsO+etLLdOshjjX7vBxzUypEqqJTufHJpeo/wDCUrvSXBKlgd/3jyTUSW9zEpiiRpGIwgbpj3qzY6hcXF82Q0UCj5i471ceUl8RFjD1aU9j6VN7PUqykropQL9njJniKzDGWUcn6UkM8Ms7zqv+kjgKRzirts5kx9oZQTkRufSlkuYIZGjCrv7BTy3vTDRaGRHLLdXQeOQvJu+bP3FFbXlF2EMs42dWx0PtVG4w8flomy3HXZ3NPjkQNGvlkcZ3n1ptCUrDr63MC+XCqQiU4Zzkk/SjTl8qNwW3gZ+WMc1WnlmuYmuXlZI0yAGHf6Uum3MkJ8yEMsz9mX7/AL+1ILq9y9ZxPGX8xDAhOcn7zfWm6osG1HBJk6Bc8Gnu13JIqNE1wzHJ9E/GnrEGmdWCIV4yRyKV3uVZWsYFrYTz3YglfyCfmCjnNdDa2qWsRjluWaYdccYHtVGeFY7lFkn8oE5+TqTU9/iZU8lmijTrIQeaHYFez0GPcRG48gJ05O8kgCrsElrlm2xEsNv/AOqqcqQJbDdG+2T5S2CWY1GmnxAB7pgigZSMdvrRuCui4nlW8MnkoE3d271mTygwkQyI65wR7ntUl1LIcICpjzhMDkCrqpFAmAqKgHzDjP5ULQG2yqnlwAB2Z36iOPnFKksIj33BYzPyIx/WhE8qBntItshP3m7ioGgknVxCpmmUbicYA9qVrjvYkvXjuChmgRoxgKoH3anSGzlfczyKsY27QcfhSWOmbbLzL2TbM/BCc0ksdshW1EnOckg8n8aq/REcvVj2aG23uI1WOQcc559ag3z39uiQsQEbBY8cUNNZXEjwzRbFUYT/AGqcwuWt0gkiAU/dCjAx70h+hPcPaRx7ZoXnKdT1AqtaW5htvNs7ZQ0nALnFOVRZERs6KD94Z6/jUF5eTu5xlgBhVQdDTXYT7ssm1uxEIp33NjOxfX60yK2lSSNhcRs/Ro2P3ahEkxaP7W4Xgfd+8farTQxFPNj+VhncxOaQ99i8bKFXEjsHlP3u2KqzG1UiARsxkOR70WrWlwmTMzRj7zHv7VWmnJkZ7BMjoGfjj2pLUuVkXVs2AwsqFh95eu0U27eLyPkJfacZx1+lQ273E0mJZUjZuoXvTxIFwsm0hTgFDQkNvQrwyLcuIog5MeMknGKvXdsBb+Z5IYL/ALWc1RvJGV0ihTCnJOP8al825WJUUAEDjnjNU11M4vdE9jdQWyf6USJOo3dF/Cop7qI3HmyOqrjOTxmq6xOmA48yQnJY/wAhTpmsWQSXMTF0PyqOTS2Y73QxPLkh+0TQsIQfkI6mmxzxyFxAQpY5Y+gqaCUXcmGjYxkjEa8gD3q3LJY2LqqxIiHqAKdxKPUg015FRkhlVlI+ZmpbUi2kaSCFG3Agk9T71WvUAJmVmWPqoHGantFjkUSsDkgfL04pdLjW9hJ7cyxLtjWJSdze/tUYwkzeaCM84UngVejMckxNyQq/wqDk0gwNyqqbjnjpn60r9GPlW6M8SPd27x2UWIui7sjNaK2qfZUR5AjADcB61RV7iRizxeVs4Cr0pkMUszmS4n2Nnhc8nFVYhPuLNDDBMGSVnuM5G7nAo8qBWDtHu3/eJ9alhtjK587Pmt0YVJ5ccP7iUYjU5BPUmlew1G477PbzwrFHIQvVueKZcWq5BSQKg6KR1qORyZNsZXJ4AXriq93BPEroZ0dccHuPahFPtYuR2FnGivdMQB0XdUdxqyLujjiPlDgBRmq1vDMkam7PmFhgc8LV5YEjgRUCuM5LCmvMlppaEcBa72eapiHcdOKW4e2ZguNgXgHoSaknhWc+ZGxUL0z0p7w28dsHuSDJjCYFKw02lYjM0EYUeX1HJPOaqSTxzSASRnyQcAKOKls3XY3mqzY4JPar0kSsiC2ZVjA5Jp7aE6y1Kv2CWRkkjwkPQIaspaGGFkhl/fMcsQeBWddT3MDeW82ST/D2FSWhn6Sy7I+7HvRYfMrhJZDzHaaVnRRkYPemxwQpKkjqpOMquKlktN6li7EZ4VelMNjOZlMsh2kcBe1G4rWJJbqGb95JD8w4zjoab9rgh5UFpG+UA+tLcwwxRjyyQV457moPs0DHz5W2EcAA9T9Kegne48rc3E6CNlKqM7e1SmxMjO88ygqMAL2qqYhbhDFcOobt3q5aJLLIdwIiXls9TQwilsyCEqkmwZY442inGScZWLIGDhjV9nt42MiqBkYzULJ54wjbC3TjrSuiuVop2EEzEys+45xirkjyONqjao4OO9KqG3i2M6qB37mmXEqeWqxjJFK92O1lYZ9lWPErt07E1Nc7DAGT/WHuay4rl5ZTE75bPJ7VYzNI3lQ5x0LN0qvUhPTREmnW8oy8gQDvzyavSXCbiFA444FQizeOHMr4XHQHrUGYI/lVzj60tyvh0LLzm1twMxmMj5mkOTWbeakJ4xFaygtn5UUZx7099LSeRBdXMkcgGY4v4uasR2ptDGsUO4/xyAcijQTvsVWkuvs0csqgxKONg5LfSmjT5ZCks7+QJOh2ZNPubpIFZLdDGGP+sIHXviqbXd9MgmmysKAhVB5Y9qaE7bG5bpMUAjMYQZG+QcnFVJFtn3LufbnnB2gn2ptulyIEkuyBu4VRzz9agntJ3vA88rwIPTnNTbUttpCzyxRTIfKVIwdv+H1rRQSvFtMW9znEhGMD2qvFai2UybvN3fdyw4+tWILuVwY2i7YVgc5/Ci99hqNtxkRu4Z0ihMnlrycn7xpl1FdtIXuAsZYfL359TU6pMikQAO/Ul8gUx5Lo22VaLexxgnOKLhbQqfY5Io/Md42mBzvPf2FBvrvzo0nUrEMYQjO6mJbTTzMZp1MyfcQDgVZhnmUPHOxBB5YkMR9BTJfkyzM8jfvGTLMPkU/w+9RGGKS1aOZ1klU5LZ61XYF/NWa7LcZwvy8VHp4tSv8ApCqRjKLjOPqaVuo+boM+W63uV2MgwgBHJFRLGRiR5DwcySEdsVqXNjA4QqwRhydvenR3cEihJYEC9ACOuKd9BcupG8UV95bKCEAxgnr70+5cW8aLDw2MFV6kDvSTeXHtj3H7TIcRoOAtLPEIB5UTZuSMOx/xpFepVnvFMiNZ77iT0A4H9KWK1R44prl9smSWRDyT6GoILkyyMiupCjG0cZatGB3WFPtEarK33Qo/maGrEppsgubwqVS2sw0sR+UbMfrUd/c3b7N5MbN1CnOK0Wult8q7oHUZwDyaqXMr+SZcqsjHr3oT1KadivbASho7uQSPyQgX7vuTUywW8KRrcu43NuG3nH1qAM9ozeUrzPjcxPGBT0kFwihcxp/GzjkihkosyRJgzRSkueNz9SPaqcstsdkWHcK2XHTNLaW0GGbzxImTsDHGDV6K2htMCCKM3L925NGxVmyn9oRCWRMWwzkN/EfpU8bsWM0kDqSMKOwH0pl8BEuY4wWRtzkjj6VXW5kuJVkjcxSScYYZwO2BRqLROxI+n3Ch5p5Th/ujuoptvafu4xE4jj/i3d/ep7lgAI5pGkYnDbKs2WnzSSMZfkgyNqnrj6VMpqKvJmkKcpytBEcdoHndzIohUZ4OeadMsQtj+9dADkADtW1HZRAAFc4qZbWEdIk9+BXO8THodkcBNrVnMWzxXBCh3MmeB7e9OutqvtA8qJRguR/KunEMQOREo+gFRXNnbTDbJGCPpSWKjfYp5fO1rnJxzz286pYYkhQfNk9c1beWCR1NzGjzscgDoPrWs+mIqMkD4Q/w9qzpdLjikLtEzNtxuz0rWFaE+pz1cLUpra6Ir1kmBaNAx/2ugqqtncRQs8lyBGeWIH6CpDcrbRYCiWd2woY8CotQvECx+budzywz8orZXOWVt2FxDBJ5L2kxMx4G4VNH5sRaQxsT03etN0trXL3HyDP8RqS6vY5ovItyzzt0J7D1pdRrYfDGfncuZN3OMjAqPbAxJyQ/8JFQ2CMs72wVmA754/WnvaQR3JlmmJdAAiDkA1RPyBt0SAoxUj35Jqqv2s3JnuThFPC9zWiL9oDho1Mx6DHSq8kj3Ehb5ZGxk7TwKN9xOy2LX2uJbc5VY2P51lh1RAwRgGbnNXbFfLQuVw5PG7qackUv2kFwpxz09qFZA7uzKjwvNlS5UMvX0FTIWWxURYZR8vNSlkuZflDALwxxgCm3ZDgtEeVGFX1pKxTvuh9uhMGWcNIP4OxqRvPmhLTW6oiHC96qRTbLmIGMlyOQe3vV+6vZVXcig49R1+lAlsRmPIzcSiKM/LtXqanJgiQbk47HNRQXEUhP2iMMwweexqCYxy3BEbbwOTige2pYgs7YbrliSeoDd6ZOsk4xldqn7oqvLd2k5WJ2K46KB1qS6uxaqvlKXY8BR1FCBvTyHLcXKwhihRVO0DPJp1pesS8kinIGAOpqrHJcZDOu9WGQAelM+2FBl49rDpjk07EqXUjur/zXJwVQHkkY/KprOGPcJNpO/kbu1W7OfzYnZohs6BW5J96JLaYvuXA3dQD0FJvoOMVuybyYQ5ctuYDI9qqzXSeWY0c72OCEFSPHGQIxlmH3vSqxlBnbyQECcDA4ppBKVtEWbqEtHHCgwO/qaVUZU2HPHAxTUmfcRKApA5Y96hW5WKUpEC8h5zQgbFEEYuczO+MZAJ71LFBAFZnUNzx3zVKeSe5ykaEN/E3YU+Kd1VYljIjXlmBp2ITQ+9ihxthjw57r2qCyMzSbV+WNOvrWrbzQgMScjsDVOdrfdsB2k8kA4pXLatqOvJ3Eedu7FVBHlVJAXIzird0+2FdqrtxwB1NVImR03SMAx96a2JluSGW6mvGNtA32hRtJP3QKcV1Nl2KY4WJ5Yn9KfPf3F3CHjKKVJyqnJI/Cs+LWGhkJ2yPtOPLPO7ntSSG5IvXNo08irdkIIsEMoyCfekmvYowXYgnGM8BaV7h3cNOTDG+Mw5+Zv8BS3FtbsZJILcle5Y5VTSG0uhV/tGA7OD5bHhz0B9qW83x+VNMWdM4iUE8+5q1qIaC2i8nZI33gEXgfhQLnzoiDvVgMfdzn8KfmLvEhuEuJLUbfLTPdTwKg0xLq1LyzyqGxhQOgq3blzamTyiyr0R+D9aRGFyMq+0dlYZB9qNh3vYSOaVp2aWdZ1UctnAX8KmsFlnXz4IAW6I2Rj61HJAjeXabFjU5eXbwTUlgZPLKeaqQxkgYGM/hSsraDu76jriGS2mEhiJlIyzgj9KzvsV1NKbkSLAshw28ZzVqQzpdJNMxMSjKrnOR6mmf2qtypW8HlQk/IVU5NCuhPld0TXCWsHlKIvOcn95IvpVW7jYyBofLO47U7Y+tPMU6o0kS+UjjhpCc4+lQSTeSEVCA4PHHNJNlOKa1LlvLNbutnKjtK/wDy0IwFqRnTTmLSyxfKSd3pUsEtw8bPd7GB+VQvJFRXIHkeWtm7sSDluc/WnqxaJDbiaS7hNxDG5JXEcgHNV4ZJI4pIp7jddng8dKuQ3TeSIrnKIDnA6U2O7iu3kd7djDGcbyOpo2HvqUodIFxCPss7CRSQ3y/eNX4YZHfybiYxqg9cH86Zd3jWkSSpF5MS9AvUmppJvOtBJNA22TnAPJod7CSSdiKM2kSsJYyXJwrsd2fpSNOxkSG5SMcbg2OSKgaNGmLQZeZRgBm+VB7dqkkfybfcgaa4xjcetGw1rsS3ESxwtKSY89hz+dUIpkkIVZUYtkKuO1XEUOY0cvJJt3GMN0pYtJhEpmhKpMep3c4pXYcqZUuoXeSJVjAReSq9as2FxbQErO5MrHCe1OFkYhO8lx5qEcLu5/OqUkIgjGZI42HIReTQ3fQcYpalzUPtCKEGXRjwfX61YhtIlKt5Ya4HG7PAFM00qtr5kiF3YdGbJFXLZEiGPug8nNY1avs1ZbnVh8Oq0uZ7EthZxxE7FDSHktitZIQqhpGA9qoJcBeI+nrT/Pz985rgcuZ66nrxp8qtFWRf3RKPusfemhUYgvKqj0HJqpJeZQLwMdOKkj8s+W3XP3qncvlaNCa1hEReEnf796ob3BwcY9KfuCoSSSD2FR+fuO2OMMQMY9aGhR5o76jjIA3PFDMCDvXimbFcjGYj6dRSyq6JgFXA9KSHzJmXqWmxSyLMnEifdrGuLJkt5HuNrsc4wO9dA8gJOD07VVmCyLnjd7100cS4u0tjjxOCVROUNzmbnUU823tpIVyuMADrWxaF0kaYxJGzABcj+dRyWsMKtKSGuCeCegpYrpIo1e6dSV64ru5r7Hk8nK/eLYKld9woL9N6jFVLVLebfjPytkDPJpLmS0uIQ6uWQ9QGwPxq15UDogs1UyAYOWxgU9iLJsqtZ3MsjqJFw3U55xU0enNDOSrxouAoxzVaWJo2KiYRg9fmyRUoeQIZGaTy14Uf3qrUmyRbKQNKI4G3zJ/F2FSuyquSxMg/KoY1iWARRn55OS3pVSUXOGQEtEn8Q5yakrVE+PtMT4UxuOQFHWq1szwxMu1TNngelWJA81qpV3Rx2Xqar2UYR986tucYUKc/iaasiXdtIbJLcBvMkGcDgjvViISOn2jcM44HYU64kt4YSszsWJxtHaktYmRDHCN6vyqt2p30FZ37jGtFli3GXLt1C9aiW4S2LxqmVxj1NWrcR6fK/nyBrgjAA6KKmiEDP56xg45+pqXroWlbXqZ1oELPcIil85CkcitULGkEs0iASMOBUENxAInlWDbI56ntUXlxXDGRpGC9D70xJ3XmRs8vkqyBQ2cKBU8j29rCGnUNMRnOOlVJ/LtlxEcr65zipbdYZ7UNcAtt6FuM07iSZFBKpdntkbr8xJ4FOnnlUgRuHGCWIojgadpViICgYXnA/GlWz+yWvlsu+YjJIo0vcPetawW3mQqzy/MH54oLW8St8gDDnANRq0rDy5U2g9GPYfSm42BcRqY85Z25J/CmRcu2i+au+52qrfdBPUVOrxIXW3RSy9aaBazYaQk7Rx2qJRBFueJlWM9T1qTRLQryTSxAnYQzZJ5qCAyG42sAqdfrVicyXKhYwNpPQ8HFLLprTuAJGSPuc4P0q7oz5XfQQwPLMGjkQhegAq01uhGZI/3pHXFVrYQRS+VEHVl6HPU1DLLM92RuLKeD60hq1tS+kCBCcfPjknpWa6pE5VIiR1yatrDIrYdyikcVYWCEKOC/HXNFx8t9jMtVtHlKkmGMryinO6rkM1sjLJ5IwhxGq4PNVpbQMWllnFsxPAPXHeqkcDtO7LOREnCBB1/GjcWqNC4aK5uPMlRzcAZCjp/hUOoXk0KRrJE6K/WNRwPrU32gxRKqInmOdrEfNx7mqt3qBjn2ySFhGcJgcf8A16SVhuVx1vNciThXWDGFLfxGpfJnggEkE0bSO3zAHJ+lNa8M8sZjkabP3geijuTU9sLfcwgIKj5nkfgfhSZS00C4Z7g+XCu6XGPLBwAfc0i6fJZWypPMELcnHJ+gxUcD3OZSzxiBjhTjr9aI5Ht3MMjoUYZyT936U9tBaPWxDHqVpbXDgxbweDLklmqWOcsylYZBDJ2HJFPQ2yL5kKLEpY/M4GXNTWjlCUJ2zk5+71B7ik0hxcupCsA86N5HxEPlWPdyfrU5hs4ds145ZFPyAHjNJBPBBcSF5E3Yxz19+KguLpPMEVrCtxIDwQcqp9z2o9AtpqNur6VlBjRpiTiNScFadAsCbQ677xv9ZjnaauWUMFsgaR1N2RzjoPpTVhFu7u4AQjJY8EmjQEnuUrm3ihuhGrTOPvHnip4byJYG23LlxwDjmmSpcMMzMjQueGHUUf2fHcYjSVViUc5/iNHqFmnoSK6qxWNWkBG5peuPUVeRhHB5i4Fr2jA6n1rPjDWNoyS3CAMxCgDP/wCuoLmK7VIRHKGkJ3Dp+tFkNya3NKUCUKGkRg/JHTAquzW8aO8Lsqpx854/Cq9tbTXDOZIlSRj98vwKe1qslwsF1dqIEOSuOWNAOzVylF5bSbFjky7cDcQD71pRWstgFLyId/rztp/kC2RpokEkinCAHtUUZkDITJGkkmcrK2dtD1FH3SWHLSv5SAKo+afoSPQU2OUlXU4iQknJHLVWkvJxI6kFgvHmAdT9KrJqrrM4mWSSTGEVUPH1pWZV0h8LRwXIWKF5C/CqxPX1pJrkNdtEFEchOCStWra+X7vlStct95ypAWrcTW88TXAZXIXA+TFF7Ba+xUhWOH7jFgOp9TUqStcPk8ID0qjLIQm4jg88VYsnHljFeTVm6k3c+iw1JUqaSNWI46VOEJAYH2qtAw2nNW1kBGMDAFCRtcfJFFhDGxLnr7URwOSPnwD19qrs5Vj1B6ihrlmJNCsFmaQRETAYE9jmqkzFZC6thh0IquJHfowH1NVZZpC3rjvQ2CiTy3cjuGcgEdhUL6kx3AfeH61VkfKn1rMlnMVwM9DwaxnsaKmpHRITMm77rEcHNVpX8tgD3rKF3JAyuJAV9M5qcXySkluWcYAB6H1qFIhRlF+RYlWOfHmkhOpxWf8A8S9rstNHkhuD1B/CrAfBKN1qK2Vo/MkkTbDEflI716eEq3XKzycyw9mqiJbr7DGfNiyIk5Ce/wBKvRXPmWw4RWcZAHBxVO5vCtriK3YbueB1FNsLmPAhMR8wjOTzge9dr2PJTtKxE91DdS4VMBPvuc1sQtst1YkNEOnuaheC1uoGghGxfvMwPGaqKZEIjXdIAcDLcUPVaDS5XqWJ55fORWjHzdQOgHrUy30ccQgiBIAyWA4qpdpIkJIjLSdyDxinQShIwkkRy/RfWi2gJ6iprDyvIgjAiHyggU+zEswJMaE5OG6YFQyRMJ+nlxLzj19qjmvXLb44ikfTJ6n8Kdl0Em18RfuIFMRjjiGccuao7ngTekgLdBt5P0qdpZxAWY4UjAYg1SS5ghZSz5Y9WK96S1B6Mfbwi4m825iZQnzYY8sal8y4lkzFCVizhR04plteMmJJI2fcSF96tRXLB26lTyFUZ/CncSVkNW0lkx55CxjnHqaigS4T5Nu6It17AUsk8iOpkhYIOdv+NVpruWWRGAxGeiA4z9aV+hdupcjt4WV0twUb1eo5U27R8rS9l9PepbYq+JpOGAxtHrUb+Ys5eNQGPVj2HtTJvZWJEhDR7lkKPnkDkflTDcrbRSmR2aUDlmp1vNE4LxyKWB5LdM1Bco1yr+Y/yn+IenoKFa4SukRWYubrMjOGjUcZH6VLJHLKFIBXvjFWLKNVSOMFgvTGf1qacSNMsUIwg+83rTb1JUVbUzZYDJEVlPI4VVNTW9vI8SLkRhOcGnGHZd7vlQDgFjV17cyRsS2XPQdM0NiULkPlFYyyznPegfaJF74HfPFQ4aFAZiCM4CqeKZd3YDCGJ8SHtUstNC5jRwS++XPYdKk81JJN0KhmHUn1pFhQovltuYDkA9agmbZMoJxH32+tNaid4jprS5nYuZPy6D6VBm4BIUSYHoK1oHd4vkyV7A1G6BGxLu30XBxvqiCWwuXB+0FHTGdy87qgma9ESRs3lt92NAPvDuakhF8lvsldmlbjZj5QPc1ZC3CRICglmPG4MNqCle2hVm9SOK0jvAMhmjRcvuIAz74qM2NrDbie5+ZAdqohIBqRrKWBy7TlhjJjQ/Kv1qGcQm1mZ7jzIDySMdfQUegeqCeCCRswhoIwmcA/K5pltGl1JvjnjjfIAQ81BGzRQBXclmYBEbkBe+auho0dI7a2CZHzFeCaNhJcxLf2srI8Us/lx9mQZzWTDaYgzPdPKJG2Kdo3AfStm6tHkiAuUEKA5Ub8lvrWa7PHKSCqy9BH1/WklcqTaLX2mGzhW1tYTIBwXJBOartcTXku1RLAkfBkUcAfWo7a1vriSWNYoi394NnbVuSzmjSONmSYYAPzYwffFUTvr0AQIFCshjgYfNIRuLCp5rZILcfZ1P2cEYVVyWqCW2WRi890cRchBkCpI5WhjWSJfNZujElQn4VKbLcV1YsMJjnMgiUQgZbf1qSKaaWPfGybWz/rRwPpWNKs3nCOCV5GlP70jpn0FWp0llEYmiMSINoHUn3wKrlIUhyrNJceRAQrtlm9RSRI8sUm8p5ysVGMlqtaZNJFbuJTGWbjceNg7ZqW2hjEThWYIc7pM4yaTHFditaWESpiaTd5XO1fX3qG2hhkkLNCJLonIQmmXce24KLcIIxzhW+ZjV21mURZDLHtH/Aj9aSZTVyEXMnmlPskijOMAYXNJeRpJKC8X75eQvbP1pLoF5xNMsjxDkRKec+pqaHbOnLbG/2v4R6079SbX0IZXmkHnebGskfHlKeM1Qd0e4yJGa9kIAGOF+takiWtqY0Qicsfv9eaS4j8pSm5RLKeNo5p3E0JYSTxNLaLv848mQgYq4s0h3MIidg2tKy8GqQhcSbgr7Ix95DnPtThfvCMyAsmT8hHAFJ+RUbrcd5l1saXYrRscAZxmiRY1i4b94qHKp90UxdSdhkwlY2HCKMsPSqFzM7SMqQTxRqOd33TUS0i2aw1kkOkcNaqoHzg1JYnHB4qosxGCDgg1eI23BIxgncMeh5ryY9z6bZWNKOQhcDpUqy8mqkbYAJ6VJGc9BgVQkid3B5FRhiQeRim49ajUHBH40i0lYlcgDgnNVZnwThuKlkAA5JqpMw7UMpIaznr0qvIA45pxz3qJ29qlq5WxTnjIyP4ais4ZBIr87QwAA7mrTHK5pLaZonVNvzDLHjpnpWbii+Z2sXLgotxhCcHqPSrNndLFv3YORwD61muCHy3WnxYaZA4JHYD1reg7VEzhxcOai0aq3AVgCzTgjlscLS2r4hcogVWbG7GKpRQXts6h9/74Y27clQPWnukvmC1yVtwMl8Yya9f0PmL9WTwytjy3IKqcH3HvUt7LCqI8UYyWACr3qolhmFAzmNG5DDqfqTVtrDbbKzMGIGQRxmh7gloSO0roN4+QjHlryT9ao313cySxwpAyKvU46VJFI0UZaNido5J/pTo8xxtLd7UEvGQeTQlYG+bYuCaLYn2tyFUfL7mpZfKgh81YGZjyCRmqcyqyKA4AH3cDOKbFe3Ex+zmMuw4O4cAeuaVirkd5I8zR3LqFX+FOu406DyYkKSgSM53Y64pLuJlXbDIjeWeeM4NV7KFHu2U7iF5LDjJpt6EqN2XYJEyZgg3fdVeaQZ3BPMwxOSAeRViymJkk3KwjUcAjrVN02zYto3VmPfqaE7jasW5mZXUNu8gfxdzVS4tcxmVEAJ+7u4OKbfRtCgkmlYuOkee9SeajoHuGLPFyVzxQJvdFVy8LKJMCLuRwKlbeYQ7tiPpn1pZrs3SgrBtJONpFWArpEouwrHqo9KZK8ioTDCYmaEJCvr3q7NOWh86G3JiHPpVaUPOm+VYywPCj0q3NeKnlwyjYoHIoGn0KMeoywEGSMCRugJ6Zqw0c87ovm7CTuJX0qCdYzumuFBTjaAKtre/ZrYs8SjcPlz6UPyBdpA8AmnUKA0aD7x55oMkgky6lIRwTjk1XDXE0SzLKIIuuMdac10uU875oQce5NLcbsitIXmuGVAVg7saEtI3iY7SpP8Ay1J/lWkQksTDOARkKKitEkmjkQx7VHY0yUrMr2sZgUpBKdjdWx/WrENkIpN4cvu5FRbZI8iaRVUnAQVLHFcCRYoJAR1Oe1IvqOuJJ4hhhk/whRnFOBOB5qEv3yKcrtAWMoXcOgHU1VeYuxZ2lBPZQcChaiehC+qXH2hYJvKhR+Cqnc2K0Jpre2CtE0S4G0k8kmsuxihieSRIlfJINxIen0qW1XTJGlSMyTXJ+8xPQUAm1uEN6ZGe3TZMXJL88qKjhtoLmTNtG8cYxw/CA+tQobdG8mzc28QPzvwWf1FW7/yt0UUMjlccE8inbXQm+mpebToYV4mkcPy5HArOt3gjmlkilRCvCPI2T+Apk1wI2jt47mQRsPnO3dU62MEqDJQRnphPm/E9qVrFXvpexUv7idoT5l1GznhOOWq1DZxQaeWmZ2umHzOp7elRag6q6wFF8lVwpVck0xYre1uTO0v+jqA2GBPNANq+wh1GSxVVjtJWgbg5Bzn29atKvmrk27xxnnk4JNPhvheXI8gqN3zB2HT6DvVh5FBZJLhii8tnAyfahuw0rmKpLXHkiCaUqcsFHy49zWxHPFPEQQUVRjyzxinQ3YjgeSNf3f8ADtGDSJJM1o08CRGSQ4UEcj3NDbYRikZvlSBHdFdEDZVUAyR61bsbgyW4myfLU7dr46U+KAmCQ/aA0pGJGHb2FVZU8wIjW4SOI4AY5/GgW2rHSzRiGRTAypIeGPVqS33WiCO4aJYAAw3cn8KtRytO4imi3RqpCseD+FZ0rTyXCxNGZGQnZgZwPeh6aMpK+qLUU1ij74AguM7i5Gf/ANVW1vZHb/R7VpJW6yheAPWq0dwllA6MEaTH3iBn6VLFqyNHGUiZFAwS4wM0nrsNe7uMmkmlkcfZ0ChcEnhnPeqMdldTh0WIQp94sG4I9K11PmkowEozksg4WnTzNHbeWsLJB0LYApc1gcLvUyrOG6t1+0SoChOBHHycevvTdOCvPPKbaRlJIDseR7D0q+b1mCCNhHAPlzjJP0olWWZA0UDIinIGMbvqKdyeUr3a3LKqRERRk5VCcE1atCsVsAWM8+MYAwBVVlnJZwU3BcBH5Oajms5v3JlbytoyXz1NA9b3Ekns4ZnDSOZhy+OMe1Vry7YRFiHZH4BLc4qkyL9sdUn85cF5HUcgelQX06y3UkhikVFASNmz+NKa0ZdKXvL1LKEH6Yq7G+UhIOcZU/hWdbtwD61dgl8sZxkId2P0NeStz6d7GpCflzjP4VIrlM4PWov9WHQOQM9PUUzf8+PQVQo6lvdmkH0quknGe9OMpIwOBQMe6gghj+VVZFGe9K8gwcGoZJOu08VLLRNJHGEyrc9cf0qrIBzxUkWH3ZbBxwPWkDKql2/AUBexBMot4gzDLHkCoRG7FZJiBLIN+3ptXtU17G+0zTgohAYA9x7Uy3Z5Y2mk5Z+mewpAnoMBI/8Ar0RyeXcxN1IYUxzgGq8jncMHB7VMXrcKkbxaNe91CR7poHLRMvV8cfSnRuby3MbcsD8rL1P51Qa1muLhYHcBGO4yE4JPtV9F+zvsjfaUxlmPX6V7TfY+Ste/MXIWmAIk8sLH91WOfzptxPcyOA8PJ6EHim2cmBJ5u35jxT51imlRPOdSOSAKTKWiIEhme4VPLBiX73NW5TNOWQwAY43t0x7VHJM8cXl2cTAZyc96DHfXOz50Rv4tpzVNpK7JjFt2QsSkxvtGZScKQOauado0qqXuJm3NyQpx+taVtDHCowBnHJqVp1HAOTXFUxL2iepRwMVrU1Fis4IhhYx7k1MixgfKFFUJppHO2I/MemaltBIQC5CkdVrkdRtnfGEIrRFworDG0c1C9rEXDYAYdx2q0I3AygDr19KjMU2MiEnPJ5pqTWwnGEtzFvNObf5sRDSDkb+cVT2yIpAiAfOTz9410DHjDjB9KqzIrcH8DW9PFSWkjkq4CEtYaMx0LmdQIsO3c8AVWvIXeUxmZkkJ+8RwBVi7aSG4DOMxgcEdc1TuZRPGDMo2Dpg8k13wlzK6PIqx5HyyWo+K2mRfKgmBcH759alx5MZfUFMzjptXrUsWGMQ8rYEHOO1T3MvlQGR8OW4Ve4p3uTy2RVuJd1orpBgtwo64pjRQ7Iy7tnqSw6fSj7ZtjEUUeCeBg5NV5nVQI1VjJ1JIzimkS2ty7LtulCrFnb+R96bEUiRi4+fOMY60+zmEVqsYwoIxuPWop7ZmlRlkLY7D196V+g7faFEjNOHKqi/qatC4LqGRQAe+c1mPG0cyrcAsrdCOi1oxrbIi/Z1ypGSewoYRZUvDAZwzMrTfw89KUTCEk+avHJPrUe2AE+WMM7feBqSGKPbsmTIzwT3qrE3dyN5vtDAwsC55yRkCrkcYMan7QQccgDvTZpYocRiPapqlLqMcL7NuMUrdh81tzQgul8nbbnemfuheKrWtrCu6S4t9k0jH5AcfninW7KjF2c2sA4VCMn61VuoftNysMdw8qMdzsBjA9PakV6k6rE8jG0gSErwwb+M+2aUxysRHcRxxI3HyDLH8e1VtkQk2PKRChwFTlic+pq6BHHcho53d8ZEcnIA9abQk7kV3PBaxNZadDGWA5Y9vqaiheaS3SK1iMsh6v91fxNWoprMxyq4FzLIfu7do/CnRqZCse/7MU5AANK/Qq3UbFZpZMA7QvPP/AKxi2cewpLq6Fv5kMEY244DrgfnVCeF5pJZ3O9UysbDgE1PDayG1dp/9IuJMYC42r7UbiWnQmhuvPgYsFjkX5UdFyWPtUEYltrdVukV5ZDl2kGCKmstQPmvFcIS8Q+6i/dqG+uVuFeSMMfl7qf5mk1dlp8quRPI7O0fmOIj1Ypj8BUqJNaqGYsrHGAfuqKbZvdSxRlVlKplmIX/GpLK6nnlwLWVp3PDP90Ci1gT5nsSWeZZV/fFYgcnjAY+wq5DDLNeySRpI0Y6K/Ck1sQ2yEIZUQuo7CroKqeBjFc08R/KejRwLfxuxQh05m2mURr/sqKsJpkCowVQN3Ugc1bVucjNSDr8zqPqawdWb6nYsJTj0MuXR4TEEU7QDkHAJqiNDMUm4SebHyfLccV0BYZIyDUchx1FJVprqDwlKXQ5u/tZ4rUpbxiNcZYjn8qzofNkjADPPbIOQ4INdcTnOaoXlsJkwCVI5BFawxPSSOargOsGYMkDTJ9ogBjiT7qE8+9Zy3M4kKKZnJJIUnj86vXdvdxRrG1wGy3QJjIpTZA4kviUjH3SpwT+VdkZJ6nlTpuLs1Zmevmy3yqGUkHMg3/pVm7aWZ/Nu2jWFMhRu3ZP4UXf2UxSJGPLQDqOWNUGjL26xIfnJ+VelV5sjZ2RJqE0tzDDb2ked52sUTbwKiaK9WCX7T5ZjRSAqnkcU93uhITbSrGF42kZPPrioLuBbeBjJeMUxmTA+8TUy7GtO17kMBOxTVkSCNgzZ2kEHHpVGF8RrU03zIK8Z6M+pjrE1oJl2JklwOMg9RVlYhlcEkkZOO1YNlPJDOEWF5YyfnxgAfjXWQJBBHHKjqWPO1hjFXF3M5S5dCFICwCqp3d6d5bpGSBjPFWPMZcPn5ie1OScMrrMC3pjjFUTzMyzC23ioGjcBlx1rQcAHngmhGwpAAOfapaKU2ZRRosZBHoatR+SkXmXGBHGM8/xGp5H3rtMRfHQgZxWfLaSTvvuCQvaPpilsHPzbmfcXE19dZckRdvTFaAIEIUYwKikREPyjHsKYzE9OazbNVqRzDrzVSbghhVl8kHiqc5wDQinsakjG6nhZIslQMnOMfStU29t5imT96BzktkL/APXrFgltoYomeUhmAyF6/jV+0uEiiCNJHHBkk4OWNe0tUmfJy0k0X7ZbNDJJEsYbqPWoreRLmR4lH70nd8gxt+pqpLboJll3ZUcqucZq/czR28RmKgTMMYTr+NUQtdx0SSbpFlkZQOF461PYxrZwn5suTliaoIXiRGnldnb5sEjApJL0O2yM5Ud/WuDF1re4j18vw9/fZrG7Xtn86pX086ANbIWcnOMdqWzbu4BHvV23ZMmU8lB0PcVxWb3PTcOUW0E1yFO3bIwGR6GrqxTrNtXGQMEAdTUlkwCO8fynFWI3Xy8g4PfmrUEQ5NMIpp1UqylWXsetTSXIVQAdrDnOetVZ7gBTt4J7+tZ0sjNkkmnsJQ5tzQnvonYB0x23CqcjDPynIPORWfJJ03dKiin8tiGOUx61jKTuaKny7Fu4VZYyrDINZqRRRyBJQNqj5BirQuFZeGzVW5VZPv8AI7iunDV+WXkceNwyqw5ktUJILg3GUcFT3HOKju22yDZAzOTzg9Ksx28gjEMTGOM9T/8AXogja180PIpQ9O5Nerc8Dl7iaeQZWCRJEwGSx6ikWJ3u3Ev3Tzu7mmIkMcO5ZALiRuBnNSxGSIEXRwSOGHWj0DtcLm33KwKlsD5Ah4FZazT24a3jBeU9W7LW1sMVuqxZCdWYnk1VMkU8LC3ZVYdW700yZLXQUwvLCiM2+RBxjgZphX7PBsDkkn5sc0+M3MdsCMFc8l+M/Si98wbQF5PRVOaH5jV94ogl3yBVgj2j1NRwrNFMHuWLqp+XjAFPDS/aNsqsFAwpXoKuj7y7l8wD1oJSEk3SwASOo3dAKW102KOBVkKs3qcVBf3KW5G2MF/Qdqk80MqlozuI5+bFLYtWZXmW4nBIhDp0yByRUdvNbWzTrAJlZuCjHk/SodUuTbXiyQxy+YeiJkpmtSOwW5iW71JVjn2/KIzzTewlq3Yyp7qO5KQwrskHJUcn657VNaAuTFHnccr5znOPYVan0vTI41ysyzOdzEMc/nTbeFfN8sRGOOP7gAyx96Lp6BytO4RSR2Slkk8+Y/LgDH4Cn+YlsZJbi3lMmMlR8wAqF1RmkKSSQopCndglj7VPcRLFbsTOZSBnYw5PtS0Ks7ErXaPCswtt0I5ROn6VTR5DPO5kEeBxCnJJ+van3JFzNHtVUuQvCA8AVLHaqQZYjCHY4OMmjQLNvRkdtdiKVIwVjlYnd6OPxpZhHqMpeKRiicOEGF+hpLcot5K9wjY24DEYX6UPLLEVSFYhA55VOw9TS9BpdyzDm5cPDMREhChEPU9/wrWto1iXA+91JqlbxRQDMKAEjGQMZpXuDvCKNznoK4K9bmdke3gsLyrmluaoYEDByT0UVOkcj9difU5rJjuxa53N5kp6gdqnTUFZMsSp9Kw5l1OtqX2TegiiA/eysx/2flFWUjs87jGGPqzE1zJ1Davy8mmC+nZh85A9BTUyPZTlq2dPcCzVD8iqPXNZ0rWz8Rysp+uazJJiwyzE1VEmX75obY4UmupqPbyKOJFfNVWfBKtw1QtM4GMkVDJcAj5xn371DNFzdR9yquOQCR0OOlcxLbajJcmBVaSMtnzGOFFb7Tjs2V/lVSWbY4YE49jWtCu6bs9jkxeFVaPMt0Zg0+S0nEbHz5JOC+eFrSiiW0UqV8yYjlyc4qrcwSNcYWAmTGXZnwB9KjiuYYrZ4CWBPDOTk/SvT1aueFonYpG5SGSbrKRy+DxmsVoLy5lZ3yYmOWD9vYCtmNIZLYyKsiQg7QoGN3vms2eW1IkUzyD+7GnXj1NNuw4q/UZCeMHtVtugqlarucAEfiavAZA+lePPdn1FJ3ihIXKuSTxW5pt4mAjjI96w8AHkZNTwklxzis1JplzgmjpsW8uNpCjrkHFAigfGyVsf71YUc4XKt9ymrM38OcDvmrUkY+zZvvZoT+8mcr25pBb2sK/MCT15bOax0mcKRknPrTvMKjqT7U+Zdhezfc2ZLpVQgKAPQVmzzlzzVUSMTls56c04MSealyuWqdhXj3dagmXaeKtdqjmAxnFZtlopMMLk1n3jVoTNxg1nXHOaaKRc0y4iSNkuIUKuPlPc0+Sa1WVAEUDPIA5AqDT1QQBmh80kcBj0q1GsCTsqwxrI6/MDyRXswl7qZ8tWj+8a8zRW6sTFiKIFkHyuTVaKWWWUtNGVBBHmt0H0FNmuEsYF+yogkHryx/CmtdXN0hkZfLZRgxDqPeqXclrp1G3U2IzgnrjmiyOMA9TVaJxOxjdvv9/erNopyCevQ15FT35uR9Th4KnTUTZiyE6Vct12nPPIqtbMCoqysmMYoLb6GhHOY4zjvTBOWHT8qgRgY23NjnH4VGSF4Riaepmoolmlb14FU5p2PfinyP1qrIRg4OTSaNYpEbzHtycY5qASHIDd6JCD9agd8keoqGi7EiMFlOCeG7VclPAK8g9/WqTEx2xlx8zd6lyQsYbhsZxULQzlqWFkuJE2xFCBxgnFNQBF8q5lOCMs3p9Kred5b7i21cVoW9zAIHeQGWTGCW6V7GHnzwR8zjKfs6rS6mbKifa4hkiPGUK55+taQRZ4084NhOTjvVO3uY2nJYFwwwPQe1akDeUSsKje45z2FdEjkhZlO5L3Eg+zN04IIwAKtW0ttFE0nlR8DBPvTZ7ZHmAeQRt1OON1VrpyZFjjTC9Pl/nS3HtqV5WNxNuaQ+UOg6AVFNPJCWYKWduAFHH51YaCO3f5kDcfNz3qzDGiQ7oIvMZuu7oDVOxCumM0y3l8v/SZEJPOcZxVyZUjj5IdzwOeBVS5nliGxogM9Oab5Ly3Me2RPMA5XOam3cu6toPhtreBmlkBlkzzuPAp6SW0g3Ou0n2ovB5YK7A7jkntTo44ZkDvtUntin6iu9kRxRLA8b3GLiaTIxGcbKrXHmxySPbup8rBx12ipRE9tOJ0iC5GAMkZPrzT5nTDMsLyTAfOV4GT9aWw9xkq3E9sZluXZmAyfT2xVeORYlYwS7Cg+eRjy3qKtWVsUhDXTARdfLh9fc05ryDzXRY4Y1jHRuQfrR1C2g/zopLKJuBgZAx3qDcy5t3fErHcFA5P1Pao5buIyJiMyysfl8teFqcR30kUpufKijwdpyAT9T2peo79iqY97iRpYZLnOCudoA9KjmklR41WDNup5MZyD7YpYrOCNGWaWOR2G0uDgD8akuWa3AtrWceVtyFUdMepp36Ca6osIZr4BZZREmBhF6kfWoraPy7opz8vUsOtM0u3lu0kukH2cAYBc8n8Kfao8W7zZ/OYn72MY9qxrycIM6sJTVSormjvOVVBljS29xFAzFjumHXjvVOW48mNip+Y8D2qGElzk9TXlrufRW0t0NG3QH5jyTyamdFI+6KZa8YHtV1R8rEYz0rRLQXM0VlhLcAU9UZMjHT1qxblVlVpk3KOooNq53yIo2nkDPQUWJdTuVXkHQmq4fDZFTzWz4yoqiQyEq35VDv1NItMleVm5NNYhonJYAjt60jA7BkjHXNVpvl5BzQwuVJZ2hmB7HrTnf8AdntVZlM85B6Dkn2ptxcgMVxwBjIrOxpvoOgW+nllNuFJOAHduOO2KrGOIERSqxlBJfa2B+tLawyXbOImfchDABsD61HceTPcxQbZFWJiXkzjd9a9jDy5qabPmMbD2daSRanuY5zGiIQmMBB1+tZwt4nSZLseXsOfcir0k0bzJNApQkEeYx5P0ouYoyjRQHEzjJMh3cVpdGKT3MW1ZXkJjGEzwPatJFOOKzbRBFOyb94U4DetbESivIqbs+lofAhhj7k01gcjaTUhyWK1MI/kAA5rI6L2II4yThj0/WpEUBvnBAqURg4LfypzYBwoyKaIbHLFlSc49DTWG043DjigNgjIH0p4w3H8NMQJESPlJahlOQMgGgZQ/IT1pjybm+cEe9TcaJOnWmStnPFN3DPWmyN6UgsVJT1qhMeDV6ZuOe1Z8wIyfXihFItWbQraR7JcXTEjaOcCnSATMFSKR51PLA4zVG0eKFZGTAuWO3J6Vc095FjAdt7Z4AGcn617FLWCPmcQ2qsl5ircxxZTyHWVukrmm3M5ffIFwduDJnrRcbGzE0fnyD5mXI+WqM7u8UjyoY4gAIl/Hmrk+WLsZ0051I37ixMxIIOD2rdQKFhmjJKSD5s/3u9YNlz9K1bCdIJGhuBmB+R/sn1FeQfVvY3bc8cHirKvyKpgJFJiNm2EcFqnjdWxjrV2M7kwc8/WmeYc+9K3TPpUPmYNBSdyfee9V5gvah5eM1UlnAOKTKSGydahHzSKKVnzTYQZZcA4A5zSZeyLMxaVreJiP75/3R61F5jSOzk9eBT7tvJQwxuHkkOSwHRfSoY+mB0qWrGa2uK7AMCRnHapvLLSIJ2YK54jz2+lVZjg8VYW3luWS5ikTdGOVB5ruwT3R4max+Fo1YooYgUZfmPKnHSo1kMMwXBPGSwqmjyCD7TIpBU/c7mgXjXM4d4mERGMDrXceQOuVluJfMJY9wuMYFWmheOJJghYDtnFWUmjihyncfxHoKQyIqo85KxjkAnvSuVypbmfcYkLPcLscnGAefwpv2iUhEtI5BtPJbirDSxTXXmAB2UYAAqHL28zuuck8jqQKaZLVnqW/nmXy5GHm45YdFqststphoZGeT+JyeBU1rPtYKibFkP3iep+lXpO6EZjxzjvSv0Hyp69SpHFOrb2Kuh6kdTSvPLIcpGFUcAYoeWK2jwVdVHcmozqEbndHE+0+vemG3Ui1GOUQjZ51werFuAB7Cq8d7BLaqVVEEPUO5yT9O9Xp03uEZjI4ITcCQqior8W9uiwxwpviG4OADk0kVJmX/pHm/bFt5fIzhUJI3+/0q5aQi2HmGCNbiYnLOwIUU5L2S5sGkMpRm4AxwPpVNLWaO4gR0kkBGdzHFPbQjfVGuZxGyh2DKBwEXan4miK/s5HHmIkarkD0aoovtMs4cQqLcDgScAH1qrc2eXLCMzytnDK2FSpZrFNhPZr811tEkbtlcnkenFPhitoVWSGUB2Y+YGXr9KfaaMTbEXV8AScYyTj2FPS1so51S2aSRk6lmOPxptiirDdR1CPH7h2AAClVQ81Hbsxh+bIPJ5GDVudVXCwFMdWKrtAqpE+5SSwbJPI71y4r4Eehl/8VsS8H+ih8/NkEetSwHkYqNgDHz06AVWt5G3bc8156Pd3R0ED8itS1jDOo3AbqwbV/fmtFJCCOfxFaxZlNGvKgjwSysPTFOaeLYFjUL6msYznPLZpxlyuafMZez7lm7JjyUcYrLLbixPJI60s035VWM2e9Zyd2axi0hd5VCF4qpcOCDnr7VO0mR2zVKfc2SAcDqccUmUtysSS6qv3pHC1T1EmJzHz94n8K0rOAy3kI7KGfP4VkXuRMwJJCnFS1oaRd5DLJpTdP5E/kuFzu68VJJbwvIPtEjyj7zZO0sffFQ6WVbUGDBj8h6dQc1Z/sy5acs00sO84Hmjgj+lejhf4Z4WZfxn8i3qFxLMLeO1tUEMYxliB27Vz881yiuY5ltoicHzFySa3I47OO/VZpZJpIxjefug/1NUtUvILhSxVDcI2I1IGK6kecZ+nnDYdtxB+90z71vQkYFc5ZSHzX3AAhjkDtW9bsGUdq8Wo/eZ9TRXuIsP8/K0+3bBw3T61EZPlxTVbkdazNTQJHQcA+lKIN3If8DUCtkDAJPbihjNyMEY9TVEEh/dsS/B6c0MVAJzz7VD5rL98ksPQcVG07ux5OKGwSY/zlwBuyfrSNKrcAjNQu64ycZ9DUDgcHp9DUFpItFsDOfwqGSQgnNV5JSCAfzqNpMjqOaAsPmfJPPWqM8hzz2pXkwarSyEg9KEOxYs4kZmkwrSA42MevvitSzT7HaOygSTEkgZ4Fc0N7tmBgJOnPpWvZq7AIXG1gDIB1r16D/do+bxitXkWHu547Z7j7NH5hOBhqzLyaZ4dtztL5BG09KtXt5ZRyFk3L5fIDfxH6Vn3TCVVuJDmWRuAOwq6j9xmeGX72OvUvWAG3NX5YhJGfXtWbZvjAFaKsTHyK8hux9PrYnsL+SBRHMu5B/erct3EuJI1Xaf7vasq1WN02yL+NadtZOnz20oHsTVRb6Gc2vQveU/dSM8iomgOevH0oW4uogfOi3KO4p636kD5CpHPStOZdTK8uhWmjAGCD9azbhMHg5Bral1NJgVkCn324rIury3BO3cW9AKltGkJyXQqSSeXkVLFPHb2xll+8clR61DLLLMuYrU8dzTVsXLebdtuYDhewo9DSU01Zk0EnmgzN95vXtT1OMnoaiMny4HSgOcA9qzbGloFw2RirumAuISu5VUHcB/FWbMcir+iXPlfLglicKAM114R+8eXmS9xPzL0sjLul8oFR0U9fwFVprqLcDuEcnZM4p8plklbz05HAGMZzT57ezeMebAqyr0BPWvSeh4a95jVmS4t0JjImXgdxUwWS7VbaT5HA5cfyqu0ciMuxSP9hOKsWEQjaRWcqTyd55pXdgSTdieGJYZ0iiXHrJnrUtxjL72AA6Ed6bL5awl1Ylh2B61Qs1uZQXAPlepPNHmD7Elu8QONrSMP4j0WrdsuIm+ZpEPJJ7VUMbzndHMECcEYqW3ZZN6iTCqfuE4zQxQ7DY7h7jzGlX90nAB44qxCcxjbGCPUCq14iTKVGVx3HQGoI7i5RdiBXCnGc0+lwW9ie3JWNoVSR0zwidPxNRwwzT3Oy6QQxr93JwKPtaz2e2BWjKj5VHDN+FQvPLGgUgifHEcnX6k1NmUpLqXJbbyYWlglikUE8YGBRaFUtVluD5knTLHlf8KrxXEUqiJLgAnlwEPJ9BU6pHHDvdot54AOWLfSnstQWr0M2OR45GZpnntgdzBV/wA8VYjlNwSdOzCzDJ80fKRUUkZjSRzaygscJGo4I96a1tqc8m9lWG2UZORhmA7AUtx6JE8EBjJF5fDf1LKDhR7c1Nc6hEkHl6dtcj7zDk4HXPvUVhBauXkleVJW+6HPCj6U2Y6ftMMMLNEuQ5BPzH3IotdiTSRVgmnu0kitomEUowzHGBU0S+WfLHAXjiq1lPN9jMEVuioz/KV+ULj1qSBipwa5cXsj0ctd22alnGrvh13c5xVG7HlysMYxweMVd0+UfaF3NtHXNGs2shvR8zCGZQ5Y+orjSuj2Oa0tSvavnFXBNjA9Kz4ysbMq5OB1NP3EnIosaaMttMeuaQXHbNVGPXJpgcZ5pFWRbeYnpUHmDBHGaa8gx+FVxISTgcGhgkTmWmRiWcsiOQmMkDvUTZz1qex2xOzyBgSCMikkRLRaE0MiRQzyAkNs2j865+8I5IrX1by4VSKJskgM/wDhWFeNhM96mb6DpK+pBpUyx6kxaUxEqQGA75Fbl3dWygRNM80xHLlsgf4Vy9lKI71yyB1K4YexIroHbS4QzIiruX7q9q9HCfw0eJmX8Z+hFcuskZi8xfs6nJkU9/TNUGhthGxYZucjywG6CrH2yzu2jiCBSD8qIMj8as3WnWgiMvlHzXPJRsGuq9jzrXOb098ySE9dxrdtJMKSeg61zungAuQP4q2Yid2c8YrxKnxH1dLWKNMEOeTge1TKwGME/jVOEoq5U89waVpVUcn8qi5djR3FlGxxn0JxTT5ozjBP1rN+0Ig+9kmozNJKcQRsx9RRcXKaDT4JEgOe4zioJLtGUqpwPrSR2M0wzPOR7L2qVdKtVA3uS/1p2YlKKM6W5VW+8DT0uAw+9k+lW5LOyUcxZPvVd7GEHMTMmfTpS5WWpRZDI45NUnlIfqcGidZIsjBbnqKqO7Zw4I5pFosySZNVmOMkUjOCOKhYnBz0NMTLenOxaUKm8EDPtVm4ugFSGFR9mHLhRjNZtjK6TNscIrDDcckVsmzAHmxNtTqAeT9cV6eGfuI+dx6/eszmETmJ5IHUKcKDxn0+tMvSgmXAxJnn29q0o0hEqC5maUgbtoOMVj3hjF2fKQKC3XOSa0rP3GZ4SP72JqWR5FakJ49uorKshkA5rSAO0Y4xXks+kiX4cgZBwO9aNtcmNRg5A5rJjb5OvvUiucgLxVRdjOUbnRx30anLZORnAqdbhGUkBc+/eubWbHHpwDSC6bAwec9q15zH2R0LvGnzGOPBHWqkssPVEUtWMbhz1P4UvmnkjFTzD9mX57jCHYABis2a4LNgEgHrR5m5eevcVC/J+Udf0qJPQ0jBIMHHWnR8jBoAxx1zRj059cVBpcbIeelT6QkkkzxxMEz1Y1Wk9+lW9KZolkkHRcEgd668M7TPPzBXpE0YlN2fO3MI+g3YB96tS28xcBHw3B3dcCopjBdJvlkEQ9M9ac8m6JN8pjjT+EfxV6l0fPWZI4McqhZi8rD+LjFWvs4JEdwxZuvynrWXaRpJfks5IAyDnpVxrtLSdnth5kjfeJ7Ci3QSfVkd2fIlPksSTwFarLSXBiRGUAucFQcYFC+XKRM0Q80dMd6fDNKZ/ljQMcg560B5EN1CLdEWJnC4+Y5zmoobNJNzecCzHoDzirs6BWBkxnqEDUs3lIrStEQxHyhetF2NxW5ELJlUrGQIxycnOfapgHVVG5V46AVTAuZCCyOiJyFHersZn2/vFAPpupa9Rq3Qx7a9jtZvkkDnHJGBt+gq+sVpOBM/nmUjocn9KlhksZCry28ccyjjaoOPrTLa+kkS4YhpFDYCou3iiQ46EbQzwWxMccCxHhET7/1NT6e4lYosq+ZGuGZkHye3FVLueF4ziJY5m4wWPFRabPuj+zwwwyJkjrj/APXR01FdKWhopcJBIY4bjzAD87SHgfT0qo9xPc3RMUUjADr0UVZi061EiI9sschGWZm6/hVy7uRDG32b5FjHQHhjSuUkjBiW6uZpPN3gLkF2AVQPQUKtsY0jwtvBnLOTkt+VWr0tdxZneOMyDCRZ5J96zbiG7NsLO2KSSORkKuQv1NP1JSa2Qkn2qJne3uIp4ycLGE25FEZbywXxvHXb0oVvs8n2Nwz3Ln94+MBR9e1NztBCnIz65rkxWyPSy74mXLWQeapI4HWtxG+2o1s0qrIi5iDj73tXNxEg5FXZGE6xsDtkQcEd64YSsevNXHeWVG1otsgOCvekt43eRgg4A5q0FM8aScpMON3rVrT4vJ3l0JBWtdyeeyMV9xYnFKLZmjLFsHsK057T908ocew71ElpizWWSQhichRS5S/aFGe0njgEjD5TVfBOMg4Fa7FhbMHOR7mqqozAkRts+lS1Yam+pTwgQkswPbjNOSaSAZLFgegNXZVd4QgQIP7xqlNGkXRtzepqJOwk+Yo3LFnZmOSeTWVdvlSK0rnPNZN10rK9zpgrEGkTLFqRZxnKkD61uJNbzJKGjhaMfeyBnNcxCjvdARoHYg8E4zWzaxuqu1yI45F+4qDdivUwr/dnz+ZL98Nub6C1Zo7KEFSvZAGFJA8kqhZg8ESrn5jyxpJYkjujLcfvrg9GUYwKRtSubq22iBpGVTliuAox1rqex5yvcxrBz68ZragcMH5wcenWsfTUwBnPI4NaKQZmYIW2+1eLPc+rpW5Swt0NgGN3bFPt4llfLuQvZafbWapgrlQR9c1cFqqDevy4POOlQkaOS6ANPtWTnIY9yanihFsDhvMHTGMGhhGF+ZufXNEV3HbkksGPqRVXsZu7JUmdgVSNk/3qa9vO4J8xcewqvca3Fn5uT7VSfWNxIQPg9hSckNQl0RPc292GwpVyfeqE1xPC+2WNkA79RVqLULhsCOB2PqRU32dbnJvjID6YwKVk9i7uPxGVLdiQMFIaoEVCSzHcccegq/daXbBcwbkzVFrSaFSQQw96exV4vYinyCDniqznOatzBiqjb83sarSLgNkjNITIIUDzcjPoM961kcoqLE7C7fjB5CisyDHnLnOCf4etXJY7hGLW74QjO516/jXo4V+5Y8LMY2q3EktpEkeW4cbcYO08tWcGLSYJ9wPSrlwksls3nSL5nQFKoY8u8KkngD73XpWmIfuGeBjesb1gMYz1rVhjyO9Zdj91WIJwa2YiOOQM15Z7+xIkWeabIu05zkelWI/u5AI7GmyICc0yblWQnaSCT61Esm0kVPLGUUsRkdKq7eCccZoKJkYF85H+NSFgRx1Peqqtkjj6VKHGQCCKLisSjJ707llwD+FN+7yDTkJJOeKQCqpA9/SlBCnk0xm45PNQySc4FILXJpOSfb1pbSQozY6kYAJ61EjbuM8+tOiieWYLGwVjzkjNdOHfvpnHjI3pSRoxJHIm6WEbgd3IqyLeIKskpVS3Qt2qFhKhiEQhdsfMAefrVqIG6jLTquxT0BzXq3PnOXoPht0hilDKGz90jjNU4oJJpyqDLn+8eB+NT3MzxKgZgIjwBjrUElzcxxgyELH3IABppsTiiYK1tdBZS0jt029Fp1/bmLMscsgkA6NVUhpTG6t948Velje4jAl6qOQvU079SLbohRP3QnCNIzDlhzirls8R2iZmaTsPSqtvK0c+wsEi9CatNHEZvtDfIgHGDwaTKXclvr027biuQPSqqR3Mo8zaqhuQDUAH20SlX4HTB7VLD58MYRQjj+8WoHe+pRa6lSWaCzgiaHks3JPuaZNc75QsMh2gDEagjcfQYrVmHlkPa7khRSWiUDn8aZZXMEm24dUtfLGEyetCYOK7mfaWZu5JZ9QghBX7qFiTWhLbu9sqrbohU/KBxj6in35PlmeNRI3Xft5qGCZ7oLFIWTzBuODjaPeldj5UtBEunLPFcSoAgzh+tRRWhciQXr4b+Dy+AKiu9NQTeYlw0ihsLGRgfj602O8kJeR2XYvBbHJ9ABQHky5stjK873CFsbRvUg1Es6RWrQ20m64foF4/lU6WomVnupxFGBkxqRuNUC1kUYW9wYEXqqjk/jS1b0LVktSjFaXExZwFyGw8sjjGPYU8YTcoOQpx60z7ern5l/dN9wH2ojOewGT09K5sXsj0MttzOxaib5RgVMx4GB+NRQjnirBTABB49K849lFi2nIwj9K1IblEXKtz056Vg7Qx5PApwfaOD+FUpWJlTTOgadQCrIjhuoFNWS3Ee3aACORWF9odgcECmO7Do2celPnJ9kbe+3U4JGTUE98kUfyflWO87AE8D3qjI7OeWOKhzKVI0Zr8uWPaqm8yHJNQjLDHapoUKjk1m9TZRSIrgfKayLrpW1OPl+tYt6NoOKRUTLEvlXAIYg4IrVgncAqspR5OMHmsORwk4ZyQvIOBmtKIWskW23wCPmZiecV6eG+A8PMV+9+RYnt0WIu3mDZ95lPLn0FZtzJdTRSPAxRcYMefuqPX3rRhurZGQWiPcEDJPWs3U5ljUCJdsk7EspHIFdd9Geco3kifT0zCozzxWoF8rGV++vFQaTEQApTJIxitXyFMYDxtkHivFlqz6mGiKgS625VRg9s0sEd85bYAB/tGtO2t5kQlVH0J5q5HbykBXAwec0khuRirpVzISZJgB6Cr0GjWmAZjI59zV4w+Q2Vlz7Gk3Rg9WLei01ZdCXKT6kS6baRPujhVhUvlxBhiFVPuKaPtbEbIiq+pqx/Z/mrumnYH0FO76EWXVkT3CRcfJn0FVZblHzuwSavfZbeNuFXjuahmVOiFRk1Lb7lRUexmSCM8K2W/lVS4dANucn0q/NCGY72B+lQrEoJ2gD3qTXQxhE+9iUwuO9V5Ix8x68VuOGw/ckc1mzR8E9zximgbMNzJHcJ5eN2eM9K0xJKU2XChpCMDB4qtdxYiBH3h0qKQ3s9srKwVV6A8ZruwrVmjx8yi+ZSCGKZrmQCM7FGWOe9Z8Um+8kPzdf4qvTPJHar++VZc4Ydh9ayrdtsz7jnnr61rifgMsv8A4jOnsX4HPFa9rKWILdDXP2TjaM+la1vMAP5V5jPdsbEUvOF6Gp1OTkYNZMUpDAA9KuxyqDljTTIkiWUMre1U2CLknJJ9KsyyM+SoGCO9VWjIwd/HfA6U7iQhiGAwPNCEA89aJLpASq4B9cdaid1OCWDH2pXLVydyecEEUCReM8VAzcAZqKRsqMcEUgsTyyLnA6ZpgIOearCQc9R701ZAr5PINA7FyMjeOeD29KlcvjEZCt6ntVLzFzwTVhHRyPN+5/F9K2ou0kcmKV6cvQ17SVLa1zbOryEfN6mltI3WNpVkHzfwUWEcMRWSNgFPTHem3UkTXBG4L/tKa9hHzEtNSwLwIgiuIWlLfdJ459qiS1QtvMLSk5yGbIWpMxw26RyAyHOQcGrBkxiPy1VD/COtBSb6sprHIuWmfIIIVVHK1qQqz2a/ZmxKw/i5zT0ijZiuVDgcDuBVG+vZLIL5S5YnGcU1qQ1yu7JIgDIRfqEVON56sfanXckUUXlhshhxuPQUy6ZHtEmuyyvkEbeaRZLe6UhVyAPmfHFPzYmnqkSWqxfYdscmBjkgdagQTMv3VAzxx2qS1eO1LeWpZD91QK0UaVl3HjPIAHQUr2DlTKMqy3ETwWasFXHLZAP1NUrXT5LreokDOpwfkwqj2rStp7pY2iWRt5AzgZH51Vnu5YGigmaKBDy8qc5oRTSerJpNNKxRh7wyhDxGmFB+ppb6XLotvCqzKM7V7fWq32uzZXeBz5anmVzyfoKFm8uN2jQeUMM5b77e2DS1K0C0urqa5FulsWmOSzlcqo9quGJGlxIheVfuKVAANPtLu5eMra2qwgj5QXwzVkXzTx3Bedm3j7zRnODRuGy0C/juhdKXWIYGd5zzVMWGn+fFDI8wunbedvT/APVV1fPvHWF/kVOWQnczd+T2qqwna+klWJ0kIwi8AcetPyEu6JbuFI543uBnaT5SqOv1qsCXlYtjOcnHSmG6u7cStIFMwOPm5HNNtHZgGfG48muTFK0UenlzvNmhEcDFWNx28VUibnOKmEgz83Fecz2UgOTyKYSe5/CnNICOB070hTcucjnt3pFkUkmDhBmlTpk9TR5ezk0oBPI6UDIny/GKaIxVhgNvBqM9akECoD06CnlStKBRIRt65pCuVZ244rIvyMVpXMg5HSsm8kGw0i0Y5ETXIE4JjHJArR+z24CE8o/8KHk/WsO8k+chs9O1W4DNHEED75MZ+QDivSw3wHi5h/F+RbBt4ZJIXtnDOMIqN096a7weUI4BliwXJOT19apwOu9mldoCWP72Q4yPQCrAaPy4UgjYKXLCRhy1dFRpQbOGguarFHTaV99SFBK9fetdHjI2vkc1l6fHjBzjIrYhhiJ+evHbPpEh27HETg/hQiXDDe+QntVtVhT7tWVmwuFQn8KAb7Ipw2ithlyxPc1bS2mU8bB+FPjuCuVWHGfUUvLkF3P0AqtDN36kZinLczAfQUp015RueY/hUjSnoqN9cUCeeMZCDb70adQs+hVfSowcs7n6moZNOgyRz+dWZ7h3ZQGx7VCyuTy/JqHboi1zdyhcWChTszWeYvLbkMfatuSKXqHzVSSLn95nNIpMzJeEOVwD1rPuBgjI61uTRBhxjArMuUzyaZSMm5XKD6ViXssm2NROMZ5XuAK6C6G0HArm79VDli+znB+ntXXhJe80edmUf3afmPmkSRcoFZwOGIzk1lQbvtDbzzu5xV+SNltlMYURIM57ms6zO6ckeveurEfAcWX/AMRnRwOFjU4+taUMoKAd6xY2xjnvWjYoN4LMdvtXls99bFlZscck+wqwkzZGUcg+goNum7em75vU5qzb5CFFUMfeiwnIdA7tkHco60/zIVTBfk+tN+zzK3LDB7UoghU4eJST1zTIuisypK/yk/UVFJG0bEAF/cVoGKFgoiTb+NPChFwBlu5p2Hz2MUu68srBT3xRvbHXNakyAgg9/esxoVVjyyjtilYpSTI2lwTxwaZ5nRicelLIoTG0lvwqEgE9qAJ0bLd6v25BkGSvPXd0rMibGAcVehXcNrAkEdBWtL4kcuKf7t+huaWqyxEI4Ean5uMZpdQgtosPFhsHoelRaZJM9qyvbHjqOnFaX2KA2wM0nyH+HPSvXTsz5lq6C0umupVUgHYO61BqWEuwxDKT+GRTntSuzypnG08KMYI9zU95by3Vqn2l1jkHTHNUmQ02ifT4bdlDoWeQ/eYsTT7qKEhlCne3QGobNFsYcTFpFb+JR0pYEt3ZpFmLOeu48iku43qrEunyAReS0Jk7MW6CrKRwCTyvJCxgZLDgVWtVjAZImdhnJqQmSQtg7VHGT2p7gtEivfwyxESQMWjzjbjHFNcy8bWKcdDV6F2Hyu6eWOhpp1QhiEt0lAONwpD0Iy0uoOygPa26fxIACxqnJYSW0JEqSzyS5+ZhwFq7bTzuI9qKo74IwKZMLlpd8zuAvUk/KRQtGDV1czCYxCsq25cINoyOhqyzytbh02yXDHDEdhVmZ/OtoYopIXU9MDpUFhY6amWmnlaQj5lUlce1O4uVbXIrRrkvmQpuPA9gKfeLACoMToM73GTyfXNWmFkP+PWDcy9G38D61Wlu7fzD5zvcOvAUHCZ/rSbZairWIJW/0MuFlEsp+QRggkfWoETUlUiOWNI4/wCF+Wb8a1bm9lilDXIZIVUYG3IH5Vh32pQXlw08bMEUdCdu40ikgMO4TSPcILokAKBkA1XG5ZGV/vAnP1psd1sm86VUMzHGF7UzzN8jOD1Oa5MU9Eejl695svb8AUbzxk1VDEEZ70u455Neez2oot5zSo+GyOtQh+gFSpktz1pDZKckY70zLLkYqYJtG7PPpTGRmOaGJSI03ZyelPxzxTlyOAAc1FPIkfA5NAXuLJKEGCahabIwKpTy7nyajE3PBqLlco+6fisi7fir0shKHmsm6bg5NBaM8SAXqkoHA6qTVmaeGBlaBljL9gefzrMky0wAOC2RUotLlp1Xz4igGexOK9LDfCeFmP8AEL89wXRIPJNwd2cnt9TTtOkkuLkLKcqn3cdB9KJ50QxW1s23cPnY1Z0yJvtLbgQBgDIxkVrXdqbOfBxvWR1VhEDgBjitiCPyz8wz71mWQKqvFakeSOTxXlHvl2IpjoKt/LgFe9U4o0A68/WrSsVXAK4pozZPEmTkE04fKTuAx64quCT0c/hUiqD94kiqTIaHSMuM7gKry3Ee3G4GpxbxnkjIpktvESdqgUO400ZjPCGz1oEu9sonSr3kR7fuLxTQsYHIArOxpzopEyEHjFMkVivbNWpBH/CahcZHUUDKMyARkHr7Vl3A7Dmtab61mz9TSLRk3K5UAiuWvvMF7tEatEOSzdq6u65BrltTl8u9VOm7uegrowr985Mer0WRXLpDAwGZFbk9gKzLQAysRxk9BU180gciWQCIHOAaXSozJIGHPPeu3EaRR52A1qM6GxhBAEwyu3oe1WoYwkhikcDHQ+opba2d22tkFRjirZ01ZW4YjaOue9edue6nYeHH2ZcOCUP3Pb2qtPqka8FWXnjiryaVAU3bpFcDOM4qeCCDYI/KUv8A3qSRLa7Gb/bHyfMjAZ6kGmf2wryAnBA71stb/aBiRDtToo70yaGEsqyWyrH0zt5qreZHMuxky6vDt4bmq51lMY5P0raW309XO2GNm7EjpSEWsZI2p+VFvMpSX8piNqisOj47cVH9v3kgq3HtXRCOFlACpt6jFU5rJCxYDac9aVl3Gp+RkGZpDtVW3emKkjVjw6EDFW5Ldun8XZhUSq0Zw5yD60bDbuQMCrjHStG2mMeHVSSvYVnyNlzg4q3by+SA47VrS+JHLif4bN2HUmeMSJjy2HzetMecPaZ3kvnlT2p1vdwBAY0DADLALk0xBHLcGe1iKk8MjDGfevUR849wadZwotGYuvJx1/Cta0iLpzM3mkch+1UAJVyYogrg5ZlFWYPOUtNOq4YY9xTTFJJF68iIgGJ1xjBBHU1RtYPOlMsG0sOGA6VNHEJSzrGsmOzN0qayhNu7yFwsbj7qc4qtkRu7kElzPC7oIwpPI71ftYmltyHUqx9BwapvxchlkDwdT61YudUWEbQrA+/FPfRCWmrI7yCJFVEJCg5bvTjdRrgLbHHt0qnbTlJGknR/LfncRVtJrfH+uAHbin6iXdFI2zxMQUkdY1wSzEY+gq7HawTwwpmYQnqrv1qO3vWuYzHcfM7nCk8Y96lkK2yBUZQ464jJzSfmVFdiQm3tm22iIqoME5z+AqNbODzDNcKqs4yq9fxJpk8NzPHGywMw3DC8VJcx3Vp5RSWKSduNpPA+lT6F+bM65jMTTTOEG44SPHDVdmtIntYUnAWTOQYxgjNSvIs0kYvAnmKcBVbvWZe3XkXMjLG4Kjbvb5iB9KfkJJK7LGrTmytF3SGVQed+OaxktrW5YymzjVTlt2/BLelWisdzEoVn45cMnP4Vet7W0dBcTK5OPl3Nx+VS79TSLXRmHbGGzhl/c8nOWDZqrG2ecYBrV1qINDGwVA5GEVRgAVmooxjvXJitkell3xMernJpqyAtz0po4PNMKodx3EHtXnntJFqNstn0qwJODjmswOyDGCfpSCYs2wEikHLc01mkyPT61OZJiB8hI9qqwIoUfNkmtC3t53XLNsjpoiTSK5uGI2hTTZZoY4+QDIe+anmdIcpHhvas24gEmWLBT6CkCsypcShiTUEb5XA70TwtnAPB71Gym36gk9jUmytYWZtzhBx61RvNq7gOautFIiGRsZas65BAYsMUwuY8mTcKFGTnoKRl8iUvK5DE5wOT+NDE/bI9vXNSzwzNLnMQOcY6mvRw3wnh5j8aL+mSjzGUxARv36mtfTMmdySxwcDd1rnbeeG2YqzTI4PJxxXR6LiQb1bcGOQarFfAZ5cr1WddYAFRxzWpHCvAbqay7HKgVqIWYV5p7Mi1EiDgipQ6KTxk1XTp8zVMgxzkVSM35kquxGUjpw8zuQKZuAOA3PtSYZm4PFUSShG678VG0fU7yfxpGAHG+g7Qn3+aQIhkgJGRIc01YxgZpzLk53H86YQOQCaixaY1wgPAqGQqOcU6SPHc1AyknjmkykQTbeorPusE5FaEykZzxVCdeCaRaMi6GM9s1yusMUuAQM8EYFdXedDXL6syLOu84ZuhrbDfxEYY1fuWYU+YVzIgZyeF25xWxoEZ2ISBzVG6uJjnCbo8Y3GtzQYQYkBP0rsxUtEjgy6GrZ01tiOVHYDa45xVuNH8vem3HQCmWiblAAAYDFWVt5AR5Z257V556xJAk6gMQAOmTT5YvNLZhRpMcODinJbXBAHmgE9iKJLC7GNtwD+FNJku19yslpPEy75/lPcc4qT+z1lz5tw7D0zinNp06n99K4B7gZFOGltIcLdtiqt5ENre5GunWaIwwGPqTTDp9oh44HtSTaPcA/u7vJ9xVOfTr9R/rQR9aWq6DVn9oJ44YCfLcc+9VZZ1GAASKGgltj+8VWJ79asKoOC5VfxqTT8SiZ+6o2aqTFnY/u2ya1n2A8YxUMiZXdgAUxGUIWB+bqe1XbJ44plaUAr6HvTWXnpREhM6/LuznitqPxI5sS/3bNhRGP31uVhG3kVHFb3KxGUS+YH4LAe9UmjMcTN9/ccbQc4q9pkkpdonaQxgZyeB716yPm3q9UaVqqArFuYMQGPOBV0qsS7JVVl4wWrIt2EPmPkeYTgZ7CpDKJULTZ4zjHf3otdiTSVzQNqsbs4kIVuoU9Klt4FKO0NwzBuxAFVbRVEI3EnaOinn8amS5iiRlRWJHPPUU7MNEMn8qHYiAh85LGnzqu9S4RsDhs5Jqjc3j3iEnA2/d+tWNPtmcG5lO6UcEdqZNr7FqNM2uGYbuQA3FJF9njQI0AYjvioFMst+ZJBuiX26VO9gsrF98q57E0MF3sPe1tWtlnhDIc8liM/SoftceoxXCMJFjU43njOPSotRtrcsBcPIrPyUibGBWjFaWiWsUQiMiIMqS2fzqUzRpN6GZYxXm3MNw8ZP3VYZGPU0kunXUUgnuLrdKepC/KFp0lrf71MM6RQhifmOSRV2K2n37yfMjT7xJxk076i5NLFeP7KzENFuL8eaxxg054drbIzGM/MXPOfzpl1aTXhfymhWTPc8J9B3qG1iSylVLqWW4/u7aQ/JjrhJZJnfyUKKoyVOM+tZ00T3V7DAYWVGHPzH5QPpWkwt3LTMJ9zHiMvnH4Diq8ZmNxN5MZUkAGaQYwPai/RlWvqiCaCwDNHE0yOgxt3ZqgkYJFJPazNdSyqxMCY3MTyxqxEhI61w4t6pHrZatHIhkjRUz09RUS28jj5E/E1pBcccYPWnysifMnK91FcJ6t30MqG2kY5f5R7VditowMY5Ham/ahlgoOPTFAuJCBiNyexxTuNpl6C0iyGbK49DS3TKq4Wb86p7b2X5VjK+5NV5rC8YEu6gegNDv2M7K+rElYgk71/DvVfeTkAfMe5qP+zpN2ZZWRP51KllBuJadiB71Fma3QsJjUlnYMw9aa4V2yRwPUVFJbhmxbIz4pXjm4EpCjuBRcdkRXZ8yVUB/AVl6iOSB2Faw8tJiUPIHU1l3xz5nTJ4oHY5yVilyrAgH1NWPMcMHJ3OBy3pUNyoWdC/TPJp0N1++aFQWhJ/hr0MP8J4uYW51clklMJVXIlaTqXGcD2FdZ4eUeUpUYXtXOhBsZRjee5HKiuo0BMWyfSjFPRBly96TOltRhRkVoxOVXFZ9scIOOa0IcbfeuA9Nkql2HTFPSInqTmkAJHBp6524ZuaaJbFBKdQPrS+YCTnrQhX3JFLKysPlTn1qiSMn1FOHc4xUYV+zY9qcd47g0gAsw+70qIls9Ked2TyKYxIPJzSY0NYs1QsT+NSMxB61G/PPepKRBMTiqFwcr1q/IcDmqMwHJoLRj3nQiuP10F5VUAn6V1+oe1cfrchS4UBc5HXNbYf+IjLGfwWZj7gQD8o3Y2jvXXaIg2KQa5EOHuYkDEgckHsa7fSQuxflrbFPU5svVoXN+0iVsfP9K0o4yBgMTVC0UE8DFacUbAghsVyHcya34bE25h2FWGCjBRJM02MFTkuv1xVhJcjlgcdgKpGcisxlP3o3YfXFRhdyYaNsCrbSO4+VWHviq7iYnBZgvemSRIkR3fIR9aZJHG3VRintF12zOfwqpJDJnq5H1pFJJjJYoV64P1qpL5AB3BTU0kZySYyQPeoXjjPJQAfWpuWkik5hDZVeahlkB/gYn6VdYL/AA9aryAk8jAoRRUZSRvPHt3pYiY5FYdqm2gCo24IbFa03aSMK0eaDRat3E0TC0zHJ/tCraXMyiNcx7wOQe9ZUaSQkyLKPLbk46ip4gjAm4yQ2QM8HFeskmfNNuL1NNApuT5gWVmX+H+GmG0mW72I6pH2yMk1VtCIGaWCIyM3AAPQVfALwpOpXzG4IBzirWhm3zdC19nDq5dyjL/Epxmo2Zo3VUlyDxz1NM8u4VT5rqyA8betWrZwi7QnX+M0xbkM1vDGhbLee5zwOBUlifJQGcr12hicZqZxFcyFHG18ctnpUc0P7swxkTE8gelA9ehYhni83Z5gGTnA70yefdIfLcBRxzTAsdrGUllXLD7p6iqr3dvEQriTOPWhLsKTdtS7dXDSiSTyY27Agg/jUcy3QtY0WSCMsBuY9QPpTYhILco0XksvAL9AaqXVuEAuZ5/MjT5VK9yfWkXdlxhCt1GIp5RtX04J+lVLu41IELGi5fkHd0HvRYYeRQLgNIOGeTnb9K0wtvFA+1/OGMvKwxjPp6Unoyo3aZXgMsUSoEzKR8879F9qL2OSUZlk3OeECtgfWoRbW80Syea4hDZIH8WP6UXVzI7kW+I7fGCCn3vxo6h9nUzH/wBAuz9mzJhfmYEttqa2lu5LclsyRk7mZun4Cr2nxQwbgEChlyRk5b6iqBhaa/kP2jYoGRGeRj6U7iURtw8U21I8rt/hz1qeKPahwAcjpVaEeZIzbo3bcQWUYrUgiBUetebiXedj3cDHlp37lbYCoVgVNWkgEa7go54xUwUMdoXNOFuwz8x+grlR3MrCGM8ttBHIFI5dzshjyPXHSr8casPkiy3rUqxTjoiinqSzLe3vMDoV9qTyroLkRD65raCT452gH2qNraSQ8yHYPShoXMZAtVZd10wJ7D0qOSG1RPurmtV7BGPRm+ppn2CNDkgZ9Kl3KTRkAxIoWL5fcCqsyqykD5mat14VRSNoqjceVHzxkVLZat0MW5s1iQgD5j1rFv4ljTB+9610VxITkgEisa8TLMSMnFCfY0V+pyOpIVKn3otA6oIxtXvuzk1Pqow30rMtrqRZWXCtF0LMOld+Geh4+YL3ky5J50kwDSxoF6Ac5rvtFXbbJ9K4MmLekcSjORlwOK9B0YfuUB9KMW9EGXK3MbtsOlXVZRmqUA71ZUgHmuE9Fk4YkDbUqjpuOajUjGRSoSaaJZNyBlQKaSWIyaQZH0phGe9USPMeT1o2/LjPNBZVHzEVGZYy3DCloGoMvqf1pmBnGf1pWeNhy3NREjPytUjQsmB61HnJ4NDbvXio/wCdItDJjgkGqcxqzMD3qnK3XNBaMvUOh5rhtfmSO7TdySMYrt78/Ka898Sswu1IOAvOfWt8N/ERz47SgxbQtNdJlcYGRXc6SCEHFcLo5d7jc7bjgdsYrv8ASh+7WqxD98WCjakjftVO0HjNaEShh8xNVLZcqDjFX4Y0I+bJrnN2SxxwgZLHP1qVHVGGxsj6UmxU6Lu/ClMrKBtj4+lUtCHqSrcnngn8MVE8zEnCY+tBkkdc+Vj8aidpyQAqD607smwheRuPlX3qvLFIWyZuPpUjifH3Vqu3nk8gVLKRDMrDjzCRVckAEFMmrMjSAcR1VmkkB5jIpFojd1zyuKgkIZjzxVgSAn5hio3KZyMUDKuB9aikHWrTADpUEgzVxIlsUIIftEzgmQL/AHScYrcht7Z4UNweUxwDkms4Qxxws7SEFvfpU2keUcMSGJ6gdMV68drnzE9JNGhMkKhWtZmRWH3R/Wn2n+jKwuVZt/AI6U4WhkldZAsakZRQOtSpFJHb7HRpMcZ/wqr6Epa3ZDFJHZB9rNJE38OCTmn295LHKvmRMUPbGQKUDzIyiFVU/wB4c1IIIrYB5DLIW4PpV+pnqthzTRozSRQFk7se1SbWjQyW+I1fnfjvTfKUwMuS0bDOzqRUEO6eAWzcKp+VX4/KgFvYeLNbyEm4IMo5VgajeygLHzny44zkVo26LbrukXaqe/WqEt1JcSNJb7BGTx8tOLbCcUhbye/kQhlDRucKpTH61Jb2TMivcA7U6RKOPrU28rukjLKc9NxIFWkjlkV3ExQAHhR1rPmN1T1vcxb27gE7Ksoi/DFSWmsSG4SFVQxNwAeCx9Tmpri0t5ofLeIFk+beSSSay9NSN55yyL8h4I6/nTtpqJb2Rrvd/Zr9F8kMTyxA+WnzahFNKy7vmQZyuODVeSCNbHdHvR343BuarW+miyMjJKWj279pHP4mkmmNxaYLp1zKXkWQySv8pI4CiohZxaa5RT5pc5c85zSwX7TxTEKUVR91XOKpX97JHIYYwFG3lh1JPvTSE2Xbby5JT5MXlKpxjuT61pxjgYrL0fmBCSSTySa104ANeTWd5s+hw0bU4omTHA6VMqxryck1FGxbg9Ksrbrjvmsjd6CI4/gjOacslwxI2AfWpYjsfHXFLLOxPAANVcj5EDRXbckqB6UCGfbguAKnVHbrIce1SrbqyZYsfxosJysUJI5QOJBVcxvj5pK0WgQE8ZpjQoMnbmoaKUjMaLzOrnAqvcQRovHLGr8+BwBiq7qBzjJqTRMyLmPC9Oax72MhDx1rfuWwTxWPdncDmlc0RxuspgEkVjhYpQuVOBjcRz+lb+vjCGsOBCi71bgjpiu7DHmZitEyxHuLgWy/uQwBLLgmvQtLH7tPpXn9jb4lEhdidwwBwK9B004RaMW9ULLl7smbUW4AAVcjACYaqkTECpVJY4JrkO9k7ugGB1pA8hHyj86YpAHTNKznjHGaRI5nk7kCm43DlzRtB680Hap+6KYChTjg7qTPbvTfOIPCikeU4PApaBZj8cdP1qPbk1EZXz1oV2J6mkFmSkY6Go2znOeKkU5GDzTWXjNFhpkMjHHIqhP1PpV6Q81SlHNBcTLvOVbmvOvEvzXxXdjC5Br0a+GFNed69HvvpOSOO1dGF+M5sf8AwR/hoGR9zEk5616HpYKgZrgfDKgAY9a7/TeVFTWfvmmHVqaN+3kPGKuxhiMg4FZ9sxzirokIHFZGjRcTftxvxStGSvyy/nUEaNIeXI+lSxWynO5mP41S1M3oALAEPIuKY23AxJz9akaCNP4AfrTHjTBIUCnYVyLzVX/lpmo3lQn79SNgDGBz7VE+MY2ipDQaZI8YDCqzkNnBzUrAEDgdarTKFyRSKVhjAZ5qJlXPAp4ORzUb8njgUJlEL4zxUD9MVK45+tQycEVcSWRR27O25wSu717VaFqlvCFgfBJ53cVTSZhcbQcgHHP0q5eQhlWc4yOwGK9eF7I+Zq255epfnlulgRUUM2OWB6UJLcyw7baR/lwCMf1qvHKwt1cnPQYpLy5kieNLcmJSMEDvWiRk2bI2pa72UOwGW2nvVJY5rpjIOU7ITjFXbbizUPl9w5zTLaGIsV2MAx/vGhaBK7aKtsDBcnzpWRjzhTxj0rVHky/69BtXo/BrMuo91y0fyhcYzt5qe3X7Pbsh+cDjpjND7iTexdjmeZgU2tbjjnuKf9mU8mML7KazhKUMbx5Uc/Lmqza3PvYFEO04oaBPuf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nail changes in a child with psJIA. Note pitting and onycholysis. Frequently changes are substantially more subtle, with just a few scattered pits that are evident only after careful inspection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Nigrovic PA, Sundel RP, Petty RE. Juvenile psoriatic arthritis. In: Textbook of Pediatric Rheumatology, 6th ed, Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Saunders, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29956=[""].join("\n");
var outline_f29_16_29956=null;
var title_f29_16_29957="Proximal humerus intraosseous site";
var content_f29_16_29957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Proximal humeral intraosseous access site",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For proximal humeral intraosseous placement in the skeletally mature adolescent or adult, adduct and internally rotate the arm (hand on abdomen) to make damage to the medial structures of the axillary plexus unlikely. Find the proximal tibial tubercle approximately 2 cm below the acromion process. Alternatively, palpate the greater tubercle from below. Access the intraosseous space using a battery operated drill.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29957=[""].join("\n");
var outline_f29_16_29957=null;
var title_f29_16_29958="Nizatidine: Drug information";
var content_f29_16_29958=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nizatidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/58/31652?source=see_link\">",
"    see \"Nizatidine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38885?source=see_link\">",
"    see \"Nizatidine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Axid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Nizatidine&reg;;",
"     </li>",
"     <li>",
"      Axid&reg;;",
"     </li>",
"     <li>",
"      Gen-Nizatidine;",
"     </li>",
"     <li>",
"      Novo-Nizatidine;",
"     </li>",
"     <li>",
"      Nu-Nizatidine;",
"     </li>",
"     <li>",
"      PMS-Nizatidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F202359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H",
"      <sub>",
"       2",
"      </sub>",
"      Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F202320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Duodenal ulcer:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment of active ulcer:",
"     </i>",
"     300 mg at bedtime or 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance of healed ulcer:",
"     </i>",
"     150 mg/day at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastric ulcer:",
"     </b>",
"     Oral: 150 mg twice daily or 300 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      GERD:",
"     </b>",
"     Oral: 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Eradication of",
"     </b>",
"     <b>",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral: 150 mg twice daily; requires combination therapy",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F202338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38885?source=see_link\">",
"      see \"Nizatidine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     <b>",
"      GERD (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;12 years: 10 mg/kg/day in divided doses given twice daily; may not be as effective in children &lt;12 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F202321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F202322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Active treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-50 mL/minute: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: 150 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-50 mL/minute: 150 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: 150 mg every 3 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F202292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 15 mg/mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Axid&reg;: 15 mg/mL (480 mL) [bubblegum flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F202278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F202294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and maintenance of duodenal ulcer; treatment of benign gastric ulcer; treatment of gastroesophageal reflux disease (GERD)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F202355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Part of a multidrug regimen for",
"     <i>",
"      H. pylori",
"     </i>",
"     eradication to reduce the risk of duodenal ulcer recurrence",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F202366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Axid&reg; may be confused with Ansaid&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tazac [Australia] may be confused with Tazact brand name for piperacillin/tazobactam [India]; Tiazac brand name for diltiazem [U.S., Canada]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F202357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fever (reported in children), insomnia, irritability (reported in children), somnolence, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dry mouth, flatulence, heartburn, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Reported in children: Cough, nasal congestion, nasopharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alkaline phosphatase increased, ALT increased, anaphylaxis, anemia, AST increased, bronchospasm, confusion, eosinophilia, exfoliative dermatitis, gynecomastia, hepatitis, jaundice, laryngeal edema, serum-sickness like reactions, thrombocytopenia, thrombocytopenic purpura, vasculitis, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F202297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nizatidine or any component of the formulation; hypersensitivity to other H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists (cross-sensitivity has been observed)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F202282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children &lt;12 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F202352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F202287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: H2-Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: H2-Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: H2-Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: H2-Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: H2-Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: H2-Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: H2-Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: H2-Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: H2-Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: H2-Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: H2-Antagonists may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: H2-Antagonists may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: H2-Antagonists may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: H2-Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): H2-Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: H2-Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: H2-Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): H2-Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: H2-Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: H2-Antagonists may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and the H2 receptor antagonist by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: H2-Antagonists may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: H2-Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use whenever possible.  Monitor patients closely for decreased antifungal effects if this combination is used.  Consider using a noninteracting antifungal as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: H2-Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: H2-Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: H2-Antagonists may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: H2-Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: H2-Antagonists may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F202312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may cause gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Food: Administration with apple juice may decrease absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F202289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F202301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies; therefore, the nizatidine is classified as pregnancy category B. Nizatidine crosses the placenta. An increased risk of congenital malformations or adverse events in the newborn has generally not been observed following maternal use of nizatidine during pregnancy. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD), as well as gastric and duodenal ulcers during pregnancy. Although if needed, nizatidine is not the agent of choice. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists may be used for aspiration prophylaxis prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F202324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/consider risk:benefit",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F202302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following oral administration of nizatidine, 0.1% of the maternal dose is found in breast milk. The highest milk concentrations appear ~2 hours after a maternal dose. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F202300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Axid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $179.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Nizatidine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $143.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $142.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Axid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/mL (480 mL): $421.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nizatidine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/mL (473 mL): $347.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Axid AR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (50): $13.50",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F202303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acinon (JP);",
"     </li>",
"     <li>",
"      Acitidin (KP);",
"     </li>",
"     <li>",
"      Acitidine (KP);",
"     </li>",
"     <li>",
"      Axadine (KP);",
"     </li>",
"     <li>",
"      Axid (CZ, HR, HU, MX);",
"     </li>",
"     <li>",
"      Axid Pulvules (BF, BG, BJ, BR, CI, CL, ET, GB, GH, GM, GN, GR, ID, IE, KE, KP, LR, MA, ML, MR, MU, MW, MY, NE, NG, PK, PL, SC, SD, SE, SG, SL, SN, TN, TR, TZ, UG, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Calmaxid (CH);",
"     </li>",
"     <li>",
"      Cronizat (IT);",
"     </li>",
"     <li>",
"      Distaxid (ES);",
"     </li>",
"     <li>",
"      Gastrax (DE);",
"     </li>",
"     <li>",
"      Jadin (KP);",
"     </li>",
"     <li>",
"      Nacid (KP);",
"     </li>",
"     <li>",
"      Naxidin (HN, HU);",
"     </li>",
"     <li>",
"      Naxidine (NL);",
"     </li>",
"     <li>",
"      Nizac (AU);",
"     </li>",
"     <li>",
"      Nizaractine (KP);",
"     </li>",
"     <li>",
"      Nizatid (KP);",
"     </li>",
"     <li>",
"      Nizax (DE, DK, FI, IT, NO);",
"     </li>",
"     <li>",
"      Nizaxid (CN, FR, LU, PT);",
"     </li>",
"     <li>",
"      Nolcer (PH);",
"     </li>",
"     <li>",
"      Panaxid (BE, LU);",
"     </li>",
"     <li>",
"      Tazac (AU, TW);",
"     </li>",
"     <li>",
"      Ulcosal (ES);",
"     </li>",
"     <li>",
"      Ulxit (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F202281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibition of histamine at H",
"     <sub>",
"      2",
"     </sub>",
"     -receptors of the gastric parietal cells resulting in reduced gastric acid secretion, gastric volume and hydrogen ion concentration reduced. In healthy volunteers, nizatidine suppresses gastric acid secretion induced by pentagastrin infusion or food.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F202296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.8-1.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 35% to &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially hepatic; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &gt;70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1-2 hours; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 0.5-3.0 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90%; ~60% as unchanged drug); feces (&lt;6%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abdel-Rahman SM, Johnson FK, Connor JD, et al, \"Developmental Pharmacokinetics and Pharmacodynamics of Nizatidine,\"",
"      <i>",
"       J Pediatr Gastroenterol Nut",
"      </i>",
"      , 2004, 38(4):442-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Abdel-Rahman SM, Johnson FK, Gauthier-Dubois G, et al, \"The Bioequivalence of Nizatidine (Axid) in Two Extemporaneously and One Commercially Prepared Oral Liquid Formulations Compared With Capsule,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2003, 43(2):148-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/16/29958/abstract-text/12616667/pubmed\" id=\"12616667\" target=\"_blank\">",
"        12616667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Callaghan JT, Bergstrom RF, Rubin A, et al, &ldquo;A Pharmacokinetic Profile of Nizatidine in Man,&rdquo;",
"      <i>",
"       Scand J Gastroenterol Suppl",
"      </i>",
"      , 1987, 136:9-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/16/29958/abstract-text/2892261/pubmed\" id=\"2892261\" target=\"_blank\">",
"        2892261",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/16/29958/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD, Kochman ML, Traber PG, et al, &ldquo;Possible Nizatidine-Induced Subfulminant Hepatic Failure,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 1995, 20(2):164-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/16/29958/abstract-text/7769203/pubmed\" id=\"7769203\" target=\"_blank\">",
"        7769203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fennerty MD and Higbee M, &ldquo;Drug Therapy of Gastrointestinal Disease,&rdquo;",
"      <i>",
"       Geriatric Pharmacology",
"      </i>",
"      , Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 585-608.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2008, 135(4):1383-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/16/29958/abstract-text/18789939/pubmed\" id=\"18789939\" target=\"_blank\">",
"        18789939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knadler MP, Bergstrom RF, Callaghan JT, et al, &ldquo;Nizatidine, An H",
"      <sub>",
"       2",
"      </sub>",
"      -Blocker. Its Metabolism and Disposition in Man,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 1986, 14(2):175-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/16/29958/abstract-text/2870891/pubmed\" id=\"2870891\" target=\"_blank\">",
"        2870891",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mikawa K, Nishina K, Maekawa N, et al, &ldquo;Effects of Oral Nizatidine on Preoperative Gastric Fluid pH and Volume in Children,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1994, 73(5):600-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/16/29958/abstract-text/7826786/pubmed\" id=\"7826786\" target=\"_blank\">",
"        7826786",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rudolph CD, Mazur LJ, Liptak GS, et al, &ldquo;Guidelines for Evaluation and Treatment of Gastroesophageal Reflux in Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2001, 32(Suppl 2):1-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/16/29958/abstract-text/11192451/pubmed\" id=\"11192451\" target=\"_blank\">",
"        11192451",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simeone D, Caria MC, Miele E, et al, &ldquo;Treatment of Childhood Peptic Esophagitis: A Double-Blind Placebo-Controlled Trial of Nizatidine,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 1997, 25(1):51-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/16/29958/abstract-text/9226527/pubmed\" id=\"9226527\" target=\"_blank\">",
"        9226527",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sullivan TJ, Reese JH, Buchmann KA, et al, &ldquo;Bioavailability Study of Nizatidine When Administered in Food,&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 1995, 2:275-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/16/29958/abstract-text/11850662/pubmed\" id=\"11850662\" target=\"_blank\">",
"        11850662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vargas R, Ryan J, McMahon G, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Oral Nizatidine,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1988, 28(1):71-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/16/29958/abstract-text/2895125/pubmed\" id=\"2895125\" target=\"_blank\">",
"        2895125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9708 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29958=[""].join("\n");
var outline_f29_16_29958=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202316\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202317\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202359\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202320\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202338\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202321\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202322\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202292\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202278\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202294\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202355\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202366\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202357\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202297\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202282\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202352\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202287\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202312\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202289\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202301\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202324\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202302\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202300\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202303\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202281\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202296\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9708\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9708|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/58/31652?source=related_link\">",
"      Nizatidine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38885?source=related_link\">",
"      Nizatidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_16_29959="Body stalk anomaly in neonate";
var content_f29_16_29959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55738%7EOBGYN%2F67500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55738%7EOBGYN%2F67500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Heart, stomach, liver, and bowel are outside the abdomen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Notice the kelly clamps on the umbilical cord leading into the abdomen, which never closed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Courtney D Stephenson, DO and A Hilton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Notice the severe scoliosis and chest wall deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Courtney D Stephenson, DO and A Hilton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29959=[""].join("\n");
var outline_f29_16_29959=null;
var title_f29_16_29960="Investigational and ineffective therapies for sepsis";
var content_f29_16_29960=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Investigational and ineffective therapies for sepsis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/16/29960/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29960/contributors\">",
"     Gregory A Schmidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29960/contributors\">",
"     Peter F Clardy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/16/29960/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29960/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29960/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/16/29960/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29960/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/16/29960/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of potential therapies have been investigated or are being evaluated in an attempt to improve clinical outcomes in sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Therapies that are being investigated are the focus of this review, although none are recommended for use at this time because the ratio of potential benefits and harms has not been adequately studied. Therapies that have proven ineffective are also mentioned briefly. The definition, pathophysiology, and management of sepsis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2552507\">",
"    <span class=\"h1\">",
"     THERAPIES BEING INVESTIGATED",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of potential therapies for sepsis appear promising in animal models, but have not yet been adequately studied in humans. Other potential therapies have been studied in humans, but have given conflicting results and require additional investigations to clarify their effects. These therapies are the focus of this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Inhibition of innate immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infecting microbes display highly conserved macromolecules (eg, lipopolysaccharides, peptidoglycans) on their surface. When these macromolecules are recognized by pattern-recognition receptors (called Toll-like receptors [TLRs]) on the surface of immune cells, the host&rsquo;s immune response is initiated. This may contribute to the excess systemic inflammatory response that characterizes sepsis. Inhibition of several TLRs is being evaluated as a potential therapy for sepsis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhibition of TLR-4 with the antagonist, E5564 (Eritoran), is currently being tested in humans. The ACCESS (",
"      <strong>",
"       A",
"      </strong>",
"      <strong>",
"       C",
"      </strong>",
"      ontrolled",
"      <strong>",
"       C",
"      </strong>",
"      omparison of",
"      <strong>",
"       E",
"      </strong>",
"      ritoran Tetrasodium and Placebo in Patients with",
"      <strong>",
"       S",
"      </strong>",
"      evere",
"      <strong>",
"       S",
"      </strong>",
"      epsis) trial has finished enrolling patients, but its results have not been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/6\">",
"       6",
"      </a>",
"      ]. An earlier clinical trial that evaluated the inhibition of TLR-4 with another antagonist, TAK 242 (Resatorvid), found a non-statistically significant reduction in 28-day mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhibition of TLR-2 with a neutralizing antibody (anti-TLR-2) successfully prevented lethal septic shock in an experimental mouse model, even if the antibody was given three hours after the initiation of systemic inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/8\">",
"       8",
"      </a>",
"      ]. Anti-TLR-2 has not been tested in humans.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2552682\">",
"    <span class=\"h2\">",
"     Restoration of the gastrointestinal barrier",
"    </span>",
"    &nbsp;&mdash;&nbsp;Talactoferrin is a glycoprotein that has anti-infective and anti-inflammatory properties, possibly by restoring the barrier properties of the gastrointestinal mucosa. In unpublished studies conducted using animal models, talactoferrin reduced mortality when given enterally up to 12 hours following the onset of sepsis. A randomized trial has been completed in humans with severe sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/9-11\">",
"     9-11",
"    </a>",
"    ] and another randomized trial in humans with severe sepsis is planned [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been hypothesized that polyclonal intravenous immunoglobulin (IVIG) may benefit patients with sepsis by binding endotoxin. However, the data are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suggesting that polyclonal IVIG has no benefit, a randomized trial of 653 patients with sepsis found that IVIG did not reduce 28-day mortality compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Suggesting that polyclonal IVIG has a benefit, meta-analyses of randomized trials found that polyclonal IVIG decreased mortality compared to either placebo or no IVIG [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/14-17\">",
"       14-17",
"      </a>",
"      ]. The mortality benefit was greatest when IgA- or IgM-enriched IVIG was used [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. However, all of the meta-analyses were limited by heterogeneity and two of the meta-analyses found that the mortality benefit disappeared when only the well-designed trials were analyzed [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/15,17\">",
"       15,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, we believe that the evidence is insufficient to recommend the administration of polyclonal IVIG to patients with sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/18\">",
"     18",
"    </a>",
"    ]. However, well-designed randomized trials are warranted to evaluate the impact of IgA- and IgM-enriched IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Endotoxin inactivation or removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategies to improve sepsis by either inactivating or removing endotoxin have been investigated and some of the preliminary data appear promising:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoperfusion through an endotoxin-avid column &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"       Polymyxin B",
"      </a>",
"      is an antibiotic with a high affinity for endotoxin. Several studies have found that hemoperfusion through a column that contains polymyxin B may be beneficial to patients with sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/20-23\">",
"       20-23",
"      </a>",
"      ]. The largest was a multicenter trial that randomly assigned 64 patients with severe sepsis or septic shock to receive conventional therapy alone or conventional therapy plus hemoperfusion through a polymyxin B fiber column (PBFC) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/23\">",
"       23",
"      </a>",
"      ]. All of the patients had undergone emergency surgery for intraabdominal infection. The group that received hemoperfusion through a PBFC had lower 28-day mortality than the group that received conventional therapy alone (32 versus 53 percent; adjusted HR 0.36, 95% CI 0.16-0.80). In addition, only the group that received hemoperfusion through a PBFC had increased mean arterial pressure, decreased vasopressor requirement, and decreased severity of illness at 72 hours.",
"     </li>",
"     <li>",
"      Plasma or whole blood exchange &ndash; Case series and observational studies with historical controls reported favorable outcomes when endotoxin was removed by plasma or whole blood exchange, including lower plasma endotoxin concentrations and, possibly, lower mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/24-26\">",
"       24-26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While encouraging, we believe that additional evidence is necessary before any of these strategies are routinely used in patients with sepsis. For instance, the effects of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    fiber column need to be confirmed and studied in other patient populations, while the effects of plasma or whole blood exchange need to be substantiated by controlled clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Interferon-gamma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decrease in monocyte function has been observed late in the course of sepsis, which may predispose patients to life-threatening secondary infections. This observation prompted a study in which patients with sepsis were administered interferon-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/27\">",
"     27",
"    </a>",
"    ]. The study found that interferon-gamma restored monocytic cell function. Controlled clinical trials measuring patient-important outcomes in patients with sepsis have not been reported, although a trial evaluating the impact of interferon-gamma in candidemia is underway [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Granulocyte-macrophage colony stimulating factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulocyte-macrophage colony stimulating factor (GM-CSF,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/43/5814?source=see_link\">",
"     sargramostim",
"    </a>",
"    , molgramostim) is a cytokine that promotes maturation of the progenitor cells of granulocytes, erythrocytes, megakaryocytes, and macrophages, as well as mature neutrophils, monocytes, macrophages, dendritic cells, T-lymphocytes, and plasma cells. Its use in sepsis has been studied in several controlled clinical trials.",
"   </p>",
"   <p>",
"    One trial reported that GM-CSF increased the peripheral neutrophil count, but did not affect the mortality, duration of ICU stay, or rate of hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/29\">",
"     29",
"    </a>",
"    ]. Another trial found that GM-CSF reduced the rate of infectious complications, the length of hospital stay, and the duration of antibiotic therapy, without affecting mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/30\">",
"     30",
"    </a>",
"    ]. And, a third trial found that GM-CSF induced a trend toward a shorter duration of mechanical ventilation (148 versus 207 hours), a shorter hospital stay (59 versus 69 days), and a shorter ICU stay (41 versus 52 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/31\">",
"     31",
"    </a>",
"    ]. All of the trials were small with few events, which is the reason why large absolute differences were often not statistically significant. We believe that larger controlled clinical trials are necessary to confirm the clinical effects reported in these trials and that GM-CSF should not be routinely used to treat sepsis until then.",
"   </p>",
"   <p>",
"    The effects of granulocyte colony stimulating factor (G-CSF) are mentioned below. (See",
"    <a class=\"local\" href=\"#H2552815\">",
"     'Ineffective therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Augmentation of immunomodulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies directed against macrophage migration inhibition factor (MIF) prevented death in a study that used a cecal puncture animal model of sepsis, even when administered up to eight hours after the onset of peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/32\">",
"     32",
"    </a>",
"    ]. The mechanism of action is uncertain, but MIF inhibition might restore or augment the immunomodulatory actions of endogenous glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/33\">",
"     33",
"    </a>",
"    ]. While it is known that elevated MIF levels correlate with poor outcomes in humans with sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], the impact of MIF inhibition has not been studied in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2553632\">",
"    <span class=\"h2\">",
"     Inhibition of proinflammatory gene expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A synthetic peptide has been developed that inhibits bacterial superantigen-induced expression of certain proinflammatory genes (interleukin-2, gamma interferon, and tumor necrosis factor-beta) by limiting T-cell activation. In one study, the peptide protected mice against lethal challenges with staphylococcal and streptococcal superantigen, when administered up to three hours after the superantigen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/35\">",
"     35",
"    </a>",
"    ]. This peptide has not been tested in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hemofiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that hemofiltration may remove proinflammatory molecules that induce hemodynamic collapse in septic shock, improving outcomes. However, the data in humans are inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Case series suggest that high-volume hemofiltration may benefit patients with sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]. In a representative series, 20 patients with refractory hyperdynamic septic shock underwent a single, 12 hour session of high-volume hemofiltration [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/38\">",
"       38",
"      </a>",
"      ]. Eleven patients improved following hemofiltration (ie, improved perfusion and decreased vasopressor requirement) and nine patients did not. ICU mortality was only 18 percent among those who improved, compared to 67 percent among those who did not. Improvement following high-volume hemofiltration was the only predictor of survival (odds ratio 9.0, 95% CI 1.1-71.0).",
"     </li>",
"     <li>",
"      In contrast, a randomized trial that evaluated continuous venovenous hemofiltration (CVVH) in patients with sepsis did not demonstrate any improvement in the clearance of inflammatory mediators or clinical outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/40\">",
"       40",
"      </a>",
"      ], while another trial was discontinued after an interim analysis showed more frequent and more severe organ failure in the hemofiltration group [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized trial comparing high volume hemofiltration to no hemofiltration in sepsis is in progress [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/42\">",
"     42",
"    </a>",
"    ]. Until those results are known, there is insufficient data to support the use of hemofiltration in the absence of renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    has anti-thrombotic and immunomodulating effects, both of which have the potential to be beneficial in sepsis. In a retrospective cohort study of patients with septic shock, intravenous therapeutic heparin was associated with decreased mortality, discontinuation of vasoactive drug infusions, and liberation from mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/43\">",
"     43",
"    </a>",
"    ]. The risk of major hemorrhage or the need for transfusion was not increased. This study was followed by the HETRASE trial, which randomly assigned 319 patients with sepsis to receive low dose intravenous heparin (500 units per hour) or placebo for seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/44\">",
"     44",
"    </a>",
"    ]. The trial found no improvement in any clinical outcome. It has been suggested that the conflicting results were due to the randomized trial using a low dose of heparin; as a result, a randomized trial comparing various doses of heparin in patients with septic shock is being conducted [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Naloxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of three randomized trials (61 patients) comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    to either placebo or no naloxone found that naloxone therapy led to hemodynamic improvement, but did not improve the case-fatality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/46\">",
"     46",
"    </a>",
"    ]. Adverse effects that have been associated with naloxone therapy include pulmonary edema, hypertension, and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/47\">",
"     47",
"    </a>",
"    ]. Given the limitations of the meta-analysis that found a physiological benefit, the absence of patient-important benefits, and the potential for adverse effects, we believe that naloxone therapy is not warranted for patients with septic shock. However, large controlled trials are justified, since the studies included in the meta-analysis had too few events to definitively exclude a beneficial effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pentoxifylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis results in decreased red cell deformability and increased erythrocyte aggregation, effects that may be mitigated by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/48\">",
"     48",
"    </a>",
"    ]. Pentoxifylline also inhibits neutrophil adhesion and activation, and modulates endotoxin-induced expression of proinflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/49\">",
"     49",
"    </a>",
"    ]. In a trial of 51 surgical patients with severe sepsis who were randomly assigned to receive pentoxifylline or placebo, pentoxifylline improved the multiple organ dysfunction score and the arterial oxygen tension to fraction of inspired oxygen",
"    <span class=\"nowrap\">",
"     (PaO2/FIO2),",
"    </span>",
"    but there was no improvement in the 28-day mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/50\">",
"     50",
"    </a>",
"    ]. A trial is in progress comparing pentoxifylline to placebo in neonatal sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;HMG CoA reductase inhibitors (statins) are in wide clinical use and have an established role in the management of hyperlipidemia and cardiovascular disease. Statins also appear to have beneficial antiinflammatory properties, such as suppression of endotoxin-induced up-regulation of TLR-4 and TLR-2. Several observational studies have suggested that statins are beneficial in patients with sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/52-54\">",
"     52-54",
"    </a>",
"    ], although conflicting studies exist [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. No controlled trials evaluating statin therapy initiated after the development of sepsis have been reported, but several such studies are underway [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10230?source=see_link&amp;anchor=H5#H5\">",
"     \"Statins: Possible noncardiovascular benefits\", section on 'Sepsis and infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2552815\">",
"    <span class=\"h1\">",
"     INEFFECTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of potential therapies for sepsis have been investigated, but either caused harm or failed to improve clinical outcomes.",
"   </p>",
"   <p>",
"    Despite promising initial data, recombinant human activated protein C (rhAPC) has not been confirmed to improve survival in patients with severe sepsis or septic shock, prompting withdrawal of this drug from the market [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/62\">",
"     62",
"    </a>",
"    ]. Recombinant human activated protein C (also called drotrecogin alfa) promotes fibrinolysis and inhibits thrombosis. It was hypothesized that rhAPC may benefit patients with sepsis because it modulates the procoagulant response that is believed to contribute to multisystem organ dysfunction. This hypothesis was initially tested in the PROWESS trial, which reported that rhAPC improved 28-day mortality in patients with severe sepsis or septic shock, with its greatest benefit among patients with a high risk of death (ie, APACHE II score &ge;25) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/63\">",
"     63",
"    </a>",
"    ]. However, conflicting data from subsequent studies eventually led to a new trial, the PROWESS-SHOCK trial. In this trial, 1696 patients with vasopressor-dependent septic shock were randomly assigned to receive rhAPC or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/64\">",
"     64",
"    </a>",
"    ]. Preliminary analyses done by the maker of the drug indicated that rhAPC did not improve 28-day mortality (26.4 versus 24.2 percent for placebo, RR 1.09, 95% CI 0.92-1.28).",
"   </p>",
"   <p>",
"    Additional therapies that have proven ineffective include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The TLR-4 antagonist, TAK 242 (Resatorvid) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The human anti-endotoxin monoclonal antibody, HA-1A [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The human anti-Enterobacteriaceae common antigen (ECA) monoclonal antibody [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Alkaline phosphatase [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/68\">",
"       68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       Granulocyte colony-stimulating factor",
"      </a>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       filgrastim",
"      </a>",
"      , G-CSF) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/69\">",
"       69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-tumor necrosis factor monoclonal antibody [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/70-72\">",
"       70-72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Tumor necrosis factor receptor antagonist [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/71,73\">",
"       71,73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Interleukin-1 receptor antagonist [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/74\">",
"       74",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antithrombin (formerly known as antithrombin III) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/18,75-79\">",
"       18,75-79",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Recombinant human tissue factor pathway inhibitor (tifacogin) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/80,81\">",
"       80,81",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/82\">",
"       82",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      N-acetylcysteine [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nitric oxide inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/85-90\">",
"       85-90",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The bradykinin antagonist, deltibant [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/91\">",
"       91",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Growth hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/92\">",
"       92",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      supplementation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29960/abstract/18,93\">",
"       18,93",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2553811\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of potential therapies for sepsis appear promising in animal models, but have not yet been adequately studied in humans. These include toll-like receptor antagonists and neutralizing antibodies, talactoferrin, interferon gamma, macrophage migration inhibition factor neutralizing antibody, and a synthetic peptide that inhibits bacterial superantigen-induced expression of certain proinflammatory genes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Inhibition of innate immunity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2552682\">",
"       'Restoration of the gastrointestinal barrier'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Interferon-gamma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Augmentation of immunomodulation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2553632\">",
"       'Inhibition of proinflammatory gene expression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other potential therapies for sepsis have been studied in humans, but have provided conflicting results and require additional investigations to clarify their effects. These include polyclonal intravenous immunoglobulin (IVIG), hemoperfusion through a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"       polymyxin B",
"      </a>",
"      fiber column, plasma exchange, whole blood exchange, granulocyte-macrophage colony stimulating factor (GM-CSF), hemofiltration,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      , and statins. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Intravenous immunoglobulin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Endotoxin inactivation or removal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Granulocyte-macrophage colony stimulating factor'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Hemofiltration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Heparin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Naloxone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Pentoxifylline'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Statins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential therapies for sepsis have also been investigated that were found to either cause harm or not improve clinical outcomes. (See",
"      <a class=\"local\" href=\"#H2552815\">",
"       'Ineffective therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/1\">",
"      Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annu Rev Med 2005; 56:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/2\">",
"      Russell JA. Management of sepsis. N Engl J Med 2006; 355:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/3\">",
"      Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/4\">",
"      Sibbald WJ, Vincent JL. Round table conference on clinical trials for the treatment of sepsis. Crit Care Med 1995; 23:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/5\">",
"      Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest 2003; 112:460.",
"     </a>",
"    </li>",
"    <li>",
"     A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis. file://www.clinicaltrials.gov/ct2/show/NCT00334828 (Accessed on June 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/7\">",
"      Rice TW, Wheeler AP, Bernard GR, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010; 38:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/8\">",
"      Meng G, Rutz M, Schiemann M, et al. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 2004; 113:1473.",
"     </a>",
"    </li>",
"    <li>",
"     Safety and Efficacy of Recombinant Human Lactoferrin to Treat Severe Sepsis. file://www.clinicaltrials.gov/ct2/show/NCT00630656 (Accessed on June 12, 2011).",
"    </li>",
"    <li>",
"     Talactoferrin alfa reduces mortality in severe sepsis: Results of a Phase 2 randomized, placebo-controlled, double-blind study. file://www.thoracic.org/newsroom/press-releases/resources/late-breaking-abstract-pdf/talactoferrin.pdf (Accessed on June 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/11\">",
"      Guntupalli KK, Dean NC, Morris PE et al.. Talactoferrin alfa reduces mortality in severe. Am J Respir Crit Care Med 2010; 181:A6768.",
"     </a>",
"    </li>",
"    <li>",
"     Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis (OASIS). file://www.clinicaltrials.gov/ct2/show/NCT01273779 (Accessed on June 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/13\">",
"      Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007; 35:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/14\">",
"      Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2000; :CD001090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/15\">",
"      Pildal J, G&oslash;tzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004; 39:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/16\">",
"      Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007; 35:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/17\">",
"      Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007; 35:2686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/18\">",
"      Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/19\">",
"      Neugebauer EA. To use or not to use? Polyclonal intravenous immunoglobulins for the treatment of sepsis and septic shock. Crit Care Med 2007; 35:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/20\">",
"      Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005; 23:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/21\">",
"      Aoki H, Kodama M, Tani T, Hanasawa K. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994; 167:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/22\">",
"      Iwama H, Komatsu T. Effect of an endotoxin-removing column containing immobilized polymyxin B fiber in a patient with septic shock from gram-positive infection. Acta Anaesthesiol Scand 1998; 42:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/23\">",
"      Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/24\">",
"      van Deuren M, Santman FW, van Dalen R, et al. Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 1992; 15:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/25\">",
"      Reeves JH. A review of plasma exchange in sepsis. Blood Purif 2002; 20:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/26\">",
"      Stegmayr BG. Plasmapheresis in severe sepsis or septic shock. Blood Purif 1996; 14:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/27\">",
"      D&ouml;cke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3:678.",
"     </a>",
"    </li>",
"    <li>",
"     Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia. file://www.clinicaltrials.gov/ct2/show/NCT01270490 (Accessed on June 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/29\">",
"      Presneill JJ, Harris T, Stewart AG, et al. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002; 166:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/30\">",
"      Orozco H, Arch J, Medina-Franco H, et al. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. Arch Surg 2006; 141:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/31\">",
"      Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/32\">",
"      Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/33\">",
"      Martin TR. MIF mediation of sepsis. Nat Med 2000; 6:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/34\">",
"      Bozza FA, Gomes RN, Japiass&uacute; AM, et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004; 22:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/35\">",
"      Arad G, Levy R, Hillman D, Kaempfer R. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 2000; 6:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/36\">",
"      Borthwick EMJ, Hill CJ, Rabindranath KS, et al. High-volume haemofiltration for sepsis. Cochrane Database Syst Rev 2013; :CD008075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/37\">",
"      Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000; 28:3581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/38\">",
"      Cornejo R, Downey P, Castro R, et al. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006; 32:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/39\">",
"      Piccinni P, Dan M, Barbacini S, et al. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med 2006; 32:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/40\">",
"      Cole L, Bellomo R, Hart G, et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/41\">",
"      Payen D, Mateo J, Cavaillon JM, et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009; 37:803.",
"     </a>",
"    </li>",
"    <li>",
"     Evaluation of the Hemodynamic Effects of Cascade Hemofiltration in Septic Shock. file://www.clinicaltrials.gov/ct2/show/NCT00922870 (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/43\">",
"      Zarychanski R, Doucette S, Fergusson D, et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008; 36:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/44\">",
"      Jaimes F, De La Rosa G, Morales C, et al. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med 2009; 37:1185.",
"     </a>",
"    </li>",
"    <li>",
"     Safety of Heparin in Patients with Septic Shock. file://www.clinicaltrials.gov/ct2/show/NCT01234285 (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/46\">",
"      Boeuf B, Gauvin F, Guerguerian AM, et al. Therapy of shock with naloxone: a meta-analysis. Crit Care Med 1998; 26:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/47\">",
"      Rock P, Silverman H, Plump D, et al. Efficacy and safety of naloxone in septic shock. Crit Care Med 1985; 13:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/48\">",
"      Kirschenbaum LA, Aziz M, Astiz ME, et al. Influence of rheologic changes and platelet-neutrophil interactions on cell filtration in sepsis. Am J Respir Crit Care Med 2000; 161:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/49\">",
"      Kleinschmidt S, Wanner GA, Bussmann D, et al. Proinflammatory cytokine gene expression in whole blood from patients undergoing coronary artery bypass surgery and its modulation by pentoxifylline. Shock 1998; 9:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/50\">",
"      Staubach KH, Schr&ouml;der J, St&uuml;ber F, et al. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg 1998; 133:94.",
"     </a>",
"    </li>",
"    <li>",
"     Role of Pentoxifylline and/or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis. file://www.clinicaltrials.gov/ct2/show/NCT01006499 (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/52\">",
"      Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006; 367:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/53\">",
"      Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006; 34:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/54\">",
"      Merx MW, Weber C. Statins: a preventive strike against sepsis in patients with cardiovascular disease? Lancet 2006; 367:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/55\">",
"      Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006; 333:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/56\">",
"      Kruger PS, Harward ML, Jones MA, et al. Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 2011; 183:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/57\">",
"      Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011; 39:1871.",
"     </a>",
"    </li>",
"    <li>",
"     Statins for the Early Treatment of Sepsis (SETS). file://www.clinicaltrials.gov/ct2/show/NCT00528580 (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     Statin Therapy in the Treatment of Sepsis. file://www.clinicaltrials.gov/ct2/show/NCT00676897 (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     Statin for Immunomudulation in Sepsis. file://www.clinicaltrials.gov/ct2/show/NCT00452608 (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     Simvastatin in Patients With Septic Shock. file://www.clinicaltrials.gov/ct2/show/NCT00450840 (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/62\">",
"      Mart&iacute;-Carvajal AJ, Sol&agrave; I, Lathyris D, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2012; 3:CD004388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/63\">",
"      Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Voluntary Market Withdrawal of Xigris [(Drotrecogin alfa (activated)] due to failure to show a survival benefit. file://www.fda.gov/Drugs/DrugSafety/ucm277114.htm (Accessed on October 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/65\">",
"      McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994; 121:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/66\">",
"      Angus DC, Birmingham MC, Balk RA, et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 2000; 283:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/67\">",
"      Albertson TE, Panacek EA, MacArthur RD, et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit Care Med 2003; 31:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/68\">",
"      Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med 2009; 37:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/69\">",
"      Root RK, Lodato RF, Patrick W, et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/70\">",
"      Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/71\">",
"      Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/72\">",
"      Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/73\">",
"      Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/74\">",
"      Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/75\">",
"      Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002; 30:S325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/76\">",
"      Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/77\">",
"      Afshari A, Wetterslev J, Brok J, M&oslash;ller A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 2007; 335:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/78\">",
"      Baudo F, Caimi TM, de Cataldo F, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/79\">",
"      Wiedermann CJ, Hoffmann JN, Juers M, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/80\">",
"      Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/81\">",
"      Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/82\">",
"      Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/83\">",
"      Spapen HD, Diltoer MW, Nguyen DN, et al. Effects of N-acetylcysteine on microalbuminuria and organ failure in acute severe sepsis: results of a pilot study. Chest 2005; 127:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/84\">",
"      Szakmany T, Hauser B, Radermacher P. N-acetylcysteine for sepsis and systemic inflammatory response in adults. Cochrane Database Syst Rev 2012; 9:CD006616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/85\">",
"      Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/86\">",
"      Lorente JA, Land&iacute;n L, De Pablo R, et al. L-arginine pathway in the sepsis syndrome. Crit Care Med 1993; 21:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/87\">",
"      Avontuur JA, Boomsma F, van den Meiracker AH, et al. Endothelin-1 and blood pressure after inhibition of nitric oxide synthesis in human septic shock. Circulation 1999; 99:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/88\">",
"      Grover R, Zaccardelli D, Colice G, et al. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med 1999; 27:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/89\">",
"      Schoonover LL, Stewart AS, Clifton GD. Hemodynamic and cardiovascular effects of nitric oxide modulation in the therapy of septic shock. Pharmacotherapy 2000; 20:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/90\">",
"      L&oacute;pez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/91\">",
"      Fein AM, Bernard GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 1997; 277:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/92\">",
"      Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29960/abstract/93\">",
"      Angstwurm MW, Engelmann L, Zimmermann T, et al. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 2007; 35:118.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1631 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29960=[""].join("\n");
var outline_f29_16_29960=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2553811\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2552507\">",
"      THERAPIES BEING INVESTIGATED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Inhibition of innate immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2552682\">",
"      Restoration of the gastrointestinal barrier",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Endotoxin inactivation or removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Interferon-gamma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Granulocyte-macrophage colony stimulating factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Augmentation of immunomodulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2553632\">",
"      Inhibition of proinflammatory gene expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hemofiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Naloxone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pentoxifylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2552815\">",
"      INEFFECTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2553811\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10230?source=related_link\">",
"      Statins: Possible noncardiovascular benefits",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_16_29961="Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials";
var content_f29_16_29961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/16/29961/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29961/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29961/contributors\">",
"     Joseph P Carrozza, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29961/contributors\">",
"     Roger J Laham, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/16/29961/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29961/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/16/29961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29961/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/16/29961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary percutaneous coronary intervention (PCI), if performed in a timely fashion, is the reperfusion therapy of choice in patients who have had an acute ST elevation myocardial infarction (STEMI) or an MI with new or presumably new left bundle branch block or a true posterior MI. The clinical trials that support this conclusion, and which have generally compared PCI with fibrinolysis, will be reviewed here. The discussion of the circumstances in which fibrinolysis may be either a reasonable alternative to PCI or even preferred is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the performance of primary PCI, such as the optimal time to intervention and adjunctive therapies, the importance of hospital and operator volume, the role of PCI after fibrinolysis (eg, rescue PCI or facilitated or adjunctive PCI), and the role of PCI in non-ST elevation acute coronary syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF FIBRINOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the primary role of thrombus in the genesis of acute coronary occlusion, the introduction of fibrinolytic therapy was a major advance in the treatment of acute STEMI. The net effect in major fibrinolytic trials was an approximate 30 percent reduction in the 7 to 10 percent short-term mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the clear benefits of fibrinolytic therapy compared with no reperfusion and its ease of use, there are issues of both efficacy and safety that limit its use. The following limitations provided part of the impetus for primary PCI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefit of fibrinolysis is greatest when therapy is given within the first four hours after the onset of symptoms, particularly within the first",
"      <strong>",
"       70 minutes",
"      </strong>",
"      as the resistance of cross-linked fibrin to fibrinolysis is time-dependent (",
"      <a class=\"graphic graphic_figure graphicRef53374 \" href=\"UTD.htm?30/18/31021\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. Any longer delay decreases the amount of myocardial salvage and functional benefit. The absolute mortality benefit compared to placebo at five weeks is approximately 3 percent for those presenting within six hours from symptom onset, 2 percent for those presenting within 7 to 12 hours, and a nonsignificant 1 percent for those presenting within 13 to 18 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/3\">",
"       3",
"      </a>",
"      ]. Unfortunately many patients present to the hospital more than six hours after the onset of symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"       \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although patency, defined as some antegrade flow through the site of obstruction, is restored in up to 87 percent of infarct-related arteries, normalization of blood flow (as assessed by the TIMI flow grade) occurs in only 50 to 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. The clinical benefits of fibrinolytic therapy correlate only with the restoration of normal (TIMI grade 3) flow (",
"      <a class=\"graphic graphic_table graphicRef51941 \" href=\"UTD.htm?1/49/1819\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef75629 \" href=\"UTD.htm?15/40/16013\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef70952 \" href=\"UTD.htm?9/52/10061\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/4,7-11\">",
"       4,7-11",
"      </a>",
"      ]. In contrast, TIMI grade 3 flow is achieved in 93 to 96 percent of patients who undergo primary PCI [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H3#H3\">",
"       \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI flow grade'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Attainment of TIMI 3 flow is much more common with primary PCI: 93 to 96 percent in the PAMI and CADILLAC trials of more than 5400 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After apparently successful fibrinolysis, evidence of early recurrence of ischemia (pain or ST segment shifts) has been observed in 20 to 30 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/14,15\">",
"       14,15",
"      </a>",
"      ], with frank fibrinolytic coronary reocclusion in 5 to 15 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/5,16,17\">",
"       5,16,17",
"      </a>",
"      ], and reinfarction in 3 to 5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. Reinfarction is associated with higher rates of in-hospital, short-term, and long-term mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]; PCI is the preferred therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"       \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Major hemorrhagic complications occur in 2 to 3 percent. The most serious is intracerebral hemorrhage, which occurs in as many as 1 percent overall [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/3,21,22\">",
"       3,21,22",
"      </a>",
"      ], 1.4 percent of older adults [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/23\">",
"       23",
"      </a>",
"      ], and over 4 percent in patients with multiple risk factors (",
"      <a class=\"graphic graphic_table graphicRef62946 \" href=\"UTD.htm?42/52/43851\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69243091#H69243091\">",
"       \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Stroke'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As many as 20 to 30 percent of patients presenting with an acute STEMI, particularly older adults, are not candidates for fibrinolytic therapy because of contraindications such as active internal bleeding, a recent stroke, or hypertension (",
"      <a class=\"graphic graphic_table graphicRef68784 \" href=\"UTD.htm?23/16/23820\">",
"       table 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H25#H25\">",
"       \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Contraindications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"       \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Efficacy of fibrinolytic therapy has not been demonstrated in patients in cardiogenic shock (unless coronary perfusion pressure is increased with an IABP) or those with prior coronary artery bypass surgery (CABG). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"       \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fibrinolytic therapy does not necessarily involve early angiography, the findings of which may change treatment. In a report from the PAMI trial, 10 percent of patients who underwent angiography were considered inappropriate candidates for PCI due, in one-half of cases, to lack of residual stenosis that presumably reflected spontaneous clot lysis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/25\">",
"       25",
"      </a>",
"      ]. Other patients have findings, such as severe three-vessel or left main coronary disease, or anatomic features unfavorable for PCI, that lead to a recommendation for surgical revascularization. Many experts now recommend routine angiography after fibrinolysis for those patients who have not had it performed for evidence of ongoing or recurrent ischemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRIMARY PCI VERSUS FIBRINOLYTIC TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three types of trials of primary PCI in STEMI have been performed: primary PCI with percutaneous transluminal coronary angioplasty compared to fibrinolysis; primary PCI with stenting compared to fibrinolysis; and primary PCI with stenting compared to primary PCI with balloon angioplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Primary PCI with balloon angioplasty versus fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early trials comparing primary PCI with balloon angioplasty to fibrinolysis showed a significant reduction in mortality with the former [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, these trials are of limited utility to current practice for the following reasons: stenting is performed in almost all patients who undergo PCI; current generation fibrinolytic agents were not used in many of the trials; and anticoagulation and antiplatelet protocols differed significantly from contemporary practice.",
"   </p>",
"   <p>",
"    Most of the important studies were included in a 1997 meta-analysis of 10 randomized trials which included 2606 patients randomly assigned to primary PCI with balloon angioplasty or fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/27\">",
"     27",
"    </a>",
"    ]. The former was associated with the following benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly lower mortality at 30 days or less (4.4 versus 6.5 percent, odds ratio 0.66, 95% CI 0.46-0.94); the effect was similar among the different fibrinolytic regimens used.",
"     </li>",
"     <li>",
"      A significantly lower rate of death or nonfatal reinfarction (7.2 versus 11.9 percent, odds ratio 0.58, 95% CI 0.44-0.76).",
"     </li>",
"     <li>",
"      A lower rate of total stroke (0.7 versus 2.0 percent) and hemorrhagic stroke (0.1 versus 1.1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Primary Angioplasty in Myocardial Infarction trial (PAMI), published after the meta-analysis, randomly assigned 395 patients presenting with an acute MI within 12 hours of symptom onset to primary PCI with balloon angioplasty or 100 mg of intravenous recombinant tissue-type plasminogen activator (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/25\">",
"     25",
"    </a>",
"    ]. Benefits, similar to those in the meta-analysis, were found with primary PCI with balloon angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/25,28,29\">",
"     25,28,29",
"    </a>",
"    ]. An important observation in PAMI was that high-risk groups (age &gt;70, anterior MI, heart rate &gt;100 on admission) derived the greatest benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Primary PCI with stenting versus primary PCI with balloon angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical efficacy of primary PCI with balloon angioplasty in acute STEMI is limited by the risks of early reocclusion and late restenosis, providing the rationale for the use of intracoronary stents. Initial nonrandomized studies suggesting that primary stenting was more effective than primary PTCA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/30-32\">",
"     30-32",
"    </a>",
"    ] were followed by randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/13,33-35\">",
"     13,33-35",
"    </a>",
"    ]. Subsequent randomized trials, including Stent PAMI and CADILLAC, confirmed the greater efficacy of stenting compared with balloon angioplasty for patients with STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/13,33\">",
"     13,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2005 meta-analysis evaluated nine randomized trials with a total of 4433 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/36\">",
"     36",
"    </a>",
"    ]. Stenting (predominantly with bare metal stents), compared to balloon angioplasty, was associated with significant reductions in reinfarction (odds ratio [OR] 0.52, 95% CI 0.31-0.87 at 30 days, and OR 0.67, 95% CI 0.45-0.98 at one year) and target vessel revascularization (OR 0.45, 95% CI 0.34-0.60 at 30 days, and OR 0.47, 95% CI 0.38-0.57 at one year). There was no significant difference in mortality (OR 1.06 at one year).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Primary PCI with stenting versus fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials (DANAMI-2, PRAGUE-2, AIR PAMI, STAT, STOPAMI-1, and STOPAMI-2) have demonstrated a better outcome with primary PCI with stenting compared to fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/37-45\">",
"     37-45",
"    </a>",
"    ]. In the two largest trials, DANAMI-2 and PRAGUE-2, most of the patients presented to hospitals without PCI facilities. Bare-metal stents were used in these trials.",
"   </p>",
"   <p>",
"    The DANAMI-2 trial randomly assigned 1572 patients to front-loaded",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    or to primary PCI with stenting (93 percent with stenting) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/37\">",
"     37",
"    </a>",
"    ]. The majority of patients were initially evaluated in referral hospitals, and then transferred to a PCI center if randomized to primary PCI. Inclusion criteria included STEMI, duration of symptoms less than 12 hours (median 105 minutes), and ability to complete transfer to a PCI center within three hours of randomization. For those patients enrolled in referral centers, the median time between randomization and arrival in the catheterization laboratory was 67 minutes, with 96 percent arriving within 120 minutes.",
"   </p>",
"   <p>",
"    The study was discontinued prematurely because of a significant reduction in the primary endpoint of mortality, reinfarction, or stroke at 30 days with primary PCI (8.0 versus 13.7 percent). The mortality benefit was noted only in the subgroup of high-risk patients with a TIMI risk score &ge;5 at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/38\">",
"     38",
"    </a>",
"    ]. The benefit remained significant at three years (19.5 versus 25.2 percent) and was primarily due to less clinical reinfarction (8.9 versus 12.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/39\">",
"     39",
"    </a>",
"    ]. At median follow-up of 7.8 years, the combined endpoint of death or reinfarction was significantly lower in the primary PCI group (34.8 versus 41.3 percent), attributable to a significantly lower reinfarction rate (11.7 versus 18.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'High- versus low-risk patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Potential limitations to DANAMI-2 included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeat fibrinolysis in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      group as opposed to rescue PCI, which is the preferred approach. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"       \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Absence of protocol mandated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      in all patients and glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitors in most patients undergoing primary PCI, both of which are recommended in most major guidelines. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H36#H36\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The PRAGUE-2 trial randomly assigned 850 patients with an STEMI who had had symptoms for less than 12 hours to immediate fibrinolysis with streptokinase at the presenting community hospital or transfer to a PCI center [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/40\">",
"     40",
"    </a>",
"    ]. Primary PCI was associated with a nonsignificant trend toward lower mortality at 30 days (6.8 versus 10.0 percent with fibrinolysis). At five years, the cumulative incidence of the composite endpoint (death from any cause, recurrent infarction, stroke or revascularization) was significantly lower in the primary PCI group (40 versus 50 percent), driven principally by a lower rate of recurrent infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential benefit of using drug eluting stents instead of bare-metal stents in patients with STEMI has been evaluated in multiple randomized trials. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=see_link&amp;anchor=H24756048#H24756048\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\", section on 'Selection of stent type'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     High- versus low-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A later analysis from the DANAMI-2 trial cited above stratified patients according to the TIMI risk score for STEMI in an attempt to assess whether all patients with STEMI benefit from primary PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/38\">",
"     38",
"    </a>",
"    ]. The score is the arithmetic sum of eight independent predictors of mortality available at presentation; there is a continuous relationship between mortality and score, which has been prospectively validated (",
"    <a class=\"graphic graphic_figure graphicRef78134 \" href=\"UTD.htm?42/15/43262\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link&amp;anchor=H3#H3\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\", section on 'TIMI risk score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a three-year follow-up from the DANAMI-2 cohort, primary PCI was associated with a significant reduction in mortality at three years compared to fibrinolysis in high-risk patients with a TIMI risk score &ge;5 (25.3 versus 36.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/38\">",
"     38",
"    </a>",
"    ]. In contrast, there was no mortality benefit from primary PCI in the 74 percent of patients who were at low risk with a score of 0 to 4 (8.0 versus 5.6 percent), and only a nonsignificant trend toward a reduction in the composite endpoint of death, reinfarction, and disabling stroke (13.7 versus 15.7 percent), which was due to a significant reduction in reinfarction (6.6 versus 10.4 percent).",
"   </p>",
"   <p>",
"    The mortality findings are consistent with a community-based sample of 1058 patients, which found that the added benefit from primary PCI increased with overall risk, that 87 percent of the benefit could be attained by treating patients in the upper half of risk, and that, in meta-regression analysis of ten randomized trials of primary PTCA, a mortality benefit was unlikely in patients with a 30-day mortality risk of about 2 percent or less, which is seen with a TIMI risk score of 0 to 2 (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?27/53/28497?source=see_link\">",
"     calculator 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/48\">",
"     48",
"    </a>",
"    ]. The low-risk patients in DANAMI-2 had a 30-day mortality of 2.5 percent with fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large 2009 meta-analysis of randomized controlled trials (RCT) and observational studies (OS), which compared primary PCI (with balloon angioplasty or stenting) to fibrinolysis, came to the following conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary PCI was associated with significant reductions in short-term (&le; 6 weeks) mortality of 34 percent in RCT and 23 percent in OS.",
"     </li>",
"     <li>",
"      Primary PCI was associated with significant reductions in long-term (&gt; 1 year) mortality of 24 percent and reinfarction of 51 percent in RCT.",
"     </li>",
"     <li>",
"      No significant benefit of primary PCI compared to fibrinolytic therapy was seen for either mortality or reinfarction in the observational studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prehospital fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the relative efficacy of primary PCI with stenting and fibrinolysis when the latter can be delivered very early, such as occurs with prehospital fibrinolysis. The role and benefits of prehospital fibrinolysis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25830?source=see_link\">",
"     \"Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     USE IN SPECIFIC SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above trials do not provide data on the efficacy of primary PCI in a number of specific settings. Mostly nonrandomized data are available for patients with anterior wall MI and prior CABG, as well as following noncardiac surgery. The role of primary PCI in cardiogenic shock was evaluated in the randomized SHOCK trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Anterior wall MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is substantial evidence of benefit of primary PCI for anterior wall in subgroup analyses from randomized trials. As examples, the benefit of primary PTCA compared to fibrinolysis in PAMI was limited to patients with anterior wall STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/29\">",
"     29",
"    </a>",
"    ], the benefit of primary stenting compared to fibrinolysis was similar with anterior and nonanterior acute MI in DANAMI-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/37\">",
"     37",
"    </a>",
"    ], and the benefit of primary stenting compared to primary PTCA was significant with left anterior descending disease, which is responsible for anterior infarctions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Efficacy in anterior wall MI was directly addressed in a study in which 220 such patients were randomly assigned to primary PCI or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/50\">",
"     50",
"    </a>",
"    ]. Primary PCI was associated with significant reductions in in-hospital mortality (2.8 versus 10.8 percent), postinfarction angina or positive exercise test (11.9 versus 25.2 percent), repeat revascularization (22 versus 47.7 percent) and, at six months, mortality (4.6 versus 11.7) and revascularization (31.2 versus 55.9 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cardiogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational data from the GUSTO-I trial and the controlled SHOCK trial suggest benefit from an early invasive strategy with revascularization by either PCI or coronary artery bypass graft surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Fibrinolysis is generally not effective for these patients. However it may be of benefit when a significant delay before PCI is anticipated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prior CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been an increase in the number of patients presenting with an acute MI who have had a previous CABG. In the National Registry of Myocardial Infarction-2 (NRMI-2), a prior CABG was an independent predictor of mortality (odds ratio 1.23) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/54\">",
"     54",
"    </a>",
"    ]. There was no difference in outcome between reperfusion therapy with primary PTCA or a fibrinolytic agent. However, higher-risk patients were more likely to be referred for primary PTCA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute saphenous vein graft occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although uncommon, an acute MI may result from acute saphenous vein graft occlusion. There is little high-quality evidence upon which to recommend either fibrinolysis or primary PCI over the other. In those patients who undergo PCI with stenting, DES have not been shown to be better than BMS in preventing restenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=see_link\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no trials that specifically compare primary PCI with fibrinolysis in older adults. The available data from subset analyses of major trials and nonrandomized retrospective analyses support a benefit from primary PCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diabetic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited data available on the effect of diabetes on the outcome after primary PCI suggest that the relative benefit compared to fibrinolytic therapy may be similar to nondiabetics. However, diabetics remain at increased risk, perhaps due in part to microvascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41289?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of acute myocardial infarction in diabetes mellitus\", section on 'Primary PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women tend to be at higher risk with an acute MI than men because they are usually older and have more comorbidities. Nevertheless, women with an STEMI have improved outcomes with primary PCI compared to fibrinolysis and the degree of benefit may actually be greater than in men. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11258?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of coronary heart disease in women\", section on 'Primary PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PCI WHEN FIBRINOLYSIS IS CONTRAINDICATED",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 20 to 30 percent of patients presenting with an acute STEMI, particularly older adults, are not candidates for fibrinolytic therapy (",
"    <a class=\"graphic graphic_table graphicRef68784 \" href=\"UTD.htm?23/16/23820\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H25#H25\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with contraindications to fibrinolysis represent a high-risk group with an estimated baseline short-term mortality risk of 15 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. In such patients, immediate PCI appears to improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/55,56,58-60\">",
"     55,56,58-60",
"    </a>",
"    ] as well as to salvage a substantial amount of ischemic myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of benefit is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a nonrandomized study of patients in the National Registry of Myocardial Infarction 2, 3, and 4, over 19,000 patients were identified who had contraindications to fibrinolysis but were suitable candidates for PCI or CABG; revascularization was performed in 4705 (24 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/56\">",
"       56",
"      </a>",
"      ]. In an analysis using a propensity matching score to reduce the effects of bias, 3905 patients who received revascularization were matched with 3905 patients who did not. The in-hospital mortality was significantly lower for the revascularized patients (10.9 versus 20.1 percent). A significant treatment benefit persisted (odds ratio 0.64, 95% CI 0.56-0.75) after adjustment for residual differences between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar benefit was suggested in the synthesis of randomized trials cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29961/abstract/55\">",
"     55",
"    </a>",
"    ]. The absolute reduction in mortality with PCI in patients with contraindications to fibrinolysis was 9.3 percent (95% CI 5.3-13.2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reperfusion with either primary percutaneous intervention or fibrinolysis improves outcomes in patients with acute ST elevation myocardial infarction (STEMI) or an MI with new or presumably new left bundle branch block or a true posterior MI. For most patients, clinical trials have demonstrated superiority of primary PCI, irrespective of whether balloon angioplasty or stenting is performed. In addition, fibrinolysis is absolutely or relatively contraindicated in many STEMI patients. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Primary PCI versus fibrinolytic trials'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'PCI when fibrinolysis is contraindicated'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some patients, such as those who do not have access to prompt PCI, are candidates for fibrinolytic therapy. The discussion of the factors that determine which strategy should be chosen is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/1\">",
"      Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/2\">",
"      Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/3\">",
"      Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/4\">",
"      An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/5\">",
"      The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993; 329:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/6\">",
"      Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/7\">",
"      Simes RJ, Topol EJ, Holmes DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995; 91:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/8\">",
"      Ross AM, Coyne KS, Moreyra E, et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998; 97:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/9\">",
"      Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/10\">",
"      Karagounis L, Sorensen SG, Menlove RL, et al. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. J Am Coll Cardiol 1992; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/11\">",
"      Anderson JL, Karagounis LA, Becker LC, et al. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993; 87:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/12\">",
"      Mehta RH, Harjai KJ, Cox D, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003; 42:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/13\">",
"      Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/14\">",
"      Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/15\">",
"      Langer A, Krucoff MW, Klootwijk P, et al. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. J Am Coll Cardiol 1998; 31:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/16\">",
"      Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/17\">",
"      Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 1990; 82:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/18\">",
"      Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001; 104:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/19\">",
"      Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003; 42:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/20\">",
"      D&ouml;nges K, Schiele R, Gitt A, et al. Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results from the pooled data of the maximal individual therapy in acute myocardial infarction [MITRA], and the myocardial infarction registry [MIR]). Am J Cardiol 2001; 87:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/21\">",
"      Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995; 92:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/22\">",
"      Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med 1998; 129:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/23\">",
"      Brass LM, Lichtman JH, Wang Y, et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000; 31:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/24\">",
"      Cannon CP, Bahit MC, Haugland JM, et al. Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. Crit Pathw Cardiol 2002; 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/25\">",
"      Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/26\">",
"      A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med 1997; 336:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/27\">",
"      Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/28\">",
"      Nunn CM, O'Neill WW, Rothbaum D, et al. Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. J Am Coll Cardiol 1999; 33:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/29\">",
"      Stone GW, Grines CL, Browne KF, et al. Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy. Am J Cardiol 1996; 78:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/30\">",
"      Saito S, Hosokawa FG, Kim K, et al. Primary stent implantation without coumadin in acute myocardial infarction. J Am Coll Cardiol 1996; 28:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/31\">",
"      Bauters C, Lablanche JM, Van Belle E, et al. Effects of coronary stenting on restenosis and occlusion after angioplasty of the culprit vessel in patients with recent myocardial infarction. Circulation 1997; 96:2854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/32\">",
"      Stone GW, Brodie BR, Griffin JJ, et al. Clinical and angiographic follow-Up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation 1999; 99:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/33\">",
"      Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999; 341:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/34\">",
"      Suryapranata H, van 't Hof AW, Hoorntje JC, et al. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation 1998; 97:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/35\">",
"      Antoniucci D, Santoro GM, Bolognese L, et al. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol 1998; 31:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/36\">",
"      Nordmann AJ, Bucher H, Hengstler P, et al. Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. Cochrane Database Syst Rev 2005; :CD005313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/37\">",
"      Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/38\">",
"      Thune JJ, Hoefsten DE, Lindholm MG, et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation 2005; 112:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/39\">",
"      Busk M, Maeng M, Rasmussen K, et al. The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. Eur Heart J 2008; 29:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/40\">",
"      Widimsk&yacute; P, Budes&iacute;nsk&yacute; T, Vor&aacute;c D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. Eur Heart J 2003; 24:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/41\">",
"      Widimsky P, Bilkova D, Penicka M, et al. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 Trial. Eur Heart J 2007; 28:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/42\">",
"      Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). J Am Coll Cardiol 2001; 37:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/43\">",
"      Sch&ouml;mig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000; 343:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/44\">",
"      Kastrati A, Mehilli J, Dirschinger J, et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet 2002; 359:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/45\">",
"      Grines CL, Westerhausen DR Jr, Grines LL, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol 2002; 39:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/46\">",
"      Nielsen PH, Maeng M, Busk M, et al. Primary angioplasty versus fibrinolysis in acute myocardial infarction: long-term follow-up in the Danish acute myocardial infarction 2 trial. Circulation 2010; 121:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/47\">",
"      Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/48\">",
"      Kent DM, Schmid CH, Lau J, Selker HP. Is primary angioplasty for some as good as primary angioplasty for all? J Gen Intern Med 2002; 17:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/49\">",
"      Huynh T, Perron S, O'Loughlin J, et al. Comparison of primary percutaneous coronary intervention and fibrinolytic therapy in ST-segment-elevation myocardial infarction: bayesian hierarchical meta-analyses of randomized controlled trials and observational studies. Circulation 2009; 119:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/50\">",
"      Garc&iacute;a E, El&iacute;zaga J, P&eacute;rez-Castellano N, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol 1999; 33:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/51\">",
"      Berger PB, Holmes DR Jr, Stebbins AL, et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. Circulation 1997; 96:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/52\">",
"      Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/53\">",
"      Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001; 285:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/54\">",
"      Peterson LR, Chandra NC, French WJ, et al. Reperfusion therapy in patients with acute myocardial infarction and prior coronary artery bypass graft surgery (National Registry of Myocardial Infarction-2). Am J Cardiol 1999; 84:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/55\">",
"      Massel D. Primary angioplasty in acute myocardial infarction: Hypothetical estimate of superiority over aspirin or untreated controls. Am J Med 2005; 118:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/56\">",
"      Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 2003; 290:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/57\">",
"      Behar S, Gottlieb S, Hod H, et al. The outcome of patients with acute myocardial infarction ineligible for thrombolytic therapy. Israeli Thrombolytic Survey Group. Am J Med 1996; 101:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/58\">",
"      Zahn R, Schuster S, Schiele R, et al. Comparison of primary angioplasty with conservative therapy in patients with acute myocardial infarction and contraindications for thrombolytic therapy. Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group. Catheter Cardiovasc Interv 1999; 46:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/59\">",
"      Kastrati A, Mehilli J, Nekolla S, et al. A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy. J Am Coll Cardiol 2004; 43:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29961/abstract/60\">",
"      Svilaas T, Zijlstra F. The benefit of an invasive approach in thrombolysis-ineligible patients with acute myocardial infarction. Am J Med 2005; 118:123.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 73 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29961=[""].join("\n");
var outline_f29_16_29961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIMITATIONS OF FIBRINOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRIMARY PCI VERSUS FIBRINOLYTIC TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Primary PCI with balloon angioplasty versus fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Primary PCI with stenting versus primary PCI with balloon angioplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Primary PCI with stenting versus fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - High- versus low-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prehospital fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      USE IN SPECIFIC SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Anterior wall MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prior CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute saphenous vein graft occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diabetic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PCI WHEN FIBRINOLYSIS IS CONTRAINDICATED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/73\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/73|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/18/31021\" title=\"figure 1\">",
"      Mortality and time to reperfusion in MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/40/16013\" title=\"figure 2\">",
"      Mortality after thrombolysis based on TIMI flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/52/10061\" title=\"figure 3\">",
"      TIMI flow and survival after thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/15/43262\" title=\"figure 4\">",
"      TIMI risk score predicts 30-day mortality after STEMI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/73|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/49/1819\" title=\"table 1\">",
"      TIMI flow grades",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/52/43851\" title=\"table 2\">",
"      Risk factors for intracranial hemorrhage with thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/16/23820\" title=\"table 3\">",
"      Contraindications to fibrinolytic therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?27/53/28497?source=related_link\" title=\"calculator 1\">",
"      Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11258?source=related_link\">",
"      Management of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25830?source=related_link\">",
"      Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=related_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41289?source=related_link\">",
"      Treatment of acute myocardial infarction in diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_16_29962="Trauma management: Approach to the unstable child";
var content_f29_16_29962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Trauma management: Approach to the unstable child",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/16/29962/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29962/contributors\">",
"     Lois K Lee, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29962/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/16/29962/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29962/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/16/29962/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/16/29962/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/16/29962/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, over 17,000 children and adolescents die annually of unintentional and intentional injuries, making trauma the leading cause of death for this population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/1\">",
"     1",
"    </a>",
"    ]. It is also the leading cause of emergency department (ED) visits, comprising up to one-third of all visits for children less than 15 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blunt injury accounts for approximately 90 percent of all pediatric trauma. When blunt force is applied to a child's small body, multisystem trauma occurs frequently. Although the majority of injuries are mild to moderate in severity, the clinician caring for children should be prepared to rapidly evaluate and manage those patients with serious and life threatening trauma. In addition, children have differing anatomy and physiology from adults that require specific attention during advanced trauma care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3477?source=see_link\">",
"     \"Trauma management: Unique pediatric considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial approach to the management of the unstable child with major traumatic injuries is presented here. The approach to the initially stable child with traumatic injury and the classification of trauma in the injured child are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=see_link\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standardized approach to the initial management of trauma patients has been disseminated by the American College of Surgeons through the Advanced Trauma Life Support (ATLS) program (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65952 \" href=\"UTD.htm?13/13/13534\">",
"     table 1",
"    </a>",
"    ). The ATLS protocols are based on the concept of the Trimodal Death Distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first peak of death occurs in the seconds to minutes immediately after injury and only prevention can impact this mortality.",
"     </li>",
"     <li>",
"      The second peak occurs in the minutes to hours after injury. During this time, referred to as the \"golden hour,\" rapid assessment and treatment decreases fatalities and improves outcomes.",
"     </li>",
"     <li>",
"      The third peak of death occurs days to weeks after the initial injury because of infection and multi-organ system failure. Definitive care in a center with pediatric expertise and resources mitigates this delayed mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For this discussion, the unstable pediatric trauma patient refers to any child who has abnormal vital signs, disruption of vital functions (eg, airway, breathing, circulation, mental function), or apparent injuries of a critical nature. Knowledge of normal vital signs by age and awareness of the ability of children to sustain major hemorrhage without hypotension facilitates recognition of the critically injured child (",
"    <a class=\"graphic graphic_table graphicRef60424 \" href=\"UTD.htm?41/23/42363\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"     table 3",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3477?source=see_link\">",
"     \"Trauma management: Unique pediatric considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INJURY CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several methods for measuring severity of injury exist. In order to appropriately triage the management of the trauma patient, one useful method to categorize injuries uses the following parameters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Injury extent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple trauma is defined by apparent injury to two or more body areas. Localized trauma involves only one anatomic region (eg, head and neck, chest and back, abdomen, extremities) of the body. Sometimes the extent of injury may be obvious; at other times this may not be readily apparent, and the clinical picture may evolve over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Injury type",
"    </span>",
"    &nbsp;&mdash;&nbsp;The expected injuries differ based on whether they occur as a result of blunt trauma (eg, fall, motor vehicle collision) or penetrating trauma (eg, gunshot, stabbing, shrapnel from explosion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Injury severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of injury and physical examination findings are useful in the determination of severity. Assessment of severity will dictate the initial management and disposition [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/1\">",
"     1",
"    </a>",
"    ]. High risk trauma mechanisms predict patients who are more likely to be unstable or become unstable and, along with vital signs and physical findings, are often used to guide prehospital transport decisions (",
"    <a class=\"graphic graphic_table graphicRef60424 \" href=\"UTD.htm?41/23/42363\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57293 \" href=\"UTD.htm?0/42/684\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57153 \" href=\"UTD.htm?29/18/29996\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of initial trauma management in children, as in adults, are to rapidly assess the injuries, determine management priorities, and provide critical interventions. Achieving these goals requires a systematic and logical approach according to the tenets of ATLS, presented below in an expanded format to emphasize the importance of performing specific procedures rapidly in the emergency department and the crucial need to continuously reassess vital functions (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary survey (rapid primary evaluation)",
"     </li>",
"     <li>",
"      Resuscitation of vital functions (eg, airway, breathing, circulation, mentation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Utilization of adjuncts to the primary survey and resuscitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary survey (more comprehensive secondary assessment)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Continued post resuscitation monitoring with further resuscitation as needed",
"     </li>",
"     <li>",
"      Utilization of adjuncts to the secondary survey",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transition to definitive care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management of seriously injured children relies on two key principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment and management occur simultaneously during the primary survey. Any identified physiologic threat to life must be rapidly treated before moving on to the evaluation of the next priority area.",
"     </li>",
"     <li>",
"      If there is any deterioration of the patient during the evaluation, the primary survey should be repeated and any newly identified problems addressed before proceeding with the definitive care of the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians should incorporate ATLS guidelines into the management of the pediatric trauma patient, but with the understanding that this offers only a general construct. In reality, particularly when multiple clinicians are involved, many steps typically occur simultaneously.",
"   </p>",
"   <p>",
"    Organization of the medical response around the concept of a pediatric trauma team may provide more timely identification of injury and more rapid treatment with improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The next section will discuss each of the key elements of the primary survey as if they were distinct entities occurring in a strict sequence, even though in centers with optimal pediatric trauma resources these steps typically occur simultaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PRIMARY SURVEY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The order of priority in the initial assessment and treatment in ATLS is called the \"primary survey\" and includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A - Airway maintenance with cervical spine protection",
"     </li>",
"     <li>",
"      B - Breathing and ventilation",
"     </li>",
"     <li>",
"      C - Circulation with hemorrhage control",
"     </li>",
"     <li>",
"      D - Disability (evaluation of neurologic status)",
"     </li>",
"     <li>",
"      E - Exposure (complete",
"      <span class=\"nowrap\">",
"       visualization)/environmental",
"      </span>",
"      control (prevention of hypothermia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the primary survey, clinicians must identify and promptly address life-threatening conditions (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). Prior to the arrival of the patient, care providers should don eye protection, mask, gown, and gloves to prevent exposure to patient secretions (universal precautions). The care of the patient proceeds more effectively if participants know their role beforehand and if the leader of the resuscitation communicates clearly.",
"   </p>",
"   <p>",
"    In trauma centers, advance notice to all participants and key units (eg, blood bank, operating room) facilitates collaborative and timely care of the critically injured child.",
"   </p>",
"   <p>",
"    Upon arrival of the patient, clinicians should place the appropriate monitors, obtain vital signs (pulse, respirations, oxygen saturation, blood pressure, pulse oximetry, temperature), and provide supplemental oxygen. It is imperative for the trauma provider to assess pediatric vital signs in comparison to a readily available reference of normal values for age (",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"     table 3",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3477?source=see_link\">",
"     \"Trauma management: Unique pediatric considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The list below provides a brief overview of the approach and a more detailed discussion of each major category follows. Use of a trauma flow sheet with a dedicated recorder helps ensure that all aspects of assessment and care receive attention.",
"   </p>",
"   <p>",
"    In the clinical setting, particularly when multiple clinicians are involved, many steps occur simultaneously. For example, IV access may precede chest tube placement, even though \"breathing\" comes before \"circulation\" in the algorithm. Also, clinical events will dictate the exact sequence of assessment and management. Some conditions are difficult to detect in young children based on physical findings (eg, cardiac tamponade), and others may evolve over time. For instance, a patient with initially symmetric breath sounds may become cyanotic in the middle of the secondary survey while receiving positive pressure ventilation and require an immediate thoracostomy tube.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Airway",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway assessment &ndash; Airway obstruction with hypoxia and inadequate ventilation is the most common cause of pediatric cardiopulmonary arrest following trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/9\">",
"       9",
"      </a>",
"      ]. The clinician must rapidly determine airway patency, presence of foreign bodies in the mouth or pharynx, and evidence for",
"      <span class=\"nowrap\">",
"       facial/mandibular",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       tracheal/laryngeal",
"      </span>",
"      fractures with potential for an unstable airway. Medical providers must remain alert for the potential loss of the airway. A patient who is able to cry or speak normally is unlikely to have impending airway obstruction, but should be reevaluated frequently [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Airway management &ndash; Clinicians should immobilize and protect the cervical spine. During the initial management, the clinician must assume a c-spine injury in the patient with multiple trauma, especially with",
"      <span class=\"nowrap\">",
"       head/neck",
"      </span>",
"      injury or with an altered level of consciousness. Padding under the shoulder and back and use of the \"sniffing position\" is important to open the airway maximally and maintain a neutral cervical spine position in the infant or young child. Note that this positioning is markedly different from adults where padding under the head is frequently required to achieve neutral cervical spine position. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"       \"Pediatric cervical spine immobilization\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Indications for cervical spine immobilization include (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"       \"Evaluation of cervical spine injuries in children and adolescents\"",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/5,10\">",
"       5,10",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mechanism concerning for potential c-spine injury (motor vehicle-pedestrian, motor vehicle-bicycle, fall from a considerable height, MVC with unrestrained passenger) (",
"      <a class=\"graphic graphic_table graphicRef57293 \" href=\"UTD.htm?0/42/684\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anatomic predisposition to neck injury (eg, Down syndrome), prior neck injury, or history of cervical spine surgery",
"     </li>",
"     <li>",
"      GCS &lt;13",
"     </li>",
"     <li>",
"      Altered mental status or intoxication",
"     </li>",
"     <li>",
"      Neck pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      guarding of the neck [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/5,10\">",
"       5,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neurologic deficit",
"     </li>",
"     <li>",
"      Distracting injury that may mask cervical spine instability because of pain. To qualify as a distracting injury, the trauma must be sufficiently severe as to make the otherwise alert, verbal child unaware of neck pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One person, manual in-line immobilization techniques must be used if immobilizing devices must be removed for endotracheal intubation or other airway procedures (",
"    <a class=\"graphic graphic_figure graphicRef80874 \" href=\"UTD.htm?14/2/14369\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians also must establish an airway if the airway is inadequate. This may be accomplished by performing the following",
"    <span class=\"nowrap\">",
"     maneuvers/procedures",
"    </span>",
"    in sequence. In most trauma patients, an inadequate airway means the patient requires rapid sequence intubation to manage or to prevent hypoxemia and hypercarbia and to prevent rapid respiratory decompensation. Establishing an airway, particularly in children &lt;3 years of age may be challenging due to specific anatomical differences from adults (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3477?source=see_link&amp;anchor=H3#H3\">",
"     \"Trauma management: Unique pediatric considerations\", section on 'Airway'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chin lift or jaw thrust",
"     </li>",
"     <li>",
"      Suctioning of secretions",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Oropharyngeal/nasopharyngeal",
"      </span>",
"      airway as adjuncts to bag-valve-mask ventilation or temporary measures prior to endotracheal intubation (nasopharyngeal airway is contraindicated if cribriform plate fracture is suspected)",
"     </li>",
"     <li>",
"      Endotracheal intubation",
"     </li>",
"     <li>",
"      Laryngeal mask airway (LMA) (if endotracheal intubation fails or difficult airway is anticipated)",
"     </li>",
"     <li>",
"      Needle or surgical cricothyroidotomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Common reasons for endotracheal intubation in injured patients include impending or potential airway compromise (eg, airway trauma, inhalation injury, prolonged seizures), pulmonary contusion with hypoxemia, flail chest with inadequate chest wall movement (",
"    <a class=\"graphic graphic_figure graphicRef79746 \" href=\"UTD.htm?23/19/23857\">",
"     figure 3",
"    </a>",
"    ), hemorrhagic shock, and severe head injury (GCS &lt;8) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]. General indications for endotracheal intubation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endotracheal intubation in severe head trauma requires judicious choice of medications to prevent the abrupt increase in intracranial pressure associated with laryngoscopy and intubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial approach to severe traumatic brain injury in children\", section on 'Rapid sequence intubation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Breathing",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breathing assessment &ndash; Assessment of breathing begins with inspection of the neck and thorax. Key findings include tracheal deviation, abnormal chest wall movement, the use of accessory muscles, and contusions or lacerations of the thorax or neck (see below). In addition the rate and depth of respirations should be determined and breath sounds auscultated (",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/5\">",
"       5",
"      </a>",
"      ]. Certain life-threatening injuries, which may impair ventilation, often are associated with specific physical examination findings (",
"      <a class=\"graphic graphic_table graphicRef79921 \" href=\"UTD.htm?31/3/31803\">",
"       table 6",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tension pneumothorax may present with tracheal deviation, a hyperresonant chest, and unilateral decreased or absent breath sounds.",
"     </li>",
"     <li>",
"      Flail chest may present with an asymmetric rise and fall of the chest (",
"      <a class=\"graphic graphic_figure graphicRef79746 \" href=\"UTD.htm?23/19/23857\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Open pneumothorax may result from a large defect in the chest wall.",
"     </li>",
"     <li>",
"      Massive hemothorax may cause unilateral decreased breath sounds and dullness to percussion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breathing management &ndash; Management should focus on improvement of vital signs with the following interventions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Administer a high concentration of oxygen.",
"     </li>",
"     <li>",
"      Deliver bag-valve-mask ventilation in cases of inadequate respiratory effort.",
"     </li>",
"     <li>",
"      Decompress tension pneumothorax either with a needle initially or by placing a thoracostomy tube. For a hemothorax, use a thoracostomy tube. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"       \"Placement and management of thoracostomy tubes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seal open pneumothorax and immediately place a chest tube.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply end-tidal CO2 monitoring and consider arterial or venous blood gas measurements [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link\">",
"       \"Initial evaluation and stabilization of children with thoracic trauma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=see_link\">",
"       \"Continuous oxygen delivery systems for infants, children, and adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      .).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Circulation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circulatory assessment &ndash; Hypovolemia is the most common cause of shock in the pediatric trauma patient [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/13\">",
"       13",
"      </a>",
"      ], and its early recognition and treatment are critical during trauma resuscitation. Compensated shock occurs when there has been significant blood loss, but the blood pressure has been maintained by tachycardia and vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/14\">",
"       14",
"      </a>",
"      ]. Uncompensated shock manifests with hypotension in addition to tachycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/15\">",
"       15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Tachycardia is usually the first sign of hypovolemia in the child. Due to the physiologic reserve in children, blood pressure may be maintained despite a loss of up to 45 percent of the circulating blood volume. Therefore, the trauma patient who is cool and tachycardic should be considered to be in shock until proven otherwise. Other signs of shock include narrowing of the pulse pressure to less than 20 mmHg, skin mottling, cool extremities, decreased level of consciousness, and dulled response to pain (",
"      <a class=\"graphic graphic_table graphicRef68694 \" href=\"UTD.htm?33/47/34556\">",
"       table 7",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link\">",
"       \"Initial evaluation of shock in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3477?source=see_link\">",
"       \"Trauma management: Unique pediatric considerations\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The remainder of the assessment focuses on sources of bleeding and other causes of hemodynamic compromise:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      External bleeding (eg, large vessel injury, limb amputation, large scalp laceration)",
"     </li>",
"     <li>",
"      Significant chest trauma with possible tension pneumothorax, hemothorax, or cardiac tamponade (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Breathing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link\">",
"       \"Initial evaluation and stabilization of children with thoracic trauma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Abdominal tenderness suggesting internal hemorrhage (eg, liver laceration, splenic laceration)",
"     </li>",
"     <li>",
"      Pelvic pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      instability indicating fracture",
"     </li>",
"     <li>",
"      Open fractures",
"     </li>",
"     <li>",
"      Spinal cord injury with shock (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"       \"Acute traumatic spinal cord injury\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circulation&nbsp;management &ndash; Hemorrhage control, intravenous (IV) access, and advanced procedures for persistent hemodynamic compromise constitute the primary management issues for the circulation phase of the primary survey.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hemorrhage control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sites of significant external hemorrhage require direct manual pressure to control bleeding (",
"    <a class=\"graphic graphic_figure graphicRef75556 \" href=\"UTD.htm?35/14/36078\">",
"     figure 4",
"    </a>",
"    ). The presence of nerves near vascular bundles prohibits blind clamping of bleeding vessels except in the scalp. In patients whose bleeding does not abate with direct pressure or who have a sharp foreign body at the site of bleeding or an amputation, compression at the nearest vascular pressure point provides an alternative means for hemorrhage control. Finally, the medical provider may employ a blood pressure tourniquet or penrose drain tourniquet for severe bleeding that is poorly controlled despite direct pressure or compression of pressure points (",
"    <a class=\"graphic graphic_figure graphicRef75765 \" href=\"UTD.htm?28/16/28937\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Severe bleeding from a large scalp laceration often responds to rapid closure using a figure of eight suture, surgical staples, or scalp clips (Raney clips). A circumferential penrose drain tourniquet can provide temporary control of scalp bleeding until repair is complete (",
"    <a class=\"graphic graphic_figure graphicRef73415 \" href=\"UTD.htm?7/23/7538\">",
"     figure 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33124?source=see_link\">",
"     \"Closure of minor skin wounds with staples\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reduction and splinting of long bone fractures may also provide hemostasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with a suspected pelvic fracture and hemodynamic instability, clinicians should carefully examine the perineum and rectum and then place a pelvic stabilization device over the greater trochanter (prefabricated pelvic binder or a bed sheet tied tightly around the pelvis) (",
"    <a class=\"graphic graphic_figure graphicRef76777 \" href=\"UTD.htm?9/7/9331\">",
"     figure 7",
"    </a>",
"    ). External fixation devices are generally placed in the operating room because placement can be difficult and time consuming and may interfere with other components of resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     IV access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, vascular access involves placement of two large bore IVs in the upper extremities within 60 to 90 seconds of arrival, realizing that in young children the lower extremities provide a reasonable alternative and that in many cases two large bore IVs cannot be inserted in a timely fashion.",
"   </p>",
"   <p>",
"    The most common type of peripheral venous catheter used in children is the over-the-needle catheter. Catheter size necessary for fluid resuscitation varies by age: 22 to 24 gauge in newborns and infants, 18 to 20 gauge for older children. The size of the cannula used in resuscitation should be the largest that can be inserted reliably. In shock or severe hypovolemia, a smaller cannula may be used for initial fluid resuscitation until a larger vein can be cannulated. Butterfly needles should be avoided because they infiltrate easily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If peripheral IV access is not rapidly achieved, the intraosseous (IO) route offers a rapid and easily obtainable alternative access. Percutaneous central access or venous cutdown are other options for establishing more permanent vascular access for ongoing care. Central access is accomplished more easily than a cutdown, which is rarely used. Among the sites for central access, the femoral vein affords the lowest rate of complications in the short term [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link\">",
"     \"Intraosseous infusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Fluid resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with compensated shock after blunt trauma, a fluid bolus of 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of warmed normal saline or Ringer's lactate should be rapidly given over 10 to 15 minutes. Patients generally need to receive crystalloid volume that is three times the estimated blood loss in order to become hemodynamically stable. In children, three boluses or 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of normal saline or Ringer's lactate (maximum dose: 3 L total volume) would balance a blood loss of 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    (approximately one-third of blood volume), assuming that bleeding is controlled. A transfusion of 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of packed red blood cells (PRBC) should be considered if there is inadequate clinical improvement after IV boluses of 40 to 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of normal saline [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27380186\">",
"    <span class=\"h4\">",
"     Blood products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt trauma patients with hypotension require rapid restoration of blood volume. These patients often require blood transfusion if they show little to no improvement with initial crystalloid infusions. Type specific or unmatched O negative packed red blood cells (PRBCs, initial volume 10 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    up to 2 units) administered through a rapid infusion system with an inline warmer may be lifesaving in these patients.",
"   </p>",
"   <p>",
"    Patients with compensated shock not responsive to initial crystalloid infusions should receive type and cross-matched blood (10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    up to 1 unit).",
"   </p>",
"   <p>",
"    The role of other blood products, such as fresh frozen plasma (FFP), platelets, and recombinant activated factor VII (rFVIIa) for the treatment of severely traumatized patients who require massive transfusion is evolving. While replacement therapy with plasma, platelets, and red cells should not generally be based upon any set formula, results from a number of observational studies in adults suggest that patients with severe trauma, massive blood replacement, and coagulopathy have improved survival when the ratio of transfused FFP (units) to transfused platelets (units) to red cells (units) approaches 1:1:1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H3986774#H3986774\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Transfusion for severe ongoing hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, a massive transfusion protocol is appropriate for patients who have profound hemorrhage or ongoing bleeding with an anticipated need to replace total blood volume over 24 hours. Use of such a transfusion protocol may be associated with better outcomes although evidence is limited. In a single observational study of 22 children with significant hemorrhage with expected transfusion requirements of 40",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    in 12 hours or 80",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    within 24 hours and who were transfused per protocol with a goal of achieving a ratio of 1:1:1 for transfusion of FFP, PRBCs, and platelets, mortality was similar despite a higher severity of injury when compared with 33 patients who received uncrossed-matched blood but were not placed on the massive transfusion protocol (45 percent for both groups) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/17\">",
"     17",
"    </a>",
"    ]. Children placed on the massive transfusion protocol also had clinically significantly fewer thromboembolic complications (0 versus 12 percent). However, the ratio of FFP to PRBCs was not significantly different between the two groups although patients placed on the massive treatment protocol received significantly greater total volume of blood products. &nbsp;",
"   </p>",
"   <p>",
"    The optimal volume trigger for initiating a massive transfusion protocol in children is unknown but some experts use the following weight-based approach:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &lt;5 kg (neonate)&nbsp;&ndash; 55",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      5 to 25 kg (infant)&nbsp;&ndash; 50",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      25 to 50 kg (child)&nbsp;&ndash; 45",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      &gt;50 kg (adolescent) &ndash; 40",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      or 6 units PRBC",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, the presence of coagulopathy in severely traumatized children undergoing blood transfusion is significantly associated with mortality and is also used as a criterion for initiating a massive transfusion protocol by some centers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with documented coagulopathy, especially those with significant head trauma, warrant FFP even in the absence of blood transfusion requirements and should also receive FFP if blood transfusion is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10183078\">",
"    <span class=\"h3\">",
"     Controlled hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Questions remain whether reversal of hypovolemia or control of hemorrhage should take priority in some trauma patients. For example, controlled hypotension may be beneficial in patients with hemorrhagic shock due to torso injuries from gunshot or stab wounds. In this setting, titrating fluid resuscitation to regain a peripheral pulse but to maintain hypotension may allow lacerated blood vessels to spasm, form thrombus, and preserve blood volume prior to definitive surgical exploration and hemorrhage control. On the other hand, aggressive fluid administration prior to hemorrhage control in patients with penetrating trauma might, via augmentation of blood pressure, dilution of clotting factors, and production of hypothermia, disrupt thrombus formation and worsen bleeding. However, little data exists for this approach in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Delayed fluid resuscitation/controlled hypotension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, controlled hypotension may be detrimental to blunt trauma patients with brain injury, as hypotension reduces cerebral perfusion and increases mortality. For this reason, we do not recommend controlled hypotension for pediatric blunt trauma victims, especially those with head injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10183093\">",
"    <span class=\"h3\">",
"     Vasoactive pressor medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoactive pressor infusions are not appropriate for the treatment of hypovolemic shock but may be necessary to treat shock secondary to spinal cord injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Advanced procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recalcitrant hypotension despite appropriate fluid therapy suggests massive hemorrhage or mechanical disruption of cardiac pumping ability.",
"   </p>",
"   <p>",
"    Cardiac tamponade may manifest as Beck's triad (increased venous pressure [distended neck veins], muffled heart sounds, and hypotension), which may be absent with hypovolemia. Cardiac tamponade also may cause PEA (pulseless electrical activity) in the absence of hypovolemia and tension pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/16\">",
"     16",
"    </a>",
"    ]. Pericardiocentesis may rapidly restore circulation but thoracotomy will typically be required to control the source of bleeding.",
"   </p>",
"   <p>",
"    Open thoracotomy, though rarely successful in preventing mortality, provides access to the pericardium, heart, pulmonary vessels, and aorta for procedures that may address pericardial tamponade, exsanguinating intrathoracic hemorrhage, penetrating cardiac injury, or large vessel abdominal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link&amp;anchor=H5360138#H5360138\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\", section on 'Emergency thoracotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Disability",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Neurologic assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid neurologic assessment encompasses determination of level of consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/16\">",
"     16",
"    </a>",
"    ] using the Glasgow coma scale (GCS) or the pediatric GCS, a validated scale for children &le;2 years (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/11,12,19\">",
"     11,12,19",
"    </a>",
"    ]. Trauma patients with a GCS &le;8 or who are unresponsive or only respond to pain have severe altered mental status that requires rapid resuscitative efforts.",
"   </p>",
"   <p>",
"    Additional neurologic findings to elicit during the primary survey include pupillary responsiveness and brainstem reflexes (eg, gag reflex). Unequal or fixed and dilated pupils indicate cerebral herniation and the need for aggressive measures to counteract increased intracranial hypertension (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Disability management'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Disability management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with concerns for significant intracranial injury or increased intracranial pressure (ICP) must be managed appropriately to reduce the likelihood of secondary brain injury from hypoxia, ischemia, and cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician should provide supplemental oxygen to keep saturation &gt;95 percent.",
"     </li>",
"     <li>",
"      Head injured patients with compromised airway, inadequate breathing, or a GCS &le;8 require early endotracheal intubation and controlled ventilation (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"       table 8",
"      </a>",
"      ). Hyperventilation (PaCO2 &lt;35 mmHg) may cause cerebral ischemia as the result of decreased cerebral blood flow. Consequently, PaCO2 should be maintained between 35 and 38 mmHg unless there are signs of impending herniation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H15#H15\">",
"       \"Elevated intracranial pressure in children\", section on 'Breathing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with hypotension require rapid fluid resuscitation to maintain cerebral perfusion. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Circulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with evidence of cerebral herniation should receive IV",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"       Mannitol",
"      </a>",
"      0.5 to 1 gram per kg or IV hypertonic saline as 2 to 6 mL per kg of 3 percent NaCl (1 to 3 Meq per kg) to promote rapid osmotic diuresis with reduction of ICP. Hypertonic saline has a theoretical advantage over mannitol because it does not exacerbate hypovolemia in patients with brain injury and hemorrhagic shock. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H24#H24\">",
"       \"Elevated intracranial pressure in children\", section on 'Hypertonic saline'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any child with a GCS &le;12 warrants consultation and evaluation by a neurosurgeon (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 8",
"    </a>",
"    ). In addition, children with a GCS &le;8 deserve invasive monitoring of ICP. Specific therapies targeted at increased ICP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Exposure and environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete undressing of the patient during the primary survey facilitates rapid identification and treatment of multiple injuries. After advanced procedures are completed, the medical providers may log roll the patient while maintaining cervical spine immobilization in order to fully assess the back for injuries to the flank or spine. Many providers chose to perform a rectal examination while the patient is in a lateral position during the log roll to assess anal sphincter tone and presence of gross blood in the rectal vault. Alternatively, the patient may be log rolled as part of the secondary survey (",
"    <a class=\"graphic graphic_figure graphicRef60409 \" href=\"UTD.htm?11/32/11779\">",
"     figure 8",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Musculoskeletal'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pressure sores on the buttocks and heels can develop quickly (within hours) in immobilized patients. Backboards should be used only to transport patients with potentially unstable spinal injury and discontinued as soon as possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypothermia should be avoided with the use of increased ambient room temperature, radiant warmers, warmed IV",
"    <span class=\"nowrap\">",
"     fluids/blood,",
"    </span>",
"    warm and humidified inspired oxygen, and covering the patient with warm blankets after full assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/16,20\">",
"     16,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Adjuncts to the primary survey",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic studies, serum chemistries and urinalysis have low sensitivity for identifying serious injuries in children with blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/21\">",
"     21",
"    </a>",
"    ]. Clinicians should consider them adjuncts to diagnosis and not substitutes for clinical assessment of critically injured children. Of the blood and urine studies typically obtained during the primary survey, the following have the greatest impact on patient management [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type and cross for PRBC allows for rapid transition to blood product transfusion if crystalloid fluid resuscitation does not reverse shock. The emergency clinician should order a blood type and cross-match for any victim of significant trauma in anticipation of the need for transfusion. For the patient with a potentially life-threatening hemorrhage, the blood bank should be notified directly (ie, by telephone or in person) of the need for O negative uncross-matched blood and, when necessary, other blood products (eg, FFP, platelets, rVIIa) for immediate transfusion. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Circulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematocrit value &lt;30 percent identifies low oxygen carrying capacity and may suggest intraabdominal injury in blunt trauma patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/23\">",
"       23",
"      </a>",
"      ]. The hematocrit can be useful as a baseline value in trauma patients. It must be interpreted in light of the clinical context, including the extent of hemorrhage, time since the injury, and the amount of exogenous fluid administration. As an example, the clinician should not be reassured by a normal hematocrit in the acute trauma victim with hypotension. The hematocrit is most helpful when measured serially to assess ongoing hemorrhage.",
"     </li>",
"     <li>",
"      Rapid blood glucose diagnoses hypoglycemia in the patient with altered mental status. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"       \"Approach to hypoglycemia in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevated liver enzyme values (AST &gt;200",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"      or ALT &gt;125",
"      <span class=\"nowrap\">",
"       U/L)",
"      </span>",
"      are highly associated with intraabdominal injury following blunt trauma in children although values below this level do not exclude a significant injury in patients with a severe mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gross hematuria is highly suggestive of serious renal or urinary tract injury and warrants further investigation. Urinalysis demonstrating &ge;50 red blood cells per high-powered field also suggests intraabdominal injury after blunt trauma in children which should be investigated with an abdominal CT scan. Although some experts consider &gt;5 RBCs to be abnormal, this finding would not mandate further imaging in otherwise well appearing children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=see_link&amp;anchor=H18#H18\">",
"       \"Blunt genitourinary trauma\", section on 'Pediatric considerations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arterial blood gas or venous blood gas combined with pulse oximetry identifies hypoxemia. In addition, metabolic acidosis associated with inadequate perfusion is common in the unstable trauma patient. It is important to interpret blood gas findings in light of the patient's current clinical condition. Some values (eg, pH, base deficit) may lag behind clinical improvement after an aggressive resuscitation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the above, the unstable pediatric trauma victim often undergoes the following testing:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count (CBC) with differential",
"     </li>",
"     <li>",
"      Prothrombin time (PT)",
"     </li>",
"     <li>",
"      Partial thromboplastin time (PTT)",
"     </li>",
"     <li>",
"      International normalized ratio (INR)",
"     </li>",
"     <li>",
"      Serum electrolytes",
"     </li>",
"     <li>",
"      Serum blood urea nitrogen (BUN) and creatinine",
"     </li>",
"     <li>",
"      Serum lipase or amylase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these tests do not usually assist in the identification of specific injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/21\">",
"     21",
"    </a>",
"    ], they do serve as baseline values for comparison in the course of trauma resuscitation. For example, electrolytes and renal function may become abnormal after osmotherapy for increased ICP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .) Similarly, thrombocytopenia and coagulopathy may occur in patients who receive multiple transfusions.",
"   </p>",
"   <p>",
"    Selected patients should also have measurement of blood ethanol level (adolescents), rapid urine pregnancy test (post-menarchal females), or urine screen for drugs of abuse (adolescents and children with suspected exposure) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/22\">",
"     22",
"    </a>",
"    ]. Although the results of these will not typically alter acute trauma management they may have important ramifications for care after initial resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Screening radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-table lateral cervical spine (C-spine), anteroposterior (AP) chest, and, in selected patients, AP pelvis help identify immediately life-threatening injuries during the primary survey [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/10,22,24\">",
"     10,22,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cross-table lateral C-spine film identifies up to 80 percent of fractures, dislocations, and subluxations. However, a negative C-spine radiograph does not exclude the possibility of serious spinal cord injury. Cervical immobilization should continue until complete clinical assessment and additional studies, as needed, rule out serious C-spine fracture or spinal cord trauma. In severely injured or comatose patients with a concerning mechanism of injury, the trauma physician may elect to maintain cervical spine immobilization, even after a complete radiographic C-spine evaluation shows no abnormality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link&amp;anchor=H11#H11\">",
"       \"Evaluation of cervical spine injuries in children and adolescents\", section on 'Radiologic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An AP chest radiograph may demonstrate pneumothorax, hemothorax, aortic dissection, pulmonary contusion, pneumomediastinum, rib fractures,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemopericardium. In addition, it provides visualization of endotracheal and gastric tube placement.",
"     </li>",
"     <li>",
"      The AP pelvis radiograph is most often helpful in victims of high energy blunt trauma who are hemodynamically unstable, display pelvic pain, or have pelvic instability on physical examination [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/24\">",
"       24",
"      </a>",
"      ]. Identification of fracture in these patients allows the emergency practitioner to initiate pelvic binding in anticipation of hypogastric artery embolization or operative external pelvic fixation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Circulation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link&amp;anchor=H25#H25\">",
"       \"Pelvic trauma: Initial evaluation and management\", section on 'Initial stabilization and approach'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     FAST (Focused Assessment with Sonography for Trauma)",
"    </span>",
"    &nbsp;&mdash;&nbsp;FAST is a rapid ultrasound examination of four abdominal locations: right upper quadrant, left upper quadrant, subxiphoid region, and pelvis. The primary utility of this examination for the unstable trauma patient is the detection of hemopericardium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraperitoneal fluid secondary to intraabdominal injury (IAI). Although its use has been associated with improved outcomes in adult trauma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/25\">",
"     25",
"    </a>",
"    ], the role for FAST in the evaluation of blunt abdominal trauma in children is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A metaanalysis of the most rigorous studies of the use of FAST in injured children reported a 66 percent sensitivity and a 95 percent specificity to detect hemoperitoneum as compared with the gold standard of computed tomography (CT), and concluded hemodynamically stable children with a moderate pretest probability of IAI should also undergo abdominal CT scanning [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective observational study of 224 children treated at a level I trauma center found that FAST had 100 percent sensitivity and 100 percent specificity for intraperitoneal fluid among the 13 hypotensive children but only an 82 percent sensitivity and 95 percent specificity for all children with intraperitoneal fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While routine use of FAST as a screening test to determine the need for abdominal CT in children with IAI is not supported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/26,28\">",
"     26,28",
"    </a>",
"    ], there may be a role for the use of FAST in the prioritization of interventions for the unstable pediatric trauma patient [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/9,29\">",
"     9,29",
"    </a>",
"    ]. For example, in a neurologically unstable child who is multiply injured and requires emergency surgery for an epidural hematoma, the FAST examination may be useful as a rapid diagnostic tool to decide the need for a laparotomy at the time of craniotomy. In addition, hemodynamically unstable children with a positive FAST may warrant operative intervention in lieu of abdominal CT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Urinary catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;A urinary catheter should be placed to monitor urinary output and to obtain urine for diagnostic testing. Patients with suspected urethral transection (blood at the urethral meatus, perineal ecchymosis, blood in the scrotum, or pelvic fracture) should undergo a retrograde urethrogram to evaluate urethral integrity before urinary catheterization is attempted. Alternatively, a suprapubic tube offers an option for emergent decompression of the bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/22\">",
"     22",
"    </a>",
"    ]. Retrograde urethrogram should be deferred when significant pelvic vascular injury is suspected as extravasated contrast dye from the retrograde urethrogram or cystogram may obscure computed tomography and angiography images thereby interfering with study interpretation and subsequent embolization attempts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=see_link&amp;anchor=H8#H8\">",
"     \"Blunt genitourinary trauma\", section on 'History, examination, and approach to testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Gastric tube",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major trauma often results in gastroparesis and significant stomach enlargement. An orogastric or nasogastric tube should be placed for stomach decompression to reduce the risk of aspiration. Placement of a gastric tube may also facilitate endotracheal intubation.",
"   </p>",
"   <p>",
"    Nasogastric insertion is contraindicated in patients with cribriform plate fracture, either diagnosed radiographically or if suspected on the basis of epistaxis, watery discharge from the nares, or mobility of the maxilla [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/12,22\">",
"     12,22",
"    </a>",
"    ]. In this setting, the orogastric route is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SECONDARY SURVEY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The secondary survey is a systematic head-to-toe evaluation of the trauma patient which must be performed after the primary survey has been completed and resuscitation begun, as needed, with the stabilization of vital functions. This part of the evaluation includes the patient history, comprehensive physical examination, and additional studies and procedures (",
"    <a class=\"graphic graphic_table graphicRef65952 \" href=\"UTD.htm?13/13/13534\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/20,30\">",
"     20,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the goal of the secondary survey is to be complete, the need for rapid treatment requires a compromise in some cases. For instance, in a hypotensive child who has sustained multiple pelvic fractures due to a compression injury of the lower body, one would not ordinarily check visual acuity before moving on to interventional radiology.",
"   </p>",
"   <p>",
"    When the physical examination is truncated due to patient condition, it is incumbent upon the team to ensure that the examination is completed after the necessary interventions or diagnostic studies are performed. If the patient is transferred to another service or hospital, the missing components of the examination should be specifically communicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AMPLE mnemonic may be used to obtain a quick, focused history from prehospital personnel, patients, or family members:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A &ndash; Allergies",
"     </li>",
"     <li>",
"      M &ndash; Medications",
"     </li>",
"     <li>",
"      P &ndash; Past medical",
"      <span class=\"nowrap\">",
"       history/pregnancy",
"      </span>",
"     </li>",
"     <li>",
"      L &ndash; Last meal",
"     </li>",
"     <li>",
"      E &ndash;",
"      <span class=\"nowrap\">",
"       Events/environment",
"      </span>",
"      leading to the injury [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Physical examination and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The components of the physical examination that deserve special focus in the secondary survey are summarized below (",
"    <a class=\"graphic graphic_table graphicRef65952 \" href=\"UTD.htm?13/13/13534\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Head",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scalp and head should be examined and palpated for lacerations, hematomas, or bony step-offs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eyes &ndash; The eyes should be evaluated for pupillary size,",
"      <span class=\"nowrap\">",
"       conjunctival/fundal",
"      </span>",
"      hemorrhage, penetrating injury, ocular",
"      <span class=\"nowrap\">",
"       mobility/entrapment,",
"      </span>",
"      or periorbital ecchymosis (Raccoon's eyes). Contact lenses, if present, should be removed. Awake patients should have visual acuity assessed.",
"     </li>",
"     <li>",
"      Ears &ndash; Hemotympanum (",
"      <a class=\"graphic graphic_picture graphicRef62387 \" href=\"UTD.htm?31/17/32031\">",
"       picture 1",
"      </a>",
"      ) or blood or clear drainage from the ear canal suggests basilar fracture with CSF leakage, as does retroauricular ecchymosis (Battle's sign) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Maxillofacial &ndash; The emergency practitioner should inspect the nose for cerebrospinal fluid leakage or blood. When placing a gastric tube in patients with midface fractures, as indicated by deformity, tenderness, or mobility of the maxilla, the clinician should pass an orogastric rather than a nasogastric tube because of the risk of penetration of the cribriform plate with intracranial placement of the gastric tube. The mouth should be inspected for soft tissue lacerations, malocclusion, or loose teeth [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/20,30\">",
"       20,30",
"      </a>",
"      ]. Jaw pain or deformity indicates possible jaw fracture. Significant maxillofacial injury is a marker for possible cervical spine injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Cervical spine and neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical spine protection and immobilization should be maintained throughout the examination [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/12\">",
"     12",
"    </a>",
"    ]. The neck should be inspected for tracheal deviation, contusions, hematomas, or penetrating injuries, which may affect the airway, the spinal cord, or major vessels. Palpation should assess for cervical spine tenderness (in the awake and cooperative patient), or stepoff that suggests vertebral fracture or dislocation. Crepitus indicates subcutaneous emphysema, which may result from laryngeal fracture, esophageal rupture, or pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the fully awake and cooperative patient, with a low risk for cervical spine injury and without other distracting injuries, the physician may \"clinically clear\" the cervical spine, if there are no focal neurologic deficits, symptoms or signs of neck spasm, guarding, or tenderness with active neck range of motion (",
"    <a class=\"graphic graphic_algorithm graphicRef70732 \" href=\"UTD.htm?12/52/13134\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/20,31\">",
"     20,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Chest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspection and auscultation of the chest should be repeated as described previously. In addition, the entire chest, including the clavicles, sternum, and ribs, should be palpated for crepitus, step-offs, or tenderness. Children may sustain significant internal injury to the intrathoracic structures (eg, pulmonary or cardiac contusion) without evidence of skeletal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/9,30\">",
"     9,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspection, auscultation, and palpation of the abdomen with reevaluation is important for the pediatric trauma patient as examination findings may change over time. The physician should evaluate the abdomen for distention, ecchymosis,",
"    <span class=\"nowrap\">",
"     presence/quality",
"    </span>",
"    of bowel sounds, abdominal tenderness, rebound, guarding, or palpable masses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link\">",
"     \"Overview of blunt abdominal trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a \"seat belt sign\" (a linear contusion across the abdomen) coupled with abdominal pain and tenderness has been associated with a three-fold risk of intraabdominal injury and a 13-fold increased risk of gastrointestinal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/32\">",
"     32",
"    </a>",
"    ]. Hollow viscus and retroperitoneal injuries, including to the pancreas, are often occult initially on a clinical basis, and a high index of suspicion based on the mechanism of injury is important for the identification of these injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13001?source=see_link&amp;anchor=H7836200#H7836200\">",
"     \"Hollow viscus blunt abdominal trauma in children\", section on 'Seat belt syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Perineum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspection of the perineum is important for the identification of contusions, hematomas, lacerations, or urethral bleeding (in the male). Although the utility of the rectal examination in trauma patients has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], we believe that it does add information regarding blood from the bowel lumen and sphincter tone in the unstable patient. In teenage or adult males a high-riding prostate suggesting transurethral transection may be palpated. In the female patient the vagina should be inspected for the presence of blood or lacerations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/30\">",
"     30",
"    </a>",
"    ]. Postpubertal women with pelvic fractures should undergo vaginal examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=see_link&amp;anchor=H8#H8\">",
"     \"Blunt genitourinary trauma\", section on 'History, examination, and approach to testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergency provider should inspect the extremities for swelling or contusion and palpate for deformity, tenderness,",
"    <span class=\"nowrap\">",
"     presence/absence",
"    </span>",
"    of pulses, and quality of pulses. Any potential fracture should undergo splinting. In addition, limbs with neurovascular compromise require rapid involvement of orthopedic and vascular subspecialists. (See",
"    <a class=\"local\" href=\"#H43\">",
"     'Orthopedic management'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ecchymosis over the iliac wings, pubis, labia, or scrotum is suspicious for pelvic fractures. In the alert patient, pain on palpation of the pelvic ring suggests the presence of a fracture. In the unconscious patient, mobility of the pelvis in response to anterior-to-posterior pressure on both anterior iliac spines and symphysis pubis is suggestive of pelvic ring disruption. \"Rocking\" of the pelvis back and forth should be avoided as it may increase hemorrhage due to pelvic fracture. The patient must be rolled and the back inspected and palpated for tenderness or step-offs if not already performed during patient exposure. The axillae should also be examined [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief but thorough neurologic evaluation including motor and sensory function as well as reevaluation of the patient's level of consciousness and pupillary response to light must be performed as part of the secondary survey. If any spinal cord injury is suspected, the patient must be immobilized using cervical spine immobilization devices [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/20,30,35\">",
"     20,30,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pressure sores on the buttocks and heels can develop quickly (within hours) in immobilized patients. Backboards should be used only to transport patients with potentially unstable spinal injury and discontinued as soon as possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Adjuncts to the secondary survey",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the pediatric trauma patient has been assessed, resuscitated, and stabilized, imaging can be performed to identify specific injuries not detected or fully characterized on the screening radiographs. CT scans are the modality of choice to identify intracranial and abdominal injuries, and their use has been increasing over time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/36\">",
"     36",
"    </a>",
"    ]. There is concern, however, about the increasing exposure to radiation from CT scans and the consequent cancer risks [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Therefore, injury mechanism and clinical factors must be carefully considered when determining if a CT scan should be performed in the pediatric trauma patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;After stabilization, the cervical spine radiographic series may be completed with AP and open mouth odontoid views. Due to the possibility of spinal cord injury without radiologic abnormality (SCIWORA) in the pediatric population, trauma patients with brief or sustained sensory or motor deficits with no radiologic abnormality and decreased level of consciousness must be assumed to have a cervical spine injury, and cervical spine protection must be maintained until proven otherwise. Based on physical examination findings, extremity radiographs should also be performed for the evaluation of suspected fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\", section on 'Radiologic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Head CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial imaging should be performed for normotensive patients with GCS scores &lt;15 (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/20\">",
"     20",
"    </a>",
"    ]. In a hypotensive patient with depressed mental status, every effort should be made with fluid resuscitation to improve the hypotension which may also improve mental status and obviate the need for a head CT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/30\">",
"     30",
"    </a>",
"    ]. Other indications to consider include headache, multiple episodes of emesis, more than momentary loss of consciousness, focal neurologic findings, or an underlying medical risk factor (eg, hemophilia) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/20,40\">",
"     20,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Neck CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although CT of the neck with sagittal and coronal 3D reconstruction is highly sensitive and specific for cervical spine fractures, the radiation risk does not justify routine use of neck CT in pediatric trauma patients. Screening cervical spine radiographs, which identify most life-threatening cervical spine injuries, remain the initial imaging modality. An anatomically focused CT on the cervical spine level of concern should be obtained in any of the following circumstances (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\", section on 'Radiologic evaluation'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inadequate cervical spine radiographs (three-views)",
"     </li>",
"     <li>",
"      Suspicious plain radiographic findings",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Fracture/displacement",
"      </span>",
"      seen on plain radiographs",
"     </li>",
"     <li>",
"      High clinical index of suspicion of injury despite normal radiographs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Abdominal CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal CT with intravenous contrast is the preferred diagnostic imaging modality to detect intraabdominal injury in hemodynamically stable children who have sustained blunt abdominal trauma. CT is sensitive and specific in diagnosing liver, spleen, and retroperitoneal injuries, which may be managed nonoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Abdominal CT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4777?source=see_link&amp;anchor=H14482574#H14482574\">",
"     \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\", section on 'Imaging'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    CT with IV contrast alone is less sensitive in detecting injuries of the pancreas, intestinal tract, bladder, and lumbar spine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4777?source=see_link&amp;anchor=H14482574#H14482574\">",
"     \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\", section on 'Imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13001?source=see_link&amp;anchor=H952288#H952288\">",
"     \"Hollow viscus blunt abdominal trauma in children\", section on 'Imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=see_link&amp;anchor=H14#H14\">",
"     \"Blunt genitourinary trauma\", section on 'CT scanning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential indications for abdominal CT scan (only for use in the hemodynamically stable patient) include the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Abdominal CT'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal tenderness not attributable to minor injury",
"     </li>",
"     <li>",
"      Seat belt sign (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13001?source=see_link&amp;anchor=H7836200#H7836200\">",
"       \"Hollow viscus blunt abdominal trauma in children\", section on 'Seat belt syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      History or mechanism of injury suggestive of intraabdominal injury in a patient with distracting injuries",
"     </li>",
"     <li>",
"      Initial serum aspartate aminotransferase (AST) &gt;200",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      or alanine aminotransferase (ALT) &gt;125",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"     </li>",
"     <li>",
"      Gross or microscopic hematuria (&ge;50 red blood cells per high powered field) in asymptomatic patients",
"     </li>",
"     <li>",
"      Declining or unexplained hematocrit or hematocrit &lt;30 percent",
"     </li>",
"     <li>",
"      Unaccountable fluid or blood requirements",
"     </li>",
"     <li>",
"      Inability to perform adequate abdominal examination or serial abdominal examinations (eg, children younger than two to three years or those with substance use, head injury, altered sensorium, or planned general anesthesia) in a patient with history or mechanism suggestive of intraabdominal injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The accuracy of CT imaging may be increased with the use of oral or intravenous contrast. The routine use of oral contrast is controversial; it is rarely of benefit in the diagnosis of acute distal bowel injuries, but may be helpful in the diagnosis of duodenal and pancreatic injuries. The use of oral contrast media can increase scanning time and cause vomiting although low rates of aspiration have been documented in retrospective studies. In addition, oral contrast may inadequately penetrate the small or large bowel. For these reasons, many trauma centers no longer use oral contrast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Abdominal CT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with hypotension are also at high risk for intraabdominal injury. Those children who do not respond to fluid resuscitation require direct operative intervention; a FAST examination may be helpful in characterizing the injury in this situation. Those who become hemodynamically stable after fluid repletion should have an abdominal CT performed. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'FAST (Focused Assessment with Sonography for Trauma)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with suspected bowel injury, who are hemodynamically stable, emergent laparoscopy may be considered as a diagnostic and therapeutic procedure. This may be useful for selected patients who have sustained blunt or penetrating abdominal injuries as an alternative to laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13001?source=see_link&amp;anchor=H10391032#H10391032\">",
"     \"Hollow viscus blunt abdominal trauma in children\", section on 'Operative management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Orthopedic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures resulting in neurovascular compromise may be gently reduced and splinted while awaiting orthopedic consultation. If the pulses are present, the extremity may be maintained in the position in which it is found. Splints should be placed to immobilize the joint above and below the injury site, if possible. The neurovascular status of the extremity should be evaluated before and after splint placement.",
"   </p>",
"   <p>",
"    Pelvic fractures may be temporarily managed by wrapping a sheet around the pelvis at the level of the greater trochanter to reduce pelvic volume and control hemorrhage (",
"    <a class=\"graphic graphic_figure graphicRef76777 \" href=\"UTD.htm?9/7/9331\">",
"     figure 7",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Circulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Open wounds should have appropriate wound care, and IV antibiotics should be given for open fractures (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=see_link\">",
"     cefazolin",
"    </a>",
"    30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"    Tetanus immunization and pain control should also be addressed (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/12,30,42\">",
"     12,30,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Definitive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the patient has been assessed, resuscitated, and stabilized the patient should receive ongoing care directed by a trauma surgeon with pediatric expertise when available. Because optimal care and outcomes occur when the critically injured child is initially resuscitated and subsequently managed in a pediatric trauma center (PTC), it is preferable to provide initial care in such facilities from the outset, whenever possible, or to arrange transfer to a PTC for ongoing management [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/43-48\">",
"     43-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of 13,351 children treated for trauma over a 4 year period in Pennsylvania found that overall mortality was lower for those who received care at a PTC or Adult trauma center (ATC) with added qualification in pediatrics (ATC AQ) versus a level 1 or 2 ATC (3.6 or 4.3 percent versus 4.7 or 8 percent, respectively). The most severely injured children who were managed at a PTC or ATC AQ had significantly lower mortality than those treated at a level 1 ATC or level 2 ATC (approximately 12 percent versus 22 [ATC level 1] or 16 percent [ATC level 2]). In addition, children with head, liver, or spleen injury had lower mortality at a PTC than any adult center and were more likely to undergo nonoperative management of spleen injury, the preferred treatment for this type of blunt traumatic injury in children (splenectomy rate 2.7 percent at PTC versus 16 to 28 percent at adult centers) (",
"      <a class=\"graphic graphic_table graphicRef59672 \" href=\"UTD.htm?20/9/20635\">",
"       table 10",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Retrospective analysis of 79,673 injured children admitted to the hospital in the United States in 2000 found that, when adjusted for injury severity, overall mortality was significantly lower in children's hospitals (0.9 percent versus 2.4 percent in a children's unit in an adult hospital and 1.4 percent in an adult hospital) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/49\">",
"       49",
"      </a>",
"      ]. In addition, a shorter length of stay and lower charges occurred for children treated in children's hospitals.",
"     </li>",
"     <li>",
"      An observational study of 3245 children with splenic injury admitted over 10 years in Pennsylvania found that those patients cared for in adult settings were approximately four to six times more likely to undergo splenectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the assertion that injured pediatric patients have special needs that are optimally provided in the environment of a children's hospital with a demonstrated commitment to trauma care [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/51\">",
"     51",
"    </a>",
"    ]. In the United States, experts have developed a field triage guideline that identifies those patients who warrant direct prehospital transportation to a trauma center. This critical field transport decision requires evaluation of vital signs, level of consciousness, injury anatomy, injury mechanism, and special patient or local emergency medical systems considerations. These guidelines recommend that children \"should be triaged preferentially to pediatric-capable trauma centers\" (",
"    <a class=\"graphic graphic_algorithm graphicRef81002 \" href=\"UTD.htm?22/18/22822\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For this reason, injured children should be transported directly from the field to a PTC, whenever available in a reasonable time frame. If a pediatric trauma patient presents to a site other than a PTC, they should be stabilized and transferred to a PTC, if possible.",
"   </p>",
"   <p>",
"    However, only about 13 percent of all injured children in the United States receive care in a PTC or children's hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?29/16/29962/abstract/45\">",
"     45",
"    </a>",
"    ]. When a PTC is not available, injured children should receive care at a hospital that has the highest level of pediatric trauma expertise and resources. Depending upon the region, this site may be an ATC AQ, an ATC, or a children's hospital without trauma verification (",
"    <a class=\"graphic graphic_table graphicRef66042 \" href=\"UTD.htm?19/9/19612\">",
"     table 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For this discussion, the unstable pediatric trauma patient refers to any child who has abnormal vital signs, disruption of vital functions, or apparent injuries of a critical nature. Knowledge of normal vital signs by age and awareness of the ability of children to sustain major hemorrhage without hypotension facilitates recognition of the critically injured child (",
"      <a class=\"graphic graphic_table graphicRef60424 \" href=\"UTD.htm?41/23/42363\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Terminology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3477?source=see_link\">",
"       \"Trauma management: Unique pediatric considerations\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Trauma assessment and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial trauma management in the pediatric trauma patient are summarized in the tables provided (",
"    <a class=\"graphic graphic_table graphicRef65952 \" href=\"UTD.htm?13/13/13534\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). The phases of treatment are (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Initial approach'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary survey (rapid primary evaluation) (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Primary survey'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Assessment and management occur simultaneously during the primary survey. Any identified physiologic threat to life must be rapidly addressed and treated before moving on to the evaluation of the next priority area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resuscitation of vital functions (eg, airway, breathing, circulation, mentation) (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Primary survey'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Utilization of adjuncts to the primary survey and resuscitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary survey (more comprehensive secondary assessment) (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Secondary survey'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Continued post resuscitation monitoring with further resuscitation as needed",
"     </li>",
"     <li>",
"      Utilization of adjuncts to the secondary survey",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transition to definitive care. If there is any deterioration of the patient during the evaluation, the primary survey should be repeated and any newly identified problems addressed before proceeding with the definitive care of the patient. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Primary survey'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Secondary survey'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Definitive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial assessment and resuscitation, definitive management by a pediatric trauma surgeon at a pediatric trauma center is optimal to ensure the best patient outcomes. (See",
"    <a class=\"local\" href=\"#H44\">",
"     'Definitive care'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.cdc.gov/ncipc/wisqars (Accessed on January 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/2\">",
"      Krauss BS, Harakal T, Fleisher GR. The spectrum and frequency of illness presenting to a pediatric emergency department. Pediatr Emerg Care 1991; 7:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/3\">",
"      Krauss BS, Harakal T, Fleisher GR. General trauma in a pediatric emergency department: spectrum and consultation patterns. Pediatr Emerg Care 1993; 9:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/4\">",
"      Freid VM, Makuc DM, Rooks RN. Ambulatory health care visits by children: principal diagnosis and place of visit. Vital Health Stat 13 1998; :1.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Surgeons Committee on Trauma. Advanced Trauma Life Support for Doctors, 8th ed. American College of Surgeons, Chicago 2008.",
"    </li>",
"    <li>",
"     Waltzman, ML, Mooney, DP. Major trauma. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/7\">",
"      Perno JF, Schunk JE, Hansen KW, Furnival RA. Significant reduction in delayed diagnosis of injury with implementation of a pediatric trauma service. Pediatr Emerg Care 2005; 21:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/8\">",
"      Vernon DD, Furnival RA, Hansen KW, et al. Effect of a pediatric trauma response team on emergency department treatment time and mortality of pediatric trauma victims. Pediatrics 1999; 103:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/9\">",
"      Stafford PW, Blinman TA, Nance ML. Practical points in evaluation and resuscitation of the injured child. Surg Clin North Am 2002; 82:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/10\">",
"      Dormans JP. Evaluation of children with suspected cervical spine injury. J Bone Joint Surg Am 2002; 84-A:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/11\">",
"      Cantor RM, Leaming JM. Evaluation and management of pediatric major trauma. Emerg Med Clin North Am 1998; 16:229.",
"     </a>",
"    </li>",
"    <li>",
"     Ruddy, RM, Fleisher, GR. An approach to the injured child. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1339.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/13\">",
"      Schafermeyer R. Pediatric trauma. Emerg Med Clin North Am 1993; 11:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/14\">",
"      Jaffe D, Wesson D. Emergency management of blunt trauma in children. N Engl J Med 1991; 324:1477.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Pediatric Advanced Life Support, American Heart Association, Dallas, TX 2006.",
"    </li>",
"    <li>",
"     American College of Surgeons Committee on Trauma. Advanced Trauma Life Support for Doctors, American College of Surgeons, Chicago 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/17\">",
"      Chidester SJ, Williams N, Wang W, Groner JI. A pediatric massive transfusion protocol. J Trauma Acute Care Surg 2012; 73:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/18\">",
"      Hendrickson JE, Shaz BH, Pereira G, et al. Coagulopathy is prevalent and associated with adverse outcomes in transfused pediatric trauma patients. J Pediatr 2012; 160:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/19\">",
"      Holmes JF, Palchak MJ, MacFarlane T, Kuppermann N. Performance of the pediatric glasgow coma scale in children with blunt head trauma. Acad Emerg Med 2005; 12:814.",
"     </a>",
"    </li>",
"    <li>",
"     Waltzman, ML, Mooney, DP. Major trauma. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1349.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/21\">",
"      Capraro AJ, Mooney D, Waltzman ML. The use of routine laboratory studies as screening tools in pediatric abdominal trauma. Pediatr Emerg Care 2006; 22:480.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Surgeons Committee on Trauma. Advanced Trauma Life Support for Doctors, American College of Surgeons, Chicago 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/23\">",
"      Holmes JF, Sokolove PE, Brant WE, et al. Identification of children with intra-abdominal injuries after blunt trauma. Ann Emerg Med 2002; 39:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/24\">",
"      Rees MJ, Aickin R, Kolbe A, Teele RL. The screening pelvic radiograph in pediatric trauma. Pediatr Radiol 2001; 31:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/25\">",
"      Melniker LA, Leibner E, McKenney MG, et al. Randomized controlled clinical trial of point-of-care, limited ultrasonography for trauma in the emergency department: the first sonography outcomes assessment program trial. Ann Emerg Med 2006; 48:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/26\">",
"      Holmes JF, Gladman A, Chang CH. Performance of abdominal ultrasonography in pediatric blunt trauma patients: a meta-analysis. J Pediatr Surg 2007; 42:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/27\">",
"      Holmes JF, Brant WE, Bond WF, et al. Emergency department ultrasonography in the evaluation of hypotensive and normotensive children with blunt abdominal trauma. J Pediatr Surg 2001; 36:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/28\">",
"      Eppich WJ, Zonfrillo MR. Emergency department evaluation and management of blunt abdominal trauma in children. Curr Opin Pediatr 2007; 19:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/29\">",
"      Levy JA, Bachur RG. Bedside ultrasound in the pediatric emergency department. Curr Opin Pediatr 2008; 20:235.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Surgeons Committee on Trauma. Advanced Trauma Life Support for Doctors. American College of Surgeons, Chicago 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/31\">",
"      Slack SE, Clancy MJ. Clearing the cervical spine of paediatric trauma patients. Emerg Med J 2004; 21:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/32\">",
"      Sokolove PE, Kuppermann N, Holmes JF. Association between the \"seat belt sign\" and intra-abdominal injury in children with blunt torso trauma. Acad Emerg Med 2005; 12:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/33\">",
"      Shlamovitz GZ, Mower WR, Bergman J, et al. Poor test characteristics for the digital rectal examination in trauma patients. Ann Emerg Med 2007; 50:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/34\">",
"      Shlamovitz GZ, Mower WR, Bergman J, et al. Lack of evidence to support routine digital rectal examination in pediatric trauma patients. Pediatr Emerg Care 2007; 23:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/35\">",
"      Cervical spine immobilization before admission to the hospital. Neurosurgery 2002; 50:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/36\">",
"      Blackwell CD, Gorelick M, Holmes JF, et al. Pediatric head trauma: changes in use of computed tomography in emergency departments in the United States over time. Ann Emerg Med 2007; 49:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/37\">",
"      Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001; 176:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/38\">",
"      Frush DP, Donnelly LF, Rosen NS. Computed tomography and radiation risks: what pediatric health care providers should know. Pediatrics 2003; 112:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/39\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/40\">",
"      Palchak MJ, Holmes JF, Vance CW, et al. A decision rule for identifying children at low risk for brain injuries after blunt head trauma. Ann Emerg Med 2003; 42:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/41\">",
"      Feliz A, Shultz B, McKenna C, Gaines BA. Diagnostic and therapeutic laparoscopy in pediatric abdominal trauma. J Pediatr Surg 2006; 41:72.",
"     </a>",
"    </li>",
"    <li>",
"     Bachman, D, Santora, S. Orthopedic trauma. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1525.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/43\">",
"      Bowman SM, Zimmerman FJ, Christakis DA, et al. Hospital characteristics associated with the management of pediatric splenic injuries. JAMA 2005; 294:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/44\">",
"      Mooney DP, Rothstein DH, Forbes PW. Variation in the management of pediatric splenic injuries in the United States. J Trauma 2006; 61:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/45\">",
"      Ochoa C, Chokshi N, Upperman JS, et al. Prior studies comparing outcomes from trauma care at children's hospitals versus adult hospitals. J Trauma 2007; 63:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/46\">",
"      Stylianos S, Nathens AB. Comparing processes of pediatric trauma care at children's hospitals versus adult hospitals. J Trauma 2007; 63:S96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/47\">",
"      Segui-Gomez M, Chang DC, Paidas CN, et al. Pediatric trauma care: an overview of pediatric trauma systems and their practices in 18 US states. J Pediatr Surg 2003; 38:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/48\">",
"      Potoka DA, Schall LC, Gardner MJ, et al. Impact of pediatric trauma centers on mortality in a statewide system. J Trauma 2000; 49:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/49\">",
"      Densmore JC, Lim HJ, Oldham KT, Guice KS. Outcomes and delivery of care in pediatric injury. J Pediatr Surg 2006; 41:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/50\">",
"      Davis DH, Localio AR, Stafford PW, et al. Trends in operative management of pediatric splenic injury in a regional trauma system. Pediatrics 2005; 115:89.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Surgeons Committee on Trauma. Resources for Optimal Care of the Injured Patient. American College of Surgeons Chicago, IL 2006, p. 55.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/16/29962/abstract/52\">",
"      Sasser SM, Hunt RC, Sullivent EE, et al. Guidelines for field triage of injured patients. Recommendations of the National Expert Panel on Field Triage. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6571 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29962=[""].join("\n");
var outline_f29_16_29962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INJURY CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Injury extent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Injury type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Injury severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INITIAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PRIMARY SURVEY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Airway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hemorrhage control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - IV access",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Fluid resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27380186\">",
"      Blood products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10183078\">",
"      - Controlled hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10183093\">",
"      - Vasoactive pressor medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Advanced procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Disability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Neurologic assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Disability management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Exposure and environment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Adjuncts to the primary survey",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Screening radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - FAST (Focused Assessment with Sonography for Trauma)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Urinary catheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Gastric tube",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SECONDARY SURVEY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Physical examination and management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Head",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Cervical spine and neck",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Chest",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Abdomen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Perineum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Adjuncts to the secondary survey",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Head CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Neck CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Abdominal CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Orthopedic management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Definitive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Trauma assessment and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Definitive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6571\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6571|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?12/52/13134\" title=\"algorithm 1\">",
"      Cervical spine clinical clearance algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/18/22822\" title=\"algorithm 2\">",
"      US 2011 trauma field triage algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6571|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 1\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/2/14369\" title=\"figure 2\">",
"      Pediatric manual C-spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/19/23857\" title=\"figure 3\">",
"      Flail chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/14/36078\" title=\"figure 4\">",
"      Direct compression bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/16/28937\" title=\"figure 5\">",
"      Pressure points hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/23/7538\" title=\"figure 6\">",
"      Scalp lac hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/7/9331\" title=\"figure 7\">",
"      Pelvic binder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/32/11779\" title=\"figure 8\">",
"      Log-roll technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6571|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/17/32031\" title=\"picture 1\">",
"      Traumatic hemotympanum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6571|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/13/13534\" title=\"table 1\">",
"      Trauma secondary survey",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/23/42363\" title=\"table 2\">",
"      Critical physical findings of trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/37/28252\" title=\"table 3\">",
"      Normal respiratory rate and heart rate in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/42/684\" title=\"table 4\">",
"      High risk trauma mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/18/29996\" title=\"table 5\">",
"      Injury severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/3/31803\" title=\"table 6\">",
"      Pediatric thoracic injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/47/34556\" title=\"table 7\">",
"      Classification of pediatric hemorrhage shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2989\" title=\"table 8\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 9\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/9/20635\" title=\"table 10\">",
"      PTC vs ATC mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/9/19612\" title=\"table 11\">",
"      Verification level",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=related_link\">",
"      Blunt genitourinary trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=related_link\">",
"      Classification of trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33124?source=related_link\">",
"      Closure of minor skin wounds with staples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=related_link\">",
"      Continuous oxygen delivery systems for infants, children, and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13001?source=related_link\">",
"      Hollow viscus blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=related_link\">",
"      Initial evaluation and stabilization of children with thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=related_link\">",
"      Intraosseous infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4777?source=related_link\">",
"      Liver, spleen, and pancreas injury in children with blunt abdominal trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=related_link\">",
"      Overview of blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=related_link\">",
"      Pelvic trauma: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3477?source=related_link\">",
"      Trauma management: Unique pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=related_link\">",
"      Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_16_29963="Antimicrobactivity antiseptics";
var content_f29_16_29963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial activity of topical antiseptics for external otitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Candida sp",
"      </td>",
"      <td class=\"subtitle1\">",
"       Aspergillus sp",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mucor sp",
"      </td>",
"      <td class=\"subtitle1\">",
"       P. aeruginosa",
"      </td>",
"      <td class=\"subtitle1\">",
"       S. aureus",
"      </td>",
"      <td class=\"subtitle1\">",
"       E. coli",
"      </td>",
"      <td class=\"subtitle1\">",
"       Proteus vulgaris",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cresylate",
"      </td>",
"      <td>",
"       3+",
"      </td>",
"      <td>",
"       4+",
"      </td>",
"      <td>",
"       4+",
"      </td>",
"      <td>",
"       2+",
"      </td>",
"      <td>",
"       1+",
"      </td>",
"      <td>",
"       3+",
"      </td>",
"      <td>",
"       2+",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thymol",
"      </td>",
"      <td>",
"       1+",
"      </td>",
"      <td>",
"       1+",
"      </td>",
"      <td>",
"       1+",
"      </td>",
"      <td>",
"       1+",
"      </td>",
"      <td>",
"       3+",
"      </td>",
"      <td>",
"       2+",
"      </td>",
"      <td>",
"       4+",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gentian violet",
"      </td>",
"      <td>",
"       2+",
"      </td>",
"      <td>",
"       3+",
"      </td>",
"      <td>",
"       2+",
"      </td>",
"      <td>",
"       1+",
"      </td>",
"      <td>",
"       4+",
"      </td>",
"      <td>",
"       3+",
"      </td>",
"      <td>",
"       3+",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Zone of inhibition: 1+ = 7 to 9 mm; 2+ = 10 to 12 mm; 3+ = 12 to 18 mm; 4+ &gt;18 mm.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Lawrence, TL, Ayers, LW, Saunders, WH, Laryngoscope 1978; 88:1755.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29963=[""].join("\n");
var outline_f29_16_29963=null;
var title_f29_16_29964="Pathologic skin picking diagnosis";
var content_f29_16_29964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for pathologic skin picking",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         A.",
"        </strong>",
"        Maladaptive skin excoriation (eg, scratching, picking, gouging, lancing, digging, rubbing or squeezing skin) or maladaptive preoccupation with skin excoriation as indicated by at least 1 of the following:",
"        <ul>",
"         <li>",
"          Preoccupation with skin excoriation and/or recurrent impulses to excoriate the skin that is/are experienced as irresistible, intrusive and/or senseless",
"         </li>",
"         <li>",
"          Recurrent excoriation of the skin resulting in noticeable skin damage",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         B.",
"        </strong>",
"        The preoccupation, impulses or behaviors associated with skin excoriation cause marked distress, are time-consuming, significantly interfere with social or occupational activities, or result in medical problems (eg, infections)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         C.",
"        </strong>",
"        The disturbance is not better accounted for by another mental disorder and is not due to a general medical condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Subtypes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Compulsive type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin excoriation is performed to avoid increased anxiety or to prevent a dreaded event or situation and/or is elicited by an obsession (eg, obsession about contamination of the skin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        It is performed in full awareness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        It is associated with some resistance to performing the behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        There is some insight into its senselessness or harmfulness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Impulsive type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin excoriation is associated with arousal, pleasure or reduction of tension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        It is performed at times with minimal awareness (eg, automatically)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        It is associated with little resistance to performing the behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        There is little insight into its senselessness or harmfulness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mixed type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin excoriation has both compulsive and impulsive features",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs 2001; 15:351, with permission from Adis, a Wolters Kluwer business. Copyright &copy; Adis Data Information BV 2001. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29964=[""].join("\n");
var outline_f29_16_29964=null;
var title_f29_16_29965="Less com pathogens after BMT-I";
var content_f29_16_29965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Less common pathogens to cause infections in bone marrow/stem cell transplant recipients not receiving standard prophylaxis-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Preengraftment (0 to 3 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Bacteria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Gram positive",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Listeria spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Nocardia spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Corynebacterium spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            C. pseudodiphtheriticum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            C. striatum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            C. equi",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Lactobacillus spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Leuconostoc spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Gram negative",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Aeromonas spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Capnocytophaga spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Yersinia enterocolitica",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Salmonella spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Brucella spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Plesiomonas shigelloides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Campylobacter spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Vibrio spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Spirochetes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Borrelia spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Treponema spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Ehrlichia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Chlamydia spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Mycoplasma spp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Rickettsia spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Anaerobes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Bacteroides spp.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Fungi",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Candida spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            C. krusei",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            C. glabrata",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Zygomycetes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Trichosporon spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Phaehyphomycoses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Curvularia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Alternaria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Exserohilum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Bipolaris spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Hyalohyphomycoses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Fusarium spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Scedosporium spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Scopulariopsis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Endemic fungi",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Histoplasma spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Coccidioides immitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Paracoccidioides spp.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Viruses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Respiratory viruses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Rhinovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            BK virus",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29965=[""].join("\n");
var outline_f29_16_29965=null;
var title_f29_16_29966="Treatment membranous lupus";
var content_f29_16_29966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cumulative probability of remission of proteinuria in patients with membranous lupus treated with cyclosporine (CSA), intravenous cyclophosphamide (IVCY), or prednisone (Pred)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 437px; background-image: url(data:image/gif;base64,R0lGODlh+AG1AeYAAP///0BAQAAAAICAgP8AACBzOcDAwAAzmf/AwP9AQFiWa5C5nMjczsDN5kBms6CgoPDw8NDQ0BAQEHBwcGBgYDAwMFBQUCAgIP+AgODg4LCwsJCQkICZzP8QEP+goP/w8P8gIP8wMP9gYBBAn//g4CBNpvDz+f9QUP+wsNbl26zLteTu5//Q0LDA3y58RVBzuTyFUnCNxnSohODm8/+QkGCAv6Cz2dDZ7JCm02afdzBZrP9wcI85HJ7CqUqNXoKwkLrUwldWKo9ZPBhWKo+ZfPL38wAmcjtkMatLNVdmOgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD4AbUBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwr8ZiACIQ0DNmQYhFDhwIcQs0UYICDAoAkCKkiQsBCjRo4RQ4p8FkBARUEQBEgAsEHAhJQrW04YSbPmMQMnAeC0uHOnzpw2gwrl5fMnz4o+iwoywLQp04VDo0o9VTRCRgAaBFiwWgGrVkIBwooNcGHA1LNoPUVoWcEABAAX/wRosCDgAVy5dO0qGmA2rd+/lEqaFGAAQIQKKmcaRixB8d6+gCNLTsV3suXLoipj3swZk+bOoEM7+iy6tGlCpE+rDp16tWvMrV/Ljhx7tm20tW/rHpp7t2+avX8Lhxh8uHGAxY8r35d8uXN7zZ9Ljxd9unV21QsZoBB2AFTtAiBfH/8s+6AHiSeUPYRTPPn3yswLkiDAIAAIBiOUbPzTAuIAbyEmwAV2PRCAei7Bp2Au8vkUwVMASNAWBXLhVBZiGwBAgQEaXLASRQEMQJ99C5YoS4MnCTaAhQEgtmJ4P5k1gIACAEBRYTeaqCMs8kUowEIUDWCVBU1l0F6MLQ0AQf9JNhLWZGE7RrlKj+g1VpJZiFEwgAUvmtVeSxZMQN+TZEpp5ik96sRdiAtBsEFYFESgn11zAjBBABRwB4CBBvF55p+kpAnooMIISuihvRiK6KK4KMroo7M4CumkrkhK6aWUuYfpprpYyumnoHgK6qibiErqqZaI+gBfA2ggSQTcxWnIXAe+ZVis9tG6lSLbBWCBXg9Y4KteLLWqyap8uQpJjqhSp+klJVUQl2ONQLCRiBLYulRGGFlkrQTYvtUiY9oWgl5FcWmo1ZY1ApCBSRdoEu20yzrZLDyiluSWSeayyheUgqBHgbrEEnxXBgIbDBViABcyoiCumgQVlBTF1bD/hhYBgCdLcfF3iL4p1XjnXBFAQKFWbz1An8X34vusJSCrVMidYxUcZJPi6asxYTffjNJG5Q6ilCCCXSArXAQKMDAhGGmA0wRDGrAqIjGvFG0AEVgggQYycbWdvS23k29Gcb2MSM8wDqKzvmhDRmHBhAx934wmcfQ0TOW+SwFGGWRAXwW7fkw2jEwKolJYFVHkKrNhP4JBCASAIAIJ14yt5cU7D5Z2wEob/KDBcSHc+dv3IUbs54NYWx/EOqHE8MmDwS3tBV1BkAG7KxVUSEmXE91uhBc0NZFcZTbOyAeQE6A8AR2wYM3YmAvyoFPf3Xct0Dv/VEG31oOLfVwXhGVX/+eomURWjRkN4FFKbRnAViEt1aXTBROI2BVQvjdcuJ2JU2DBuxUYAMuMxwgMLO+AIHie2ShxJxJFAlZ4ss+dICasl0gPV0SrGU4wp6sCrWkDEDBAAIgVlnItCUD3oZkFDzQzrDEtYwETlgVcpQFfNZCAjOjAAQ+IgmqYqhYDgCEOqbHDA2LAhwtMxgMcOERpFHF5R6TGD5tYExA8kQDOk2ISqYgZFDwxAZ2YgF42sEU0lZGLljHgARPwgU2EsAIbMoCw3EgzvUDgTjNkxBTROBISJIAACeghJ3CiOfJlAjETMN3OEgm2s52Rj5MxYBQ5cbvw8QWEmzDJ8BQyoD0Z0v+RkFSNJEERgept4lwSOIoqF7HHUEZklJ9Q2WCEeAmtiakuScGfv1gVIleaBpaeoI9YqGUJn2QlAO+KV8IGsUu+9JITyDLWAzFYCFpZ8DwrQoQB/DURYq3qLb36FUL0sk1lVWKbfHlA0BiBP18KApid8BgnVMdIs5SEkdFDzSMdMa8EPeJb4Yobt4CSlc2ZizHIVImtJKBM84VOYge7RMUQ0xVItNOd8OTEBJbWCQj+CiV4NGcioBeyfvmrYQkj3SBIF7ruGRQ8GStJgWD0MKw0KQBJitsI9xQAA2SALhlhoiBuxjD9bGACM+nQgOyypAFd1JcZ3YRgzBepfTaiai3/rFn5ZGTQtTnJPz5jT07QYwEA0MVI7YRAxy5gwquUBAJ0cRrUDkHU+uAklVBTmgEQA1cBbEBuGCXAJMM4FmJWyqqM6Oc+2wYWJ+krKxugEAVMKTSgjOgrgC0o5ihklYFhJJUvm+hJjtSkCpwPJxV9qiujOg3LZXN3hRRPSuX3OZb+iCKaMwvqKgtDCsWFqTU1J79mVRHiQeABCFKIW8oXInKmLUlNYZ/haBnYwXLiMIS5QIZOhNhF6OwQ0ysSIQCKPSahlnvMTNsnv7Yew9Qtvej63XANsTKicSmujMOZQPvit8bM6GsbVW0oWXvIjRhggtwlrFAdAcGjIdia5TKQ/102SAgDiWWlOD2IDElIXUG8abu6cpWfzrPTQdRJEBlQIQRMFiIWupMQBMaEXHoaxKoyo8YvpkaMLyGBN3WIozzqbi6W2CwPQK4DkxPHjlOluXxOScg5LsUfD9i8cCzZEm/Ko42jbAs17rADbfzGlSmxJXcFQKSvaCWXKWHFJ4YgAXCOs5znTOc62/nOeM6znvc8ZytadxMS0IueErxmWlzx0IhOtKIXzehGO/rPmrAXjmOh5kJH4tAiQICmN83pTnv606AOtahHTepSf5pyn6hABTSgAXkG2dKzSF4RETCQgqqEsq2oNKwd4cUigvEht3PIlncNCw/sMARhFghSb/+h6+sgQAQJOIEHBOGBE0R72oKgAQYEqQsSWFEE2H7IoIEI5T8ZG5BWBIAICHACDJyAAIIggfISyIs/0joiGwBXOoc9Kh1msYfKQ/W9DWjFe+vC3iGZqoBV0WzpIACQhZiy5LIIAhAYWwT1JoDBHxJe3RF6VA//9SA+8DjldYAED9/BB5iXbFwgPCQIud2CWdHw53zA34Lo4b2Rp/F1HzDcLtd4SDBCGAsAOc3lPpMaE5BuAoQAAztw+spDoGkaOH0XL4eIBCjQlkm/GlUosLa0AeABaCeABh9AQALCDeeW2yLrDyFMT8f9dWLHAu4DadEF6LJdSifd7pvAu0AiQJ//jKwz138HfCYEPxCP81vxrGA8QO7oKzQjHfKvkPw/FG55xEuJBNre9jg07w8YQcC0j1+QB3S4PGSHg/T90HKZP16ihxcxBK8XekQoED6yhM+wT97Ru5/I7W7Anh8Kp2rdS3RoEPD5+dCPvvShr8ONS6fmnXG09rfP/e5v3/rPwT5n2lzEHZj6/OhPv/rV7/bwJ143XqZy+zHvmffrxuc/p+LhDyslGrT5BFnURAZQFvvHcPa3G2PWLBmwH51ngGaSgC3DFH73gIJFRVkzTKlXIhAIKnExSxm4IBv4KV9hC+IHGiHIKWHCbAcIfxXYRBSQSmEBfDS3grdxgpuicB02/4MUCGn0NwgpFhYGQXla9hg7GA4KcIRIiIQp0A1J2IRLeF0JgWuVQHiNMVf3xDCsRIO2YYPOUABe+IVfyADdAIZkKIanNBgSMHOTEFc+5S6dtEwjpYWzwYXNQIZgaIbbYIdhyAkSQCQaADiZpBIqwRSjtXA2IoeyQYfMoIde2AMM8IiQGImSOImUWImWeImYmIma+IiMWAB4mAmSloOTwC9gkktC1ExBhIgh8QGhB3SboIiPsAILMIsLkAKzOAgMUIsAwAAyoAA5oAK2uACCIIs9AAqdeIzImIzKuIzM2IzJ+ImYIC3q42qXEBchVBHJ5ElAhorPVBoowHrzFoCaAP+LjpACCuCFCpACMOCJgpADBbACKoCO6wgA66gCACADBWCPn9CJPtCE/viPABmQAjmQBFmQBNmJ0HgJhGcSFVCAkkAR/kE8V9hIdKWKD0EC4Lg8IDB/lUCOj+CFgrAABSADALACBaAAAOACBfCEQLCLBeACDHCSoYCQY8iICYkJjrcJb3JmIFV5emSRA4F/O0QDnOCRjgCSJfmSANAD+RiTKFkI7qiST7iPNlmTeniTk+Ad0TQAcMN/pSFrO+R802dnfnYKSAkA7qgCPuACLvmUhLACKimMM1mV3ECToChCmiOKDlgaGel9jMaDVDkI8biOJFkEUikILSkI54iVmkD/i4RJiyvQDbQ4mbMYmZngFh2nhnspGsNXRJm2fqKGaqMgi164AJapkisZkvJYAIOwmKXgmhHxAOpkdLRQgvtwbkUkmsFgjkooCD2gACQ5CECQA76ojwDwA+n4muwYEdp1Mn23fKEhlMrjiv8AmxBBGKaFYBN4GkamPAkAftW5nFoXJF53eatxfPpgnQ9BdHt1dF6pGuiZD+o5EG6iARAgJB8IGvGJD/MpELIJV+75nqexn/fQnwHRnCbxnOYJn7r3EAYKENh5IHqZKa5BoIxwjnool97woP8ALuFRngJqGha6CBhqhxrKhOK5nibRnvnZGSOqCCVKhifKDRzqD/V5/5+aSaHn2aCZEKNgCAMGGaRCOqREKqQqyZjHYZv+8KKJ4KPO+KRQGqVSepXXiZceSHsiyqOY4KReKAOb+KVgGqZiKqZFABFYQzMx2KKcwaSIwKUFMKM9KFFAGRFseghuCqfNIkcYiKWlUaeGcKcEVHjKt50MCp6VkAKPiI9e+oiW2TjUyKei4aeIIJJ4GjYGIjxquhmSegiUSkWwY4iooKT9sKmG0KlNlD77BqmhQaqFYKpD5GLkVqFa2phv6qkwCKvQ2aezmgmuikM4mKmYwaqE0KtxWipzChHCOgjEajyUlzUNGHw7aqiXsKyNA1TbUVaqqp+7ignUGjZ+RWMTGv+qx/oQyaqaldoyMyZC2EqoA7qt01qrLrgRvwWsl1GuANCtLdNXjxqiuiqtloCv9yInKiir/loJANssYTGw0foJB4sqf6iwhcqw8PqqeUmvlmGvDXsqaIqrC9quBUsJGVuskSCq/ICxEyuymkCy+2Cy54qyWTmuvcCKGIAB1Il17vqvJ9s4y9UoMLsL34hA4mizHzsJISuCB9aV7OoNGFlEG+kLLDtEWmFJqZq03SCdy2N+oJm1oAk5QysJRcspRFex2ZoNYOmXZnu2XRsJX8sphxFHOZkJb6IY2LWvhaCystCXy9MBYylnQsCISbC3dxa0tNqyEZijk0BIGRMXcyH/P0QYDp25Q4D5CCKph265C2vLtoXXkG5EOyfBFV6xrqAUDri5Q7oJsoxYubpwuZtyAWUhJgHKQBdwTEYxu40bDlZbs17LiDBAmbzbu777u8AbvLx7joSLKqGoCUPiWw9gimAxFmHRXuLQneyWtoswuVN6vdhbmlS0dxwCR8gbFozxEjIjE3HjFEyhJeagPJxgvWS4u8L7vvAbv7+LpM1yLiphuJFQFB6xEVLITD3bC+q7CewLhqjrsp8wEcJGSVzJEFH4k+kLbwJ8uga8DXZbCwFMq5Q7wdpQwYYGwZqwApDohZA4lRqsQA9sjKxZwqLgkPwKDhfcCWepwp8gPiT4/7+88MKcEMMyHEZ1czRU68IeDMMpvMOfcFyZ+6ziesKBScRqgSBOFa6lwMGzgMOboMNMnAklQT8LgTA//A1UrAlWfMWXsAFI7Hnl8MWZEMZiXAli5GE2HLq/QAIioEMhgLuXgMaYoMZrHAlvFEdzNLa28LMHhHGdgMeXoMd7/AiEpDmvC60xi7ctuAmGbAmInMiNUEkhkhAsnMS+MLoIVMhBnMNDbBM2wAGm3AKR0AAHwAE1UUoQywvxB7kzO8u0XMu2fMtqhMJD4QAHoAMlcAAxAAmqzMoioZX+grQ66AuxfLaJpstCwcsNYAIHcAAAEAMO0AIvcAMmUAPT/AImAP8AN/DLv0zMISF3YtvFt9Brt4fL7NzOtOzMQQHN0jwCAMDLOuAAN/ACI9ACOADMADAC+9zP5BwRmOkU+GsKUswIZas81PsKlfwQ9jzO9UzNgnAAI+AAvOwAqhzMw6wgCb0IPJd/v/DQA8HLNcABDSAIvDwII1ACDfDSN7DRANDRIlFIg5qrvOAB31a6vEDSAgHNhLDSghADB+AAHFADLwAAJTACHMDLA22mzsuxLZxxDR0LPh0Q1nwDhGDNhGADL+AAL4DK+WzUDmADHv3Gl2Cvo3DVlvwxEbCxMujIwKDWosDWbV0I5nyl6HxwN4sLdn3XvvDRjUDXcwnYlSCEZaz/o8FA2PBs2JHAeRZLC4y9xI4dCaaHeoAcdFUNC39d2TxpI1CM0GgtCbk4i0LAA0Qwi8bZ06McDiaAyqsB250Avr23d5H9CgP8hQWcC50tDRwwAt98GjMwAjjgCTYNqmb0C7mNjiPd2t8wA9MczKfxAhYd3CbsC8stk77Q29BA3dM8A6ahytNcA0VMRlOL07iQ3S5QpOzd3kjI3c4g3tNcAhhd3/Z93/id3/q93/zd3/793wAe4AI+4AD+y9N8AFrdCUB10x27CQhwAjp0AsWHs9lb4VM6DgZ+4Bq+4Rze4R7+4SAe4iI+4iRe4iZ+4ijO4Q5g3BghQqNdtzToyQRA/8jvqoc+MKY4nuOSKA79vOEj8NJAHuRCPuREXuRGfuRInuRKvuRM3uROjuQt0OGyHWkGwBEgasabIG9PtNmtKsGdYQIj0OFPfRkc0OElEE/B4iGhHcUrGHVPdALc6uWcQdQdDtycAd0ePuaWIJtUeNBs3glTVkR6C7gJgARBcOhHUABAqgA/0Bl47uHkvRm87OEjAN6ttYKBzsyHxgM5uxkzEOTTLOScgeTWjQlzG9dynQlW9+Za62lE0OmhMc1mEhct8lJTXQk3J+g8jbPFexmyLiXEY1ZrHig0yAIZ2QETHue9bhm/HiVtbCOg2+Ca8AHnhnaeoLp+0ewmctzDPv8KezTJBgvroKHtJRLVUo3lngDuprvsk0HuxPbtoRzB7C4Z7l4i+orqk2AkDRNC+AvvoIDt82Dpn1DvC1IStW5/8WN4nsSQLOzvEjvv91DWoEDwChLs2okJsrlXfuUjd7TxtZvu8T64EWEDB1ACpb4JFA8f4HIfFhDtmYARf1WIE+rw1y7u/WACBq7nmJDy7xG2we5GQMO8Hw/K/27z/FDm03zRBO7fPP8eWZbYD6QRBiH0GeS80AvyRQ/xAZ/iKW4msvkJVd5jukMfHf+c5nu+iKjuRGv0+uDdGo7ST57kZvLHs12x9qu5Q88Jap+7Wh8P8q3hOoBDDxA8TOHnjJD/mSjxtnCM9Q8/EDrg4WZtPL+a2ZWw92rL9vdA8pR+8vV7zLcNCZYPCQDfDjhgyk1d1KbPAQnu2DTfCaMPD2Wu8/fyWS9ekaEQ+pKL+foQ+0NkaxSJ3pmA+47w+u/A+zgkQCt29Xt9xyHPq7qfD8ZPQP/VnoqP7kTf+BAR/caDW+cM/Jgg/I1A/O6g/Y1jYYX1+Y8A/owg/u1A/pV9iLff/MoeEe5f2a2/vs9PC/wsDPUPCACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXjAMDmIkEBJyHCwULoKWNJSMmpquIHAccrLGys7S1trelmrOesqKkuKCuBzXAwa/FyMnKy8zF/7qyvLG+zZImIwfYLQ3b3N3e3+Dh4uPiNcfU6Onq6+nPsdGs0+yL5tj29/j5+vv8/f74sOYJHEiw4CR3rOCtkmdwUIN8JRxInEixosWLGDNq1GijocePIOchXKXQFEOPDiCGXMmypUtbI02VLHXSoI19AV/q3MmzJ6KYpWaCqknQRIl9I2b4XMq06UegoIRyIjoQRz9iTrNq3boMKiepmKg2xMa1rNmztLxiAntJrEGyaOPKnRtJ7SW2ltwWhEu3r9+/di3hraSXIN+/iBOXDVxpMKXCAw8rnky5J2NKjidBFii5sufPIC9Pyixp87zOoFOrZidaEulIptmhXk27dv+y1o0YLNjNg8fuBSpMjmo527bx47JwMxJVoLnzAgqE/1pZHLn165aUL2L+vHl0msNZVsdOvnymTcK7N/fBoL379/Djy5cRnvoB8/jzN9KuiLv6/wAGqN50IY2n34Hk8ZeIf8+5oMCDEEYo4YQUPhicePchqOGBCiLCoHPfKWbghiTS1mEoAIaY2IgltvjZiYZ86B1lLLpoo2IwFqIChN49+AONGd4opGo5ItIcaDUOqWRcRR5y5GdJLiklV00a8qRnUU6pZVNVFnJlZVluKSZPXRLyJZBjpolWmYOcOVmYasYZGnqxuClikHLmuRSbgti5Ip56BjqPBgNskMF5s/j/iRicgjYqywQCVCCBBIcqwicAiv7FqKOcggKBABIAsIEAEyxyaaZ+bdrpqpUYIEAAALgKq6V0soJqX6qyqiskssb6KiEGBCusARRQMOyxyCarrLBDDLHss9BGK+201FZrgBFGWKvtttx26+234IYr7rjkChtBTxFECoAGAlhASADwxhvABRfIa++9+Oar77784ktvvwAHLDDAElQw8MEID/xqwgw3fK+kDkfs8MISVzywwT5dIIAGFgjwgKm1hnQpLQEY4JIALhkwK0sot6SyTxFUAGqpILs08iwln5zyyiu1zNLLdN2cXMgg5dySzysBzfLOfQkdi9OsGL20yzyH/4R0SErLBfUqW5sidc9MHx32XF3nQvRHX1s9NthU9/XAxy297dIE57ZUNUgR0MzS3R/lvevfgAcu+OCEF2744YgnrvjijDfu+OOQRy55pxBMEIAFGqzE8eV1r6RJpSBBsAG8cH9UOekgPVDr6AFs0NAApUdAAbyZlxUAqTKbXHQFMksAwUqQCqC76TJTAHtIMk8gc+kEESuAzwO02/HZ6Txw+8oD1Pv88FllIMAFADwgAAUhVZo71qAKH9KoAxjQ+UfPRxC96wZZ//wgGmfgPfgDKf+rIJWCFPV80qterQQCk/qd6S5gOfUVLX0CoN9HxAcqvg3kfoLAIAYHYsB3Of9QKwX8X0go4LGQTEACGpDZBhTokdu5D1QhsYAETlhCj2xQg1djRwcFIT7ycWV/4RtfSCCwvJXc7nnbAwkJM7fBhvSKXRacxwbzB8TmiRAAJPSh7XD3QY9orF4BYB7auujESHVMbw1BIBcHqA4DRE8A7QNA9CwwPYI8gIQXGMChSCgBeKExK6fDnBHlJUaPWO59HtkcGwUiu8sVUiDWixfcWCdBgVguXue6pB8nx8lOevKToAylKEdJylKa8pSoTKUqV8nKVrrylbCMpSxnScta2vKWuMylLnfJy1768pfADKYwh0lMj7gPABkwAAt1ksxlFtOUEbAXIn4VPe6tRHX/gqjmM1Ppqj7CSxAQMADoqOnAZpYiAog8RDIFIc5BhBN04FSmIG6XTeGtcxARaOc2PblDCgoRAOQ0GQmf9zESnktdoxIjPQFAz+gdUYuFcJXMxte7Q/mTfBJ9HqXeCMfoTbQCyJwoHPfZSVchMQCfglX0mKhS4bFrE7eDALs2oAEJCCADHYOA6nSx0IaW8HbwHISsDKAx1cExpXLc2FBJqMfcZSB6EzBA7qK3iXySlJOuyiPsXLUJrgK0pW5UnzbbRQEZPkAC7tIkQ1vmU5Np0xBepSdXvTrXkca1ZdqsZgRs+r10XrVxHfQe+cT3sYASFos3BYAML3BHjVVyngKI/wARUabNjmUAAgOoHTtHKlc4CjaID6ArZ/EqVuFFIJmQiuJfE7dDEgagYL8LKBH7+E8K6vR5QU2qRikbqeKta2PAGq2vNuFa2IqWuJHaQF6F59AirhZyTxUjoR6gwOO58VA6zaw7CwUAzD52EKqLADapejwATIB/g3iqybCpXkFM93ftba/oBpBPPcZKj9ml73Ov+lZBVOCR+w3wLK4LLAEb+MAITrCCF8zgBjv4wRCOsIQnTOEKW/jCGM6whn+i3/ZWwqqJ8KohFrrhWD4PpCKmBIkP8c5DrLjErkTiBrwKgY7NMBFnfZ4FdGrTMOKzdROgm4+l+jxY0TOaf4QxKv9fJSnxbaJjhIogIt5mAEjNWGNx3GwfozpSCVzAABogX0zp5Uwln/JVWR3p/65IiAjI8HkwvZqIvSqzemXudh2zppnPDKuBbqJg3W0XMuU5CC/nU7jBRY9XM7ABCtg0mq8S9J5V+asM2HQTkJoAlJPKvUkN4HZPJpVm59xl40kqA/S8HYAnHcoA0Gx0k7xc7az3vmgG4NMfc3MANBtNuPVaVPCiQCZhheods/rYyE62spfN7GY7+9nQjra0p03talv72tjO9pYeYIEAGKu7rPu2IJSrWVZIsJETKDNBTjcAdRdEE/BmSSRd3RLMvkSRLGFduTHBx9eiNHkDwBgyn4f/XlM4bxAayCREDWIB1wU5acGqKUvKVgoIvDgkDzhUw1eyQghcwK+TSNcFFKgBiSpQd9HTmJ4xkcwcZs0gLUOgzRYpEIqDggLi4wnOXXKB3FKCqoRQY6TSLQh69VAWOTQeSD6ewZZY2t3vDoDBfF6QCbguhyGJmbvkfYHvVgLohMgABTSmLlelG1RQt8TVHgBSkEj1clhviNJfsoGtfyTMTd/JBGguEIuvfBJZJbn+AHi/gSJx1WonBNvT3jy7g+TpOnl5/eLF5p+p9t18d8Tt+thHV1lgAGf8VAWCNaq2r8Jniz9gSP9ekLnn+7IbF5vNIFDjzKdDvMj8sinCrcy6/zsyVj6eJ0pNMe+PafLy64imuIc4/JZszutoozu8oL9uywlS29jPvva3z/3ue//74A+/+MdP/vKb//y3dCO85Vc61f2OWI6UH3qeSn1InFteH/luydMoxvozcnaIJxBPBW8BWBCNBHIFsTmlwHYV5D2+IwheFkSvojEAUFSIVYCLcHDshHxtREKFcFa2pwyRJFQeGBISIFm7NkTCAnopUwHY5TkUQHsG9z+qFkR/Flnu5SsSsEOU0HJCxYHp4IM/tncGEQGjk16ugjWzwjEukTYgcX0s8YCrYEDi4y6WxYOKlT4IGAk+83a6Z0PpVQGYFYLK8HJxNxAZMHLAFzdAKP8Q7SJ1rCcQRBUvVAd4IvRogoaFljZSoJBDewU/gxAA52JzvFI1ZzgQG2Aw38QSXyh7EVBwTjQrjVYKHYRHJaRGdaNZLlQKWHeI6+Az8WJ0BmGGNuN/kNSGAiGFnsgOMbOBoOA8eSQI6QJD9TSBoEhGiedebuV4BZFDhPgIpDhEsaKGK9GILfFwdbcSFZA5sYcJ87Yys1NJm2MBpXNInFB8AIBujIcO2AheGMgMmnQu3egR1jMBddg8C9cSn0Z0QxSN6PeO8BiP8jiP9FiP9niP+JiP+riP/NiPAQZv+gUJ/YUJ9xcv+fdjBmkQOgVe8ZJkfVc6+NYQIAZO36gOC0n/CKZ4e9xzkZhQZDa1b6aCi4BXgmv4ERpYkg0xgtlEhsygkuGjcRnJDNlDJy5JjosYKyT5brHIQzd5CfcDRea1axYgWQNlbDmmcpwghCjZEEopeQNhhNjDkssAlYawcwVBLHRClXhzhACUhE7kelrZkSjDLu5yOwbjZig0KnQTKc4Th1woVAZjjL0Il/PiluigNJ82dcbEM1rnEQjhlFdpiE9RK4ApCR6pPiRWQdezUpzGiYbwh2BYCJAZmIaQjJFoCERoEH+JincpmH5JmJyZCHBmX2tVaF8WLPIDXAPpk4ewiunQiZcZUaGZDJJXmOqwmUnjma8Dmn14NSSWWgNQjlbeUwHZI5KU4DP7x4KRuS67GJuiAnsx2Qx4SXuft5vAMpvMEIzW+YOg0JNBqXjdJkgacDnW6IySlI2zw44FgY3aaBDhuC7dFp3giEnA1joNgX9BCS9buA7vOY4DgZ/v6Y8COqAEWqAGeqAImqAKuqAM2qAO+qAQGqESOqEUWqEWeqEYmqEauqEc2qGFEwgAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Austin, HA, Illei, GG, Braun, MJ, Balow, JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20:901. Copyright &copy;2009 American Society of Nephrology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29966=[""].join("\n");
var outline_f29_16_29966=null;
var title_f29_16_29967="Carcinoid tumor CT";
var content_f29_16_29967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carcinoid tumor presenting as pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 255px; height: 249px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD5AP8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDi/hOrr4RiJYbTLIQO+N1dpErSKAO3GMGuT+FFuW8JWbBioJkJOenztXoEFsu1Y0AdyOAcksPSgCOw02W6uo7e3VppnPyqgHT/ACOtbSaBesSVXECYDyKuFBzjHPXr9K04/wCztGVGeRLqcAmRg3H59No/WuW8b/ETS7VIpV1eKYspH2aByEXHTIzgnnt6dqANv7J5AZPNDrzg8cfjmozMsZGxd5zgf/rrwfWvizqVwZY7C3hWM5VXkJOPcD/GuXu/G3iS5JD6tPFg/dhxEP8Ax2gD6hjuJMj904HAyVGKlD70cKmfXj7p/wAK+VV8XeJVYY17UAx6k3D/AONMl8UeIZsrN4g1ZkOQV+1OFOfbNAH0brWuaXppC3F3EJD/AAn5sHv3qlY6vZXrO9pcQTHgkCTaSa+erYSXUg8+SaQk8l2J/nXT6PpwUrGi7mOPmxgUAe5pfXCLw6le3GQfXB6Gqk16SDv3EkYJXgY/P/P5VkaPbG1tERvvkZYBiQPXg1aYL5XHHAAAJoAsC5LyBiBkehyOvFW7K6eC6jmaJHZT90/T2+v61mQhQxySOCOv3anCoG24U4P3c4P1xQB06eJtr7porgqSD8srB174HP8AjUd/rMFzH5apcysGyGuCuFI9D+PNc+EjKKAxAcAEc4NPERBY/ezk5I/z+VAE6zKysbgAlgMuF446jg0+FLcSK+6NGXB3ADGff86pgAYAbbk5OcjH1pku0hMnDEfLzxnHT/61AHRxzmLcUwRzkjk9v84qKe8mYYDRhWPAxkj681ix8OArbMdfmAwPanRTtswHJ24O04/GgDVjknMaJJJ5yY4BOQBWlBb26Rl3ULJnABTOBjpx71grdSoFAAY8c5Gf0qVNWdTyoJB59R17+vWgDpY7eORGMjW8SleAwzz6cdM1TmtoNp+SIM/A4AOKx21YMfmR8Y+6CQaq3N6JTJhNoGSCzEn9fagDZNvtYmPbgnhVU4Ht196ZLbySgjy4yQM53DJHoO1YCzlMFSQMnIDEZ4/Sp4b+eGTBm3Drz+PPBBoA1VsfOQlIo1nwBkry4HTnvWfqGliF/K1CBogHwzEdPfr3NbWkX1vPcQedIuQxcBpxGCc88kjt2FdJq4sbo7mt3jkcguzA7WwCOM/X9KAPL7myEDkyiMKMklgMD8c1Wa1hZG3W8TA8n5Afrn0/nXb3mhxMpbTdlxGq4ktmky/oSoPUewzWDe6erQtJbkMBnKj+H1/GgDAfTrR51X+z4m3DdnyUxnPT1zz6Y681VutB0qdHjuNNtWjbG7EYQ+vVcHr71sSIAcBgB2HOQOetIArZJAAHB5OD9KAMz4OwgeA9NYJksZTwAMnzX/wrQ8R/EHTfDVncW0LH7YSVkdcMTjjaD/nNeP2Pje60zwVY6XZNsYRuCy8NzI5xnPTn61xE88lxcNJM5dyc9c4oA7LxT8QL7WFaC3DQ25O5tx5Y++O3tXHSSSSuXkYs/qaiVyG+b5h3FOkUrtOckjI70ABY4AGfSp5IyYoSFY/L1FQjJ+9nB5HFXpTgRxq2AB096AIrfKycFirYGPWrUEcSSSb3YAA42jPPuaYo5BjctheeMbf8antohnkA479vrQBp6cplkXf80Y4KjgV6doOnLAy+WrZdQyjoUHOc81xXhPTxc6lChb5N2SCOcj3r1qKAWqSLGMuTjJHOOlADlz0dcrzzgZH+H5UwNmM5YkZxnAIpTuKgblIB6jPA9/bvSuSoOGBPTAHXvQAgycFi5O3IIGalUD+Lg9lzx9ajVymAmGA7Lx/9arMYKyHfh+mI8Y+n+R6UAPKyHy+AB0xn8qkQIhUEyEnIwpByePXqetOzI8W3eSSOgAJ+mfwqxHYvuzJlFxkE88H2oAq5h5xFIHByPmA/l3NIyxlPlSbbx1IwD/Sr62aKMZC+mB14HQU4WVvtZsOSSAcHr7H/APVQBlfMrDKsTznH0o3LyNjMu7C9OcdBWubWMbQeABwd3NKbOFd28kccnOO3Q0AYjRl9pIK5AyO/FOEcqsqxx5B5HvWuLeNUBznn5ic4J+vNOMKheMAE46nj8aAMXbJyBEwY4OR6fSmjPO6IdMqF4rfZF3MQFPpgZprQR5XhQOSvfPP/AOvtQBgMyKwDqyc9D1P45x2qPc2TypJPXjH9fSuhe1iZE3JtHTnPJqpcaYHOYZcYA4PI9+e1AGRjeD8mUbPG4Hv35q/Y6veaSQ9lIQo3b4pPnjYY5BHTHuPaqTxsFcEJ1OOwU5/+vQeVw4ALjle/r0+tAFrWPiXolqkb6jbXdnO3H+jKCr+/LDHrVrSvFuleIV3Wc5ec95AAzY9e2a8d+J8DLJBuwg2nt0wf1rzyw1K6025M1nK29DnFAH1Td2qyqrKqo5ztGB/nFY9zGYnf5Pm4xjn696yfhz8QIPFMi2V2I7bUyMrtHyuQCcj0PtzXbzWi3M58ziYDA6Dj6UAfG0HzR8t06fnTweMADimQZEYO4AehPWrEkMogE/lkwNxvHIB759D9aAEAVupG/qCKkihEsMjLLHmPBCM2GOfQd6gBIxjg1YDRyDMu4OBlXRQf++uf1oAkTa9uQRhoznknkGpYlDDLnaD09T9KW1R13SgIymNsnPBqdCufLbJYnOTx+GKABFjUEbGbOD8x4H5Vp2duCgeQ4Xk7RjpTIoDCyF0zxkE4AP8AjU4bA2up9QcjGfr3oA6Hw45+2wRREhWcYGcZr1N8BhliTwDuPf68V5Z4HP8AxVOnRkHJfPUcfKTXqZYs7EICp4JbAH86AGPt2Zz14Pzdvx/zxTEdUVVf7hPTPFToSeVLnkkHg/8A66a8Q8kOVPIwDj/OaAGshjPBzjhwD2z/AJ5rSso4yAeuT1z16VHpkbgKZfuryWAwce9aFvNEqGNtpO4gZ5+n8hQA9NqRbkwAOgzyDjrU6sCxw2D14PH55pvyttGCwIGMYGenH5UHJIPbByemDmgB45GFbjHUZzmg8jaSM8YI7fX86QZJb73pnp1pu4YG1SThQAeDQBJkYOTxtO4A8H6HtSfKVPzLwew6+2aYx68hXGccjjBHbNP+YMwI4xuYZ7cdKAFY4G7cdwH1/rStgYK9s8liuM+1N+YRqCCE6j3x3/SlzgnKkevFAAmEcsu0sB8uH559fSmnG1+WxngA9/U//WpCScFgCpAJ3cf/AKqUMRH3BHsB7fj7UAAGACVCH7uAeoo2jfwQD0LA5HfjniiQ7UHC7B93v+tNJBJIAO4cnb9efagCjqcKGMyxhiwyCzHrjvx0PesolScDbg8Eqcg5/GugupcR/vQdrEj5csO5yfQe5rDkBVyI8tt455OPT0oA47x9Z28unyE/NIBvRl/WvDrrAlfaPukivonxLH5tk2W5CEA5Bx1xzXzzeg+fIpzt3Ek0ANtrmaxu47myneKVDuV0bay19A/C3xrL4l0+W3v7iNNTttoEjvgzKc9eRkjHNfPcYRg+dwUfNnqfpUljeTWN150DMrjI4OKAKUOCi5P6VZtrqa3LiNgY3G14zyrD3/xqvEFMQZByB8wz+tOyMYB6980AXJbdHQy2RLgfejPVB/WoYRubHJXuKjibZJlWZW7EHGKtJMGBEignuQefrxQBJaymFXz92RShH17/AIVM8UkeA6DaCACO4FVioIKh1yOxOKlkDBFLlC4wOHDEj3xQBdWQEo2/+HjjOPapI52DAK2NpxyMcGs+NzjG7OPTnFTI24HcfmAOCD1oA6nwXdfZfFulyuSGaYKSR65H9a9inQiVlJUEHAyf6n+VfPtjMY7mAjOUcMMN6V9AQ3C3NrBcJIDHNGrfe5/n1zQBJCoaPLbeM4UjJ/L86togdkUnIB4xnp19ar2QAlZgTkDsM/nWoqr5aHJHI3Z5xz2/CgCxDCypsHCnOTjk+/X+dSx2kSqflDDOd3JPSo4goJdMncMnnkn2x1/GnqQCoTacjHBxgfSgAMI2qVHDDg4pxyQO/UdOTTCVZRgbgPXkjpRkdA4+6QS3A49utAAy8n+8flwPp/nmlHJGTnOOxGRnk570ZVc7WKjpjd2x0prY2j5jnoAf8fSgBwxvVSQAFyu4cDntRHktldoyxIG3A4/pQfmdsEdcZyOKViASxLkA9c8dqAAglW2BemD65+n9acCxK4ZWOfTvjvUZI27SSeAAexwKQgZ/eNtY+n0zQA5WQqWDRlXAYMDkMPXPelPQdBjOML/Ln/P601WHfgEc5Oc/XH4UgxsPzdeDnOaAH4IZdoAJIBGSMds80BzyST0Az657Z/CkbG8EYUHuTkHj1/OjYokOGycBQR3H6UAKucck8dDnIPbpWJeR+W4G3oTnPQe2c9a2gVGTuIUg9eMf49f0rE1ELHMSABk56n0/SgDI1aSKCymurhl8iKMmQdQBzxn3/pxivnnVNQFxNItugigLE8Dlsnua9X+LmpNbaNHaxOytct83zc4Hc/rXjAXLlQc575oAdwEO3PTHT3qMng9B609hlwoHPbFLJhDtjcEj7xHrQBHBvjVHXI9CKnMLPE1wgGwHDgHp9Kht5HVRtbAx07GnrIVO8bRnjGOtACKTnPftU0SGQMRgAckk4AqJh0ICjPb0pVxxQBNj5RgBsdTnrSoZFcMikMO4qIkjhgMHpTgWVuGIPpQBOFYEZGMnqKsQkAZcnBJUiqQlaPO75gezCphPkqxQHjOSeKALocFUMalcHBB5z75r2XwHem78Oxx8s1u2zOeoOSP614vG/msAFBfsMda9I+E92xN9buFUlFbpk8E9s+9AHpmmxmRhkZYt1BAz35q+jJLbpLE6sjKCjhgVKnuO341V00gRqG2nGfmI68/Wr0Ak8lSzrKQ3D7ccelAEiZOAQQTxnoGz2p6klmwOc4LA47VHGGJymMY4z1wP5f8A1qkyvB+Uruyv09v50AALAKWX5vlPzZA/z9aC5ZRjGeeTj+fSgZ2ZBwcjGev4U7BbgZPBO0dvagAjJyTg4zgDjmiPjaVVSDg/j1pmcSuSVG7gnp6f59KcxwmMocAcEAnHvQA0MB5ZYHOM98f/AF6emSQrLncQCc8n29xRhl7r0yc4wPSmAH5t4ByOmM5HGAP50AOyu0bunAHHT9aTO1gWT7oxyc5/DtS7SULE8sRk9vSg8NnKKSeeg/GgBFbDfLvBPA55P+RQeIj8pOPcYPuc4pyjk7WXJGDnt9PyoOdp+ZsjOVA7evvQAzdna23dztBwAfp9acBjnywwHPC8jPUj0607G1QCRz26/wBf5U7a+45GR069f/rUAMY4U7flY5PI6j8awr9jPqIRB2AAbj8ce1blwwCncI9pzg9Of89q83+I+uXGh+HZr2AqLq6k+yxZ6x7gctj2UH8SKAPLPibrMeteKZTbyGS3tkECN2YgnJH4muZBMdoTjDy5GT1CjqPzqNBsVn4Y8AfX1pjlmI3EkjgUAKsjIGKnlhg/So/unjn60pOOmB+tIc5xQAR7TGMDnHrTwACDkhvT0qKLlQB1p4OPwoAkBz3znue1A9O/oKT7pPyr7ccUpGQTjigB6+mW9cE8Ujcnj+dH/LNW2kqOCcflSkqWBHToRQAi4z1/+vUsZ+Xd8wFMX5XHP5jpTQcAknuc0ATh8kYyvod2a7L4XXoi8UQROTidWjwe/FcT0OD/ACq3pty9neQXURKyQuHVh2I9KAPpfTyV9h90/n1x6VsICVTcOo+91OevWuU0e9j1HT4b63AKSgNkjGD3AyPXNdLaP+6jdVzkDOR+VAFpVHmYU4LDnr/n0pyk5z84LH5cnvjvjpwDyajOBjjOM8EYAHr708FSMlcDIH3e/celACdl3jPTnPDd/wADTwNzhSxLcqA3THrUeE2qwUemMYOcfyp4AZVGOoB5/wAaAI5t2GxuDZ4Gc5OKdHtMS47kNtOSevt/hUFxIC2xeSzdQvQep/wotQREhYZOABgA55HfFAFlgcqDkHPUk9fTH+elIoBbO7JJ4INBXkbQA2CTxxzzSJjPAyeCDj+lAChcgH5gcDj0H1qQApjDHLZ7Ek+p6/5wai4UYAH+9jkcdvypTsY/d78grwTj/wCtQA9j8wznaB/e6DsfrSDAyN3ODwP8/wCcUgwoOe43Z7/SlOPKA2cHgZH9e59qAH7ckc4BORnI7cnNOVSpJIK/w9f6UwAFlOR6Z68/59KVmVcls5GMkDpQBUuyirjcoU5bOPyP0r5r+IviF9d16RI3b7BaZjhQNkEjq3+e1evfFvxHb6N4dubQHdfX6NHEMEFUOVLZH4187kgR7AoAznOOfzoAGI8sYJwOMVGTzznNB5B9BS/d5J59MUAAG44Izjk89qMA/cB/OhmLH+gGAPwq7pGpf2a8zfYLK8Mi7Nt3F5gTkHI54PGPzoAzY87B6VIPpmkCtGq7sqCAR707gE7RgH+VADzyinA9CM0Rv5bhsg+x6U0HKMB060qE54K5+goAn8pjaNIpDKHyQDyvHcVGGBUjgEcg4xT1BS3d2JV2cY/DrSZ3uBLhlPGRwaAEikaNwyKDt5ww3ClkYsTJtAD5YAduTxQYgjFXyPpUzxh7RXjLExEhvoTnOKAIVxncM5GMjPX3pyjnB+Xce/OKZnBBxlumCM5qViimAkEpjGD1z3oA7fwD4zGistreqZLFjtY55i/2gD169K9u0xjviBIkjlUSQyKxKsDjBB989fevlhkKnBYHJ6+1dn4J8canos9rbSzG4sI2AEL9VGf4W6j6dKAPojndjI3jOAMnAz2p4DBiRxk84Oe3TpWfpmrWerWaXNpKdhB3Iw5RvQ/lV1SGZgCctjqBx9aAHDhcsec5Jz0qBLndxtJAPBzgjtipJFKwKehAx6miBBGcfMpIIxjP+RQA2JpPtW87SnTGPp39O2MfjUgciNRjAxwAf8jNI6kSDccANuOQDzilPzKnzHB/hbAOaAHPwSAoGMnDc4IAxQrFieflxnO7r0pr8KSWJCrgkLnBo34Z9zMV6n6n60AO+bg/KGJ4Oeufb8KcWOdozs6qBngdO/Wm8gKpJQ4HHqe5BpxTP3gxXuG69KAHDIlfO0cZOGxSYJQng44OOmfelRD5gyRwPve/cU9UITGAo6Lj9fyoAVlIIGAc8jaex9DVe6kjVmEkiwwxqWldzhUUAk7vpipZmMaE9y3AX5SK8b+Nvie4gdNBs38sXEQku8ckqScJnqOmT+FAHmnjLW31/wAR32os7mB5Ctuh/giBwo/LFYq5yOMnOMUpUjg8LjvU1rGruQSVIUkEdsUARRRCWVYlDDc3bmluods7BcYBIz/Stm1jttNs/tkyyNJKP3QNYrS7mchdu4kkg5zmgCIqQAD1z070g45HX25pxOByT165po4zzj3oAktZjHH84Dp2U81bkjsnG5ZGiZhnaV6H0qhGBtGRngd6fy3IXrnpQBZWykSUFdkq8gkGq7oUkKupBHTPFG5omDIxUj8q0BOlwI47gK0hXIIXH4UAUnA2oAclV/AGhPLIIdmyOmBUl7A8TBnHyMeCO3tUKAHI75656UAWooftEZWIM0ievUimqWhPKgkZ3KR1HoaW2tpZH3RMkapgmVzgD/GrzXdlNtS8WRmX5TNHwG560AUbwRLPmBNsJA2gnJ/OiEfuJR0GAQMVp/ZLKRAkdwNucK5OQD7961fDfgzVNcmu4tPmsw8CLkTuy+ZnPC4ByeKAOcs1jkl2sGKHPIUnHpiotoVVLYDfTFaeo6RqOm3UkMpQTqcNslB2/wBaq3SgRQzcFJexOdp7igDsPAerNaXHlpOUyMrjI/CvY9IuGmhDAnf2Ujr+FfPujymKeIyAIF7gYNezeDdR8yyy247eW5yQMfpQB18Zd0UHG44OzZ09zT4xk4YYJ7daSJg0QACkZyRnHf8AlUgHQIABjIx+ueKAF3L1wMZzgDJHGOn+etBOApIBJ5A9Of8A9VJF8zPuVN2OhP6cdaMkovKsSAT81ABuw3pjJz0+vv6f56RbwkpG1t2eR/M4/CpZSUZcDLAkA5yc+/r3qrPJIrF4+F6lg2Se/SgC5C8cgTy9uCMsu3+fFTg4YbkKnP8AF/Ouf88HDZ2FuFz/AHuOanW6kRQDIcdCSeMY6/SgDeA+bhDnp90nmqt7f22nQsbphxnCoMk/UVx2veLf7Njco0ZBX72ep9vf/wCtXkuseK57qaV2diSxOd3B560AeheOfiGLGzZLFlbUJPlQbSfLXHLH3HavDJXluLh3ZnkkclnY8k+5rUlgn1CcPaxyzPJzycn8zW9o3g+Tzll1CaJYlG7y0Y8+uSR/KgDjrQBobhMt5hxtUKTk56cVf063VJN90hWBAS5K8sfSu6uRoWjJGuYkueS6KdzYzwCPX3Jpmv2Wk3OkI+l20+5xk3EjlV567R39KAPOtSu/t1wH8sIqqEjReirVPGCf1rbbRwWIjYxggYL9PzqndWKQA77qJkB5CcmgClgeUmPvEn8qTORgdMc1M/2VwBEZIz0LNyD+A6frUbxhYwVJlB6lTjH1GKAIwuFAOc4FOAGRkn3p9u6MixupbjgjqP8AGntbOFYqAUz8pJwfyoAs2bWrSoL1CyHjdnj8a2x4ZiuVaexulORkBTvAPpx0rmdjDGMmnRhopFYNJE/UMBjFAGw1vKkUlrfpIHU7QccH0NZLRMDKrEZTGTjtW1p/iK7jCxXUUd2nQM8YZq63XdHsNR0qL+yoorW73+a0UnCtwRjOOOvfigDzhdzKqKzFAc4PTP0pQ7A9Tgc44/lV3U9PubAhr20mtw3Cs6Ha3+6w4P4Vnb15I2kj1NAFqO1kYlrfawzjcrDGfoa1tC1O5sGubGc3Cm5CohQ7WB5GQfxrBUFhhAT39TXcfDHXtM0PU5xrlm8ttKmN/kh9uPY849cUAYF7pEtnuJOYkOMs2W9Tx9c11GlxeDrjw5Da3KXcF8x3vdeaODnICrg8VjasiX2vamNOtpbjSryVpraSGMsYckkDHUYzgj8R2NZItJLPZLc29zA+OFdCu4evPagDfubbRoU2aZeXc+OSZE2j8K6LwzqC28fzCQ5IH3gB+WOtcHJfRMWdlKvg7dgzz7ioILlyXZ5FJxxwcH8KAPorSdWjuIEjYgk5xyT+H6GttHy4w/APfuOP5V4b4L1gm8hh3biSuOp2jvxXtqqSAfvAgNkDqMf/AKqAJ4yFHBJBPTGMUF8bRkHOADxnr/jURQbhkAs3ZRz0/oaqXcM5iX7PKkZEibt43EoMZA5GCemSeM55NAGiZQDuUjOD/COearSSqzMofnOMkZANUbl2Vdyg8EnJ5P8A9brXHeKdZl0xSIG2b+Q2e2P8mgDuLyezgg3XEoVfRRgj8PWuV8T6uDbBdKuUnVjt2kgODg9fb3968wuPGF+xZftE00Z6rIcqffB71mahqcd4i/uFim6FUwFYe3oelAFjxFf3sl40c/mB8Y2sBnvWXBY3N5IEAAGflUkD+XSococ78hlXgEU+2W68xZNNjuPNT5g0KkkN24H8qAOyfTLzw43lazH9nmDiOKJHBDZ5Jz3HvVLWNZ+y27LZXjyXOdpIwwQflV3xsmv317b33iCMrpccOLeWSAxh3ZScYx97d+AxXBLby8L5e4npsIbP5UASI0hd5B80r5y7HP1OasQ311byo6s77V+XLAqPwxis9kwpyPX86Q/KBkYb170AaV3rt5PJvkm3BlwB5YTA9sYrNY5RvpkUikc7slOn0prjBPy8Z4NADfbnPqKVGdGBRipIzTT9MA0mODx+VAE0M3lxBYxgnqx6/wD1qVm3RIvPy5PPHJqOOJ8Lgc9sVIsMjHITn1yKAERsN6Z9e9SlyMhjt4wMd6iKSKcFWH1FXrGxScO95L5UMa54+83sKAH2Vg10YWb5YGkC7jwG5r0XxA8vhyW0h1eHZBcZBnjbcY8D+73PTvXns18xiSCzJjtkGR6jvn3qbU9YvtbkRJBuVeFUcEnuTQB3Gl6tYTzS2NtcGZJiA5mUJk+oU5/PNb9t4J025txLNZWbRKCdwXBOD07Zry+10aOWJRf3ccWBkRKQGP41rR+Ir3RrT7HDqEotFPEDFXGP9njigDota0SG33C3t44wTnCJ+n/1qz4vA+vX9uZbGw/dH+KV1Qt9Aea6X4aWb+IgdTuXD2UEu1U4G5/VvYen0r1MKN7cjI75xj3PFAHzNFompWnim10ueGSyunnEeCxXJJ4IPTFdd408KXNpoNxdSTl3RVYb2OcFgDj869T17To9QKS3S7jE3mRybfmjYdCDj9K8h8e69dT6cmlzly+1WkyAcEN0yPftQBwBjZSqiRCT6c/nTI0JfAGSD0pWYgkP1I6nipGBblg6lx0K0AW9EuDaatZTMwCpKhYg9RkZr6atZWuLS2aIDy2XJyMce3FfK4O0KV3btw4P6V9MaIDYaTax3AJlSEGUYyc4Gf50Abi7lZt+0HI285IH/wBek271BlX5Djhj6VQtJHurkq7kIONp45//AF1f2s/C8ZwCSOpz0FAFaezWRkXBVxnkj9QMf/rri/iL4Zubzw7NJGVM9sDIpxjcuBnHv/jXoAULIgUduc859R9f/rVPCiSEwzZaKQFGB6HIx/hQB8goPlXGMkAmiTCNwV/DNW9Us20/U7uzIwYZSo3Dk81TbA6lhk+tAFzTbWTVLkW8ciRy4wDIThvqfWuphkk8GGBtVsmmDMQdrDjH161y+lXzabqMUrKWjBHmKODtzXs3jyfT/E+gyJAMoIRJBIOpbGVBx+AoA4Hx54lGuR2oMeIQxwqPuKnHXHA6HpVDwn4ds9beYC9hTygCVk3JJjnkAAg/nXNzu27nOB2PY1FFNPDOk0EzxSLyHU4xQBu+INAm0m5ZZZ45oWJETIT07bs4wao2+hXV2y/ZXhkZuFTdy1Jfatc36D7fI0shGNwAGTz1ArKjdo3DoShzwQelAGjcaLqEC8xBgeAVcHNUHjljO10K89M1J9puY8bZ5ATz97rTWeSQNufJB6kgGgCPZgHJBP8AdB5phIxhRjHvTivckHPT3NMkHGGPOM0AOQYA6cj1o2gD5cGpBgD7uPTNPSSSMgI4Vm68g0AIkYRDuOM8Yz0pZJFOOcoBwBUbMSuBnBOeRUkcRlkRYwenJNACR4Cb2+6TgAVObgrGViwgPO4Hk/jUUkm87drBV+UAdqktoDJEzblEanJz1P0oAm0ZDJqcCbd5OSQRyaXVmRtQlAjA8vjA6fStLweyx68lzKuYolJKfXgCpJdGzPeahqB8q3LtII1+8QTwPas6laFP4mduCy7EY1tUY3S1b6Jd2+h7V8LdS0658LhNNthayq5M8aoFGcYBHrXXKQ3OQBx3+vavF/gnq8cesXlpM4jt5I9wUgYyDnAJ68Z613MnxH8Owz3Fs92yTxOEzJCQp65wcnp74rQ42rM6jVZ4YrXzWIAJP3ugFfNniK7SfW7tV8vypiMk/wADdcg16d4h8WWl/bNOLgfY7fJ/dnJk5yM9OteONMjsHKFSeeCOee9AhI96ORuZDjjB4NMGfnLFiW/GgHMZUeZtHQAjj2rT0PRrvWbuK2sot0kjbByB+tAG18N/D8us63HePGPsGnukshKgiR8/KmO+TyfYGvdbGCOXfPdDLOxwrg/LyOTj6Vd0Dwm2l6BZ20cTsII1DIg4kkPU/ie9XIPDmrm7k8q2eIEdGC89OeSB+tAEGmQWa36rcAJBNlG5xtOMKw9u5p+wgbXBVlJjYHgqR6j/ABq1NoWpMsknkrKi8FYZVOB9FJNUjPNO0Ydi7RoqK5HIAxjJ9vf0oAnBy6Y2jjJxz7/SnxFS3ynBOCoGD39ai8yNWJbBC5+8cHH+f51R1XVLbTbG6u5wcQJktkAj0x+lAHzv49lim8T38qom0yt90n+9XPtwAEX5iTnuR7VJe3BuLh5WZiWJPHHU1VRyjoVLAghh9frQAwsSuRtOeh6nPpXY6TerZwQ6ZcTxxgxl1Jb5lYgnaPr/ADNGmaZL4xu1FjZxRX9qgM3lkKs3JwfQMfX2qv4p0qPTtelXUo7u21BohI0bIpjDkHJDBjkfh1yKAKOvWCRSNcxDELuMgckcdcdqxpAhGUOe2MVqLqctwswkOXLbwOOp9Ko3UsMkrFI3VewYjP40AVGIwAAB3pCo4557YqRhhtvYcEjmmuTklj175oAFQKQx5ySAOOKUwqqEtKAvPXrTQQV9u+ealgljFvPHKWG4Bo+M4YUANk8hyBGWztGA3A96gk4JB2jPp0pchTkZx9Ka5wvyjHtigDpvG3h9/D2sRoj+ZbTp5sMmOMEnj6iucUYOf4j7dK+ifF/hyx8QaR9mHyXLxebZOT9yTnMeff096+epYmheSOZWWWNirgnlSDgg0AREEMR39qlYGNNnR3wT24pFYqvmHkZwoJ60s5BlOG3ZA78igBIUaSRYwcZPJ9B3q5NcE4aE4hDbUU55HrVRHdFZIzzJwW4/nTk/f3EcSD5M7Rz0oA09FuBZMbl2bJ9Bktjt+PrUuv6x/aUMEUAKJjc6nru9PcVm6jLEt1GkGQkaBc54J7mq+5VJB6nIBHesZUISqKo90ejSzXE0cJPBQdoS3/D/AC+Z0XhRRbX0k77WSL54+vzEd8dax5BueWUS7tzlm47fSteyuLPTrSNSizX08nzN5mRGmOFyD1zVfWlt4b2VbRJYmChwHfcO+QPatjzhNHje9tNRtUILbPO9OntWYigoMMC3pjmrOlymHUImRtiyZQ7Tjg9qgGFT5lKnOPpQBaNnLHMiThl3gFDjINe8fA/SHgRr9oEnSI7flHP4V4VZ5kuEDDBU5BOf0/Svor4RXn2fw4CgmRZpGcsjlcjhQfrwaAPY5rgW9msirn7oVBx6Vg6pPdXLRY2zRSLhEKbT167SeDz171Lqc4aK2jMjNGUT7r5Y5xk5+n681TEkZkxKWlDL8g3kbM49/wD61ACIbm3vRCHbzEAGYjjB44qO5todYuA0SrDd42rKPuSnGfnXjBPrVmSIwTpOgjkC8GLecEAAcN7etR284iiWKEncpGJCxQZOO569+aAOVvVuBMyOvkzx5R19wa85+MF9JYeFo7VRtmvbrDE9QqLk9/cV7F4ujiNxZXUMis08fzkEjJGOQD+FeFfGlvOtNMlQ71UsSwOeTigDykg5AJAGKSJWaQCP7x9fSk3cbRjb3xSu+SVVQoOOM5JoA7D4deJJvD2qXa20Udylwqhlcld20nG3061W8aeI7nxBrH2i5ijijTdBGi5JVAx5JPU8+30rm7Kc291HKhGFOMk9vpVzV7cRyvJwFkbehJ9aAM6KVklU8HscirE4QuAwIdvm3E8flVVvvYHfp7VJK2/aSfmxjrQAOuwsDw3bNRHOO3J6VMJY8bZl3p7NzU89p5L71kW4tcbvMU57dCByDQBTIxxx7ioxnIzx1xT9wOedo7gGlOwRjazEkfNxjFACFcchgfXg1oaHpMur3jRQ4UIu5iegrPPHOR9O9eweBtBbSvBlxeSxH7behJMMduIwwA/Pdn8KAPQtNKXmnvbgESkKyMBkKw/p/hXlnxU8I3AaXxHp0LPCxJ1BFYZikzjfjOSDnn0Neg6XMYnXGAMAHgY/Kta+gF1Z3EhBeGaJop4SP9YjAg0AfLh3HDHnnGTR5bMzbBlfU44rrvH/AILm8LTW1xaz/atIuziCdl2lG6+W4yecd+/tXJkNt8pWAVyCSBjp/SgAiChZW3DIG31xmnJiM5yQT8oOe3fpTVG1ZApBHTcO9AygI6AnINAEefmOetTRlhG0jEnt65qFOWx/SpZSAxjBBCkjOMZNADVHr0HOc1u6hLbXGmWk6Qyi8jXbOxOVI7H+dYUSF3wMMSQMVcmZvOeMZQYC4XnpQBBCxRkfeFAPGO9WZDFvWdNxMnJzyAf8aqHJ5OCfTGK07G0e7WK0Yxxlm3I54C+xPYfyoAXT7Wa/nht7VZHupj5arnqTjvnjvX0b4eh+xWkFha9LeMRrzgMQBnj3Oa8z+Fmh/wDFSRMsqShQY/OCkqsjEKNp9gTXuK6LFpM0A+1Nc28kpgeQxj5WIyOnTqKAL94QHjcDgqu732j+WM1NZ3Qt0Ty42VmXO7gDr2z+FWzDsaYxgGWLayybM7hxkAe/eq9/i3CzXu21XBCIEyXHAGF5x0oAmjvGC7ZyWZm52gAnA4JPtWbcOG+ZQY3VQPkIzwep9P8A9dV1voArLumU4xvwG56dMf1rbAZLZLhBAkO3c0oXJOO3PSgDL8SF306yIDfJkPk9jjv+BryP4pac17oFwyLuMbeYOc59a9l1MGSzihVts11MqJvBySByTzXKeK9JRIJoBJ50Thhv2YGQBnv0P9KAPkw52YzgHt/9ajGByCOnBq5qdm9jfS28gOVbA4xkZqowZT0AGTnNAAAG45zjp71oTBW06PDNvhGSjY6HuKzUJHIOPYU8SGOYtgMCTkE9Qe1ADc4BGOnPB7fhSplZFLDA69OoqQqySNFlRxgEDGah5z1oAJGLZJJLHmlhlaGRWjOG6n8qQBXXb92Tkgg4z7U3YwHzDC9ckUASmZZjulA83sQBg/UVHg8g7RSEHOGOB15Nafh3Rb3xFq8Om6egMrjc8hHywoOrE+gH50Abfw10CXW/EME0sDSabaPuncAYLYJVBnqSQP517p4xmFl4YvppyRJJ5YTb/CA6/Ln1A9queFNEg0jR7WzsIxDZW5O0yLhpXwcyvz1/P2rlviVeGbRb7yuYUCAHpn94vzDHqf0oAeYTCQDnaQACDkE+v6Vp6fdiMbJJCynPJPT9antJYrqDYoJAUDDYPGOT/wDqqnNaSKGeJd0YJOSozgdjz1oAn1jSdP1S1+y6nAbnT5GDNEp27ODh1IPUH+o6Zrwvxz4Wk8KamEWQ3Onzjdbz4IOP7rejDjP1Fe+afdh0VHbDrwOhxj0OamuIyY5R5NvcW06bZoHOVk65/HmgD5YJ/dgY4J9ajP3h+deneKfhpdLcy3XhiPz7ZmLG0dwskXfAyQG9h1rzeSJ4Ll4riOSKVDtZGXDA+hFABCcPuyBgZH1pudwOSC2SePWnRjdKWfcO54yaEGOAvfqaALenoFuUdijc8A8/So2VImZpmyw6Kp5zQSHhyB87csSRgAUTSbyDGAAVAbngnnn8qAHQuqxhgpMmcDB6VbtjPcSx20KDdPtRdrHIyQMVWsLae8uY7SzhkmmmO1I05JOa9n+HHgS4sn2ywtLq8mNyDBS19dzA4yBQB1nw50ZYbnS7JWXZZJ50pQnkKc+vGWIrupJEeW9Fwim2P711JJG4DIxg/eyf0qbS9Mt9K08QW7HamZLmdhw7jHf068VTguI5bpgm4onIkYbdwPUjPT2oA6OxiDwWc0pIm8td4yckkDPf1ribyZ5L+6a6mLyLLJGCzE4w3AHtXcmEmaKeNiUWMKi56jOeTz2rA8QaLc3F8t7p0ZZpQfOhLKDu4AYZOOg5GfQj0oA59ZBgAvggZDA5+uea2/B0u+e8iErLarGjGMngSZJ4/AZrGTSdSkdo49OlkK5BZ2WMA9gTmux0jTRp2lLaCPMpUSSyFhtkkPJ98A9MjpigCp4ozE1tJCGBRZRvDfdJ2/kevPtWBcW5vNH2wFjdWzb06kyccjrXTazObHT4lZzNcHn5iCT0z17cVjWqC5mKWLMsjHfGC+CpAGR78+lAHg3xJ8Ox3VmdRsogJ0IJCHkjj9eteVsgHDo4+pxivrLxBo/nRTXdnG4UY+0wLkMjdMgHt9K8s+K2i32tRW2o28KzTWy+SxQBS6gcEjPUdPWgDyALEoDqWbk8Hj9RUT8jJx8wzwf0qTHlTN5iNuXqtISQjfIDnnHpQAgBdVBIaQDpntTSp2npn88U6Nigz0J44bkggimqrRSemPQ9RQAxRyPr0zipGXgNwN3cdBU1pbTXlwIbWB5ZW6Koya9P8LfDM21zFd+LfliU5+yI6kv6AkE45oA4Dwx4c1DxLfm20uNWC4MkznakQPcmvojwL4NsdA0mSC0YHjN3eAEPdEE/KOcBRnGB6ZOTXSeH/D/2kRma0Wx0lQBDbRDb5nPYZ6cdT1p/iDWYLZJbe0hPnBSifKAIh07d+KAM/wARXMdvClrBKPPz+8KMMRrj7nHf1rzbx5hPCt+dxxiM9f8ApovauokJUgAYwegIB/E/5zXO/EG3ceBtTmdRs2xYYnnmZO9AF23lkRMx4GF6cjmtqzvBKo8zYrd85P8A+usGONSBh8/rg+tATltxVSAcHPGfXv8A5FAHQXFowKSWrbHHI4IDfrxT7DVSHeO4QIWADDbwcE9efXuKzbW9KMqySs0XtWhLbwXqhxMTjvkZH69KANcaWl8hls50WcD7jA9fcg/zFc34z8LW+uxquuWRjuk+5eRArIOOMtyGH1qxYPdRPcxo7K6D5GWTJIPfrgjpXUWOtIVSDUldHU586Hc6nj+JDkDr2oA8NufhcEUi21vc/VRPakL/AN9qx/lXL33g/wAQWk0i/wBnSTrk4kt/nUj1FfVka6LdxndLZO2cjzEaMfjyKsx2uhjcS+n9Sfknx3+tAHyZZeD/ABHeKqR6TOgGRumXy1/M11eh/CPVL9WF7exWz4GIbaE3DHr1OQo/OvpJI9EjfcrWPBB5kBwcdwTUjanp9qpWK4gPH3YyT/6CCKAOD8GfDGPQNMYRy29tM/D3LxeZOeen3tqj2GfxrttGsorKyjtNPREstn72dwQ7nue3+FVL/wAT2wiY2iPM6nrMCijnrz1rmJ77Vrwo0l8RFnPlpIQre2Bjj60Ab/iK4JNnb25H2aJMhd52yNxzz1A7dKr2kRjWW6mlSGBeuAWySOijHWq097HJFEBAEwMHMvA+gI/SqVyTMZN0xZc/Ku75RwOgzgUAasmv6n5aGNo4Y4znaAdxGP4s5zW5o+pXt6SFubGZhlmQxMjjp3BII561xpjCiNfOz0Jw3B/Wl3XFreJfWchFxCwd1VuJUzllPHt+dAHoMt1PM6Q2JiNwRuYvGSq4OOcHn/Oa5i/8STMfKtrsEhRkpD5Yz3xuYnt61oeLW/4ltulpJIlrdSF3MRPzLtztJHYk1yJMcbpH8wQ7QDjA9SB3zx6fiaAOisr06+6Wl3JbGcITFIg+8R1Vh0z3qG+sZYJjCzugVuoTGDgY9qwxGWhSRZSu1jtJYjGO+Qa07W9HlOmoGW5XIAKud/XgnOR69aAOvhjItY7xUR7oxL5nAxIcDJrAutFs726We3mj0+4kG4qcOh9QRwQc1XvdZmjggh0fcigAySysCzH02k4Ap9rrG11/tOyhl9Zbc/OffGACOfWgDhPG/wAKE1KUzbfKc8me1QshyTjK5/rXl+rfC/V7RpPsskVwOiqUKEgfXvX1LY61panEc7QsP4ZS/P0HOKtvf6bIreZeWRByCJJV+mME0AfGg8CeJS2H01kBOMu6qP51v6P8MNRvJc3V0q46x28ZkJ+p6CvqZ5dE7y6aOvIkQHkdj1qYatpsOUGoWsY44iYEj8s0AeXeDvAk2lW6R6bpgEhzuubn5R9fw+hru9I8J21vfrcT3aXkkRz5e3CBsHO7knjnA4qa98SWbI6QxXFy3IGf3aH6se1c1q+rXd6sqPL5Nv5bDyIW2p369z/L2oA1PFXipreWWz0+RXOzbLMuflPouO+OtcDvlnY8lmY59eSadZ2zSkYDbVHBBABPt71feS1s1yx3PggAMwc/XggfpQAQWQhKySSIzA8bTk/p+Nc58WJXXwHqmQseRFgNySPNT346fpWlc6hJMwMW2FOwX5j+o/rXFfFCUt4TvfMfe5aMZOc43j1/pQB0CMNo9xlQxA574qcO+35VG08/dPA+tQL/AKl/9z/Cnw/6v8B/SgCfLZyi+xZhjH51PFNLDKJYldcdcAYNU0/1zf57mqY/5Cc3/XBP5tQB1Md2t5H8wVJ+fvdM+2e2anSWeyt1ikjZgp+Uo4GR2B5zXOr/AK63/wC2v/oYroo/+PI/Uf0oAbaXUMzlGBjc9AzYyfTNWY542eVQqErwR36etc/ef6qf/dqHRP8Aj8P+9/7UFAHWcLjdCqHO3PljPvjp+dDeWjYAK7eOQBj8B3rItP8AkL6n/wBd4f8A0Slaekf8en/fX/obUARrOkoxCElMblZBuOQw/HrjHHvTvMDplPlAUH5mHGePr/8Aqq5N95fo386z5v8Aj3T6t/KgCwkhX5nQqMcru6d+D/jUSzjcA4w7HcoVeGXr/Kki/wCPdPoart/x+x/Uf+gigC4UTk7GG7BGGUEdBxn6U6fekQJVSwH8b7cn60+2/qv8hUI/4/2+n9DQBsXuo2//AAj1iBGzG1ZQpYj0A+nestmVUQMQA2MEH5f0PNVZv9e31H86VP8Aj+s/+ui/0oAlPlmQZaRtrHBdjt4/L8qVJA6vs+UlgGJfoQPQmqupf8fUP0f+lTxf8ftz/ur/ACFAFpv3afcAGeD2wcc8GmGTzcBVXPAyWDcYzjrUcX+r/wCBf0p8X+ub/eH8jQAExfekjOex4U4/D/69NJUjhcHG7lsgfyz9Ksr1T6j+dQS/8g2T6N/KgAQb9uI2XOTtJ/8A18fjVXz4lkbLlIc4B2bc8cnJ7U7U/wDj0l/3x/KsWL7kf+6P50AbEl/bvFKkblnKnlCQQfw4z+NDS3Twn7UVSHjf8+Sw9MZP15rTtf8AUwf7p/mKytf+/H9T/M0AVrvUMjyY22DGOFGTz0AyOKz2k6/dXORkKADn8cU6P76f59ajk/1a/SgAAfb/ABMu48DAGMema5P4nyj/AIQ69BZgS0QA4wfnB+vrXd3330+p/wDZq4b4t/8AIr3H/AP/AEJKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan showing smooth right lower lobe nodule, adjacent to the posterobasal segmental bronchus. This nodule was proven to represent a carcinoid tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_16_29967=[""].join("\n");
var outline_f29_16_29967=null;
